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Abstract		
Background: There has been an increasing awareness of the negative impact of 
inflammatory bowel disease (IBD) on bone metabolism and bone mineral density 
(BMD). A number of potential mechanisms have been suggested, including 
malnutrition and the use of steroids. Although it has been known for some time that 
the immune system can influence the cells of bone, the specific contribution of 
interactions between osteoblasts and T cells in the pathogenesis of IBD-associated 
osteoporosis in children has yet to be clearly demonstrated. This body of work consists 
of two parts: an in vitro study investigating the influence of T cells and their activation 
products on the growth and alkaline phosphatase activity of the Saos-2 osteosarcoma 
cell line, and an in vivo study comparing the phenotype of lymphocyte subpopulations 
in the gut and peripheral circulation of children with and without IBD, relating these to 
measures of bone metabolism and mineralisation.  
Methods: For the in vitro studies, Saos-2 cells were incubated with increasing 
numbers of resting and polyclonally activated immune cells, with and without the 
presence of transwell inserts. The expansion of the Saos-2 cells and their alkaline 
phosphatase activity were measured, and flow cytometry was used to establish the 
activation status of T cell subpopulations in the immune cell populations. 
The in vivo study recruited 30 children undergoing lower gastrointestinal (GI) 
endoscopy for investigation of GI symptoms aiming to identify 15 patients newly 
diagnosed with Crohn’s disease and 15 healthy controls. Immune cells were isolated 
from blood and gut biopsy samples, and analysed by flow cytometry. Samples of serum 
and urine were analysed for bone turnover markers. Confirmed cases of IBD had their 
bone mineral density measured by dual X-ray absorptiometry (DXA). 
Results: The in vitro study found that populations of PBMCs and CD4+ lymphocytes 
had similar effects on the growth of Saos-2 cells, and whilst activated immune cells 
significantly inhibited Saos-2 cell growth it was also observed that resting immune cells 
increased Saos-2 cell growth. These effects were lost when immune cells were added 
after saos-2 had become adherent. There was a reciprocal effect of Saos-2 cells on 
the activation status of CD4+ lymphocytes, increasing the activation of resting cells and 
potentially limiting the effects of polyclonal activation.  
  iii 
The in vivo study found that children with Crohn’s disease had significant reductions 
in BMD, reductions in both bone resorption and formation, lower total lymphocyte 
counts and increased expression of CD25. Linear regression showed a positive 
correlation between the numbers of circulating CD4+ lymphocytes and BMD, and a 
negative correlation with their expression of CD25. These correlations were not 
statistically significant, but the power of the study was only 20% 
Conclusion: The findings support the hypothesis that gut activated immune cells 
mediate low bone mineral density in paediatric Crohn’s disease. However, the findings 
also raise the possibility of osteoimmune interactions being important for the immune 
response and bone metabolism, in both health and disease. Therefore, further study 
of cellular responses in the bone are necessary to better understand the relationships 
between these two important systems.  
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1 Introduction	
Inflammatory	bowel	disease	
Clinical	features	
Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gut with 
two distinct phenotypes: Crohn’s disease (CD) and ulcerative colitis (UC) (Bouma et al 
2003). CD affects the entire gastrointestinal tract from the mouth to the anus. The 
mucosa develops a cobblestone appearance with ulcers separated by normal or 
oedematous mucosa. There is a dense infiltrate of lymphocytes affecting all layers of 
the bowel wall with the development of granulomas. UC, apart from some ileal 
involvement, affects only the large bowel. Only the superficial mucosal layers become 
inflamed and, unlike the cobblestone appearance seen in Crohn’s, the pattern of 
inflammation is continuous. Figure 1-1 compares their histological appearances. 
Although most patients affected by IBD can be recognised as having either UC or CD, 
if the features are unclear then the term ‘indeterminate colitis’ is used.  
	
Figure 1-1 Photomicrographs of histological specimens taken from patients with IBD. Photomicrographs 
of histological specimens taken from patients with IBD. Left – mucosa from a patient with CD showing full 
thickness inflammation and granulomas towards the serosal surface. Right – mucosa from a patient with 
UC (at low-power magnification) exhibiting mucosal inflammation and erosion. Reproduced with 
permission (Bouma et al 2003). 
IBD (both CD and UC) is an incurable, life-long condition. It causes significant morbidity 
including malabsorption, abdominal pain, and diarrhoea. Treatment involves the use 
of steroids and other immunomodulatory drugs which have significant side effects. In 
more severe cases surgery (including resection of significant areas of bowel) may be 
required to control symptoms.  
  Page	2	
Epidemiology	
A systematic review of studies published between 1950 and 2010 showed that the 
incidence of IBD varies between geographical regions (Molodecky et al 2012). 
Incidence is lowest in Asia and the Middle East (5 and 6.3/100,000 for CD and UC 
respectively). Incidence is markedly higher in Europe and North America, but with a 
higher rate of UC in Europe (24.3 vs 19.2 per 100,000) compared with a higher rate of 
CD in North America (20.2 vs 12.7/100,000). The incidence of IBD was also shown to 
vary across Europe (see Figure 1-2). This variation had been previously demonstrated 
in a European study in which 20 centres across Europe used an agreed methodology 
to prospectively identify patients (Shivananda et al 1996). Incidence in Northern 
European countries (including the UK, France and Norway), compared to those in the 
south (Spain, Greece and Italy), was 40% higher for UC and 80% higher for CD.  
Although the majority of studies (60-75%) reporting trends over time showed 
statistically significant increases in the incidence of both UC and CD (Molodecky et al 
2012), the details of these changes varies in individual studies. In Northern France 
there has been a 29% increase in the incidence of CD from 5.2 to 6.7/100,000, 
although with a 25% drop in UC from 4.3 to 3.4/100,000 (Chouraki et al 2011). Data 
collected by the Mayo Clinic over the last seventy years indicates that the incidences 
of CD and UC have increased from 1.9 to 7.9 per 100,000 population, and from 2 to 
8.8 per 100,000 population respectively (Sedlack et al 1972; Sedlack et al 1980; Loftus 
et al 2007). In Denmark, the incidence of both have increased, but with UC rates 1.5 
to 3 times higher than for CD (Binder et al 1982; Vind et al 2006). 
 
Figure 1-2 Worldwide incidence and prevalence rates of IBD. CD (left) and UC (right) are ranked into 
quintiles representing low (dark and light blue), intermediate (green) and high (yellow and red) risk of 
disease. Reproduced with permission (Molodecky et al 2012). 
It has been observed that 25% of IBD patients develop the disease during 
childhood (Kelsen et al 2008). 4% of paediatric IBD is diagnosed before the age of 
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5 (Kelsen et al 2008), and the incidence gradually increases with age (van der Zaag-
Loonen et al 2004) reaching a peak onset in the early twenties (Chouraki et al 2011). 
A recent review of studies published between 1950 and 2009 found the incidence of 
paediatric CD has increased but not UC (Benchimol et al 2011), although subsequent 
studies report increases in paediatric UC (Lehtinen et al 2011; Henderson et al 2012; 
Malmborg et al 2013; Ashton et al 2014). In Northern France, between 1988 and 2007, 
the number of children diagnosed with CD between the ages of 10 to 19 years has 
increased by 71% from 6.5 to 11/100,000 (Chouraki et al 2011).  
Some of this temporal and geographic variation may be explained by differing study 
design, and epidemiological studies will often describe normal variation, but the 
increasing incidence is real. There are plausible mechanisms by which environmental 
factors can influence disease expression (Ng et al 2013), and temporal changes are 
seen in studies published by centres with consistent data collection methods. This 
means that although IBD already has a significant impact on health outcomes, the 
global burden of IBD and its associated morbidity will increase. 
The	 gut,	 its	mucosal	 immune	 system,	 and	 the	 pathogenesis	 of	 inflammatory	
bowel	disease	
Structure	of	the	gut	mucosa	
The gut is exposed to a wide array of antigen, present in the food we consume and the 
commensal bacteria that reside there. The gut needs to be able to transfer nutrients 
across the mucosal surface whilst excluding bacteria. The gut’s relationship with 
bacteria is further complicated by a need to clear pathogenic bacteria whilst 
maintaining an appropriate population of commensal bacteria. The immunological 
structure of the mammalian gut, as with other mucosal surfaces in the body, has 
developed in such a way to meet these conflicting demands. 
The gastrointestinal tract consists of multiple tissue layers. The innermost mucosa has 
three: an overlying epithelium in contact with the gut contents; an underlying lamina 
propria consisting of connective tissue, blood vessels and immune cells; and an outer 
muscularis mucosa for local movement of the mucosa. Surrounding these is the 
submucosa containing larger blood vessels, lymphatics and nerves; the muscularis 
propria for movement of the bowel; and an outer adventitia. 
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The small intestine is the major absorptive site of the intestine. Both the mucosa and 
sub-mucosa are thrown up into plicae (folds), increasing the mucosal surface area. 
The epithelium can be divided into three zones: villi (fingers) extending outwards into 
the bowel, crypts (tubular glands) extending down from the base of the villi to the 
muscularis mucosae, and the neck zone where the two meet. Lamina propria is 
present around the base of the villi and extends up into them. The large intestine lacks 
villi but tubular glands are still present, extending into the mucosa with lamina propria 
found at their base. The microvillous brush border secretes mucin and anti-microbial 
peptides which regulates access of bacteria to the mucosal surface, and tight junctions 
between the epithelial cells prevent unregulated exposure of antigens to the immune 
system. Antigen is then processed by an extensive network of organised, gut 
associated, lymphoid tissue (GALT). 
	
Figure 1-3 The structure of the gut in relation to antigen sampling. Tightly bound epithelial cells separate 
the immune system from commensal antigen whilst M cells provide a route for dendritic cells (DCs) to 
sample antigen. Reproduced with permission (Artis 2008). 
Peyer’s patches (PPs) are specialised lymphoid structures which form part of the 
GALT (Jung et al 2010). Found primarily in the ileum, PPs become apparent at 24 
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completed weeks gestation and continue increasing in number into adult life. They 
consist of aggregated lymphoid follicles, structured to facilitate processing of antigen 
(see Figure 1-3). Each follicle has a germinal centre containing dendritic cells and B 
cells; and a sub-epithelial dome consisting of T cells, B cells and dendritic cells. 
Overlying these aggregates is follicle associated epithelium made up of micro-fold cells 
(or M cells), specialised in the transport of intact luminal material including protein and 
bacteria. Efferent vessels connect PPs to the mesenteric lymph nodes and the wider 
lymphatic system. Evidence of PPs importance to the mucosal immune response is 
mixed: in one mouse model a lack of PPs limited the development of tolerance to larger 
protein antigens (Fujihashi et al 2001), but had no effect in a rat model (Enders et al 
1986) or ligated murine bowel loops (Kraus et al 2005). Despite these heterogeneous 
findings specific structures within PPs and lymphoid follicles, pattern recognition 
receptors, have a clear role in moderating the GALT’s response to infective organisms. 
Pattern recognition receptors (PRRs) are found on cells within lymphoid follicles and 
PPs. They recognise specific compounds found on bacteria e.g. lipopolysaccharide. 
Two types of PRRs, toll like receptors (TLRs) and nucleotide-binding oligomerization 
domain-containing proteins (NODs), have roles in the innate immune response to 
pathogens with polymorphisms in their encoding genes associated with chronic 
inflammatory disorders of the gut. TLRs are transmembrane proteins, homologous to 
the IL-1R receptor family, first identified in Drosphila  (Medzhitov et al 2000). Toll-like 
receptors are necessary in the recognition of commensal bacteria and the 
development of tolerance (Rakoff-Nahoum et al 2004), and TLR-2 maintains epithelial 
integrity (Cario et al 2004) and the response to lipopolysaccharides (Cario et al 2000). 
NODs are cytosolic proteins, similar to R-proteins that form part of plants’ innate 
immunity (Inohara 2002), and expression of NOD2 by epithelial cells in humans is a 
key component of their antibacterial response (Hisamatsu et al 2003). Mutations in the 
genes encoding TLR-4 and NOD2 are associated with a greater risk of graft-versus-
host-disease (Elmaagacli et al 2006) but also have a role in the pathogenesis of IBD. 
NOD2 has an important antibacterial role in humans (Hisamatsu et al 2003; Wehkamp 
et al 2004) and mutations are associated with an increased susceptibility to Crohn’s 
disease (Hugot et al 2001; Ogura et al 2001). Polymorphisms in TLR4 are associated 
with a greater risk of both UC and CD (Franchimont 2004; Torok et al 2004). 
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Mucosal	lymphocyte	populations	
Dendritic	cells	
Dendritic cells (DCs) are included here as they have an important role in determining 
the response of lymphocytes to antigen (Wyllie et al 2015). DCs sample antigen by 
two routes: those within a PP sample antigen taken up by M-cells, but there are also 
DCs outside of PPs which can extend processes between enterocytes to sample 
antigen on the mucosal surface (Rescigno et al 2001). This antigen is presented to T 
cells, with co-stimulatory molecules, inducing either a regulatory or effector response. 
Pathogens require an effector response and their presence in the gut can cause 
epithelial cells to express pro-inflammatory cytokines, such as TNF-a, which favours 
the induction of an effector phenotype. Commensal bacteria and food antigens need a 
regulatory response and intestinal DCs, compared to those in the spleen, produce 
greater amounts of the regulatory cytokine IL-10. Also, whilst there may be differences 
in the responses of PP and LP DCs (Strober 2009), they both induce expression of 
FOXP3 (indicating a regulatory phenotype in lymphocytes) and specific gut homing 
integrins in naïve T cells (Mora et al 2003), and shift the isotype of B cells towards 
health-associated IgA production. 
Lymphocyte	populations	
CD4+	lymphocytes	
CD4+ T cells (T ‘helper’ cells) play a key role in the triggering and coordination of 
immune responses. These cells are able, when exposed to a range of 
immunoregulatory proteins including cytokines and interleukins, to develop into 
phenotypically and functionally distinct subtypes. Relevant to IBD was the potential to 
differentiate into one of two phenotypes: TH1 cells, secreting IL-12, IFN-g and TNF-
a (Neurath et al 1995); and TH2 cells secreting IL-4 and IL-13 (Boirivant et al 1998). It 
has been shown that within the lamina propria of patients with CD, CD4+ lymphocytes 
express cytokines consistent with a TH1 phenotype; whereas the TH2 phenotype 
predominates in UC (Fuss et al 1996). Two further groups of immunoregulatory CD4+ 
T cells have been identified: so called T regulatory (Treg) cells and TH17 cells.  
The interleukin-2 receptor alpha chain (IL2R or CD25) was initially identified as being 
necessary for lymphocyte proliferation (Hatakeyama et al 1989). It was subsequently 
found that the elimination of CD4+CD25high lymphocytes in mice resulted in widespread 
autoimmune disease (Sakaguchi et al 1995). CD4+CD25high lymphocytes, now 
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recognised as T regulatory cells or Tregs, showed little response to T cell receptor 
stimulation and suppressed the activation and proliferation of other T cells (Takahashi 
et al 1998). Whilst initially thought to develop only in the thymus as natural Tregs (Itoh 
et al 1999), exposure of peripherally circulating naïve CD4+ cells can induce them to 
develop into a population of T regulatory cells referred to as iTregs (Chen et al 2003). 
The transcription factor forkhead box P3 (FOXP3 or scurfin) plays a specific role in the 
development and function of the CD4+CD25high Treg cell population. Retroviral 
transduction of FOXP3 into CD4+CD25- T cells converts them to the CD4+CD25high Treg 
cell phenotype (Fontenot et al 2003; Hori et al 2003), and can inhibit the development 
of IBD in mouse models (Hori 2003). Furthermore, a deficiency of FOXP3 in mice 
results in hyper-activation of T cells (Fontenot et al 2003). FOXP3 is the gene found to 
be defective in the Scurfy mouse strain, a mouse model of autoimmune 
disease (Brunkow et al 2001). In humans, mutations of the FOXP3 gene also underlie 
the syndrome know as immune dysregulation, polyendocrinopathy, enteropathy, X-
linked inheritance (IPEX) (Bennett et al 2001). IL-10 secreting FOXP3 cells have been 
identified in the lamina propria of mice with numbers increasing with remission of 
colitis (Uhlig et al 2006). Tregs also produce IL-35, a member of the IL-12 family found 
to confer a regulatory phenotype in naïve T cells (Collison et al 2007). These 
observations show the importance of Tregs and FOXP3 in regulating the immune 
response. 
In 2005, two groups of investigators successfully identified a type of T helper cell which 
is now known as the TH17 cell (Harrington et al 2005; Park et al 2005) which, in contrast 
to CD4+CD25high Treg cells, is pro-inflammatory. These cells selectively express IL-23R, 
CCR6 and the transcription factor RORγt and have been found in the peripheral blood 
and gut of patients with CD (Annunziato et al 2007). They are also found in the 
chronically inflamed tissue in psoriasis, rheumatoid arthritis and asthma (Pene et al 
2008).  
CD4+ lymphocytes are mainly found within the lamina propria, usually at a ratio of 
greater than 1.5 when compared to CD8+ lymphocytes (Carrasco et al 2013). Table 
1-1 summarises the cytokines inducing them to develop and the main cytokines they 
secrete. However, these lineages are not strictly maintained and there is evidence that 
T cells can convert between a Th17 and Treg phenotype, and that Th1 and Th17 may 
have a similar developmental pathway (Zhou et al 2009). 
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Initiating cytokines CD4+ lymphocyte type Produced cytokines 
IL-12 
IFN-g 
T-box transcription factor 
(T-bet) 
Th1 
IL-2 
IFN-g 
IL-4 Th2 
IL-4 
IL-5 
IL-13 
TGF-beta 
IL-23 
IL-6 
Th17 IL-17 
IL-10 
TGF-beta 
Treg IL-10 
IL-35 
Table 1-1 CD4+ lymphocyte subset cytokine profiles. Cytokines initiating the generation of different CD4+ 
lymphocytes subtypes, and the cytokines they subsequently secrete. 
CD8+	lymphocytes	
The intraepithelial layer’s main population of lymphocytes are T-cells with no B cells 
present. Three quarters of the T-cells are CD8+ lymphocytes, consisting of two 
types (Wyllie et al 2015). The first, type A intra-epithelial lymphocytes (IELs), behave 
as other peripheral CD8 cells. They are primed in the GALT, drain into the mesenteric 
and thoracic lymph nodes, enter the systemic circulation, home back to the lamina 
propria and transfer to the epithelium (Hayday et al 2001). They are cytolytic, produce 
a Th1-like cytokine profile, and have antigen memory. 
The second population of lymphocytes are known as type B IELs. Unique to the gut 
they are found in the small intestine (Hayday et al 2001). They include CD4-CD8--T 
cells (expressing neither CD4 or CD8), T cells with a gd T-cell receptor and CD8 cells 
with an aa T-cell receptor (rather than the usual ab). Type B IELs develop in the 
intestine, rather than in the thymus. They seem to have a role in maintaining epithelial 
immune homeostasis and response to infection (Fujihashi et al 1990; Roberts et al 
1996). 
B	cells	
B cells of the intestine are also different from those in the circulation (Wyllie et al 2015). 
The role of gut derived B cells, also known as B1 cells, seems to be the production of 
a non-specific immune defence against bacterial invasion. Unlike their circulating 
counterparts (known as B2 cells) they do not mature into memory cells and produce a 
non-specific IgM to bacterial carbohydrates. They are found exclusively in the lamina 
  Page	9	
propria, and their presence in epithelial specimens indicates contamination from the 
lamina propria (Carrasco et al 2013). 
The	mucosal	immune	system	in	health	and	disease	
The	healthy	mucosal	immune	response		
The gut needs to develop tolerance to commensal bacteria and dietary antigens. This 
mechanism is called “oral tolerance”, and like that preventing auto-reactivity of the 
immune system (Faria et al 2005; Wyllie et al 2015). Exposure to low doses of antigen, 
presented by antigen presenting cells (APCs), generates T regulatory cells within the 
gut (induced or iTregs). They migrate from the mucosa to lymphoid organs and, via 
the systemic circulation, to target organs. They inhibit effector responses to that 
specific antigen whilst also demonstrating bystander suppression which inhibits the 
effector response to other antigens present in the same anatomical location. High 
doses of antigen produce tolerance through clonal anergy or deletion of reactive cells 
- although there is overlap between this and the response to low doses of antigen. 
Interventions such as caesarean section, perinatal antibiotics, and use of formula milk 
means there is an inadequate (or inappropriate) bacterial exposure to produce the 
necessary development of oral tolerance (Bedford Russell et al 2006) and may explain 
the increases in both allergic and autoimmune disorders (including IBD). 
In germ free mice development of oral tolerance was only possible with bacterial 
colonisation which had to occur in the neonatal period (Sudo et al 1997). The type of 
organisms colonising the gut is important and does seem to affect an individual’s risk 
of allergic disease: colonisation with B.fragilis in human children is associated with 
greater numbers of IgA secreting cells (indicating the appropriate development of an 
immune response), with those colonised earliest having the highest levels (Gronlund 
2000); and colonisation with bifidobacteria was lower at one week of age in children 
who went on to develop a confirmed allergic disorder (Bjorksten et al 2001). Supporting 
this is a study in mice which showed that early administration of antibiotics removed 
bacteria from the gut with subsequent reductions in the number of gut lymphocytes, 
and a shift in their phenotype from Th1 to Th2 which may increase the incidence of 
allergy (Oyama et al 2001). There is some evidence to suggest an association between 
antibiotic use and development of allergy in humans, but a causal link has not been 
shown (Bedford Russell et al 2006). Probiotics, though, have been shown to reduce 
the incidence of atopy (Kalliomäki et al 2001). Delivery of human infants by caesarean 
section delayed bacterial colonisation, compared to those delivered 
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vaginally (Gronlund et al 1999); and mice delivered vaginally showed a TLR and NFkB 
(part of a cellular, pro-inflammatory pathway) mediated response of intra-epithelial 
cells, not seen in those delivered by caesarean section (Lotz et al 2006). 
There is a fundamentally different immune response required to clear invasive 
pathogens (Wyllie et al 2015). Invasive organisms that evade early defences reach 
epithelial cells causing them to release stress molecules which activate IELs and 
attract populations of inflammatory cells such as monocytes, dendritic cells, polymorph 
neutrophils, and lymphocytes. There is a local secretory IgA response, but also 
systemic immune priming with the generation of cell mediated immunity and serum 
antibodies which usually clears the pathogen. If these responses are unsuccessful in 
clearing pathogens, or if disruption of the epithelial barrier exposes the gut to known 
antigen such as commensal bacteria or dietary antigens, then chronic inflammation 
can develop.  
The	loss	of	mucosal	immune	tolerance	and	chronic	inflammation		
A number of observations in IBD patients show that factors impacting on the ability to 
develop oral tolerance may underlie the pathogenesis of chronic inflammation.  IBD 
patients have a reduced gut microbiological diversity (Manichanh et al 2006; Frank et 
al 2007). Faecalibacterium prausnitzii has anti-inflammatory effects and is reduced in 
patients with Crohn’s Disease (Sokol et al 2008), whilst there are increases in E.coli 
species (Kotlowski et al 2007) which show greater adherence to epithelial cells (Martin 
et al 2004). Loss of the mucosal barrier in active disease, with greater attachment of 
microbes to epithelial cells, has been shown in human CD patients (Swidsinski et al 
2007). Humans affected by IBD, and their first degree relatives, have greater gut 
permeability compared to controls (Hollander 1986), and greater intestinal permeability 
predicts relapse of IBD (Kiesslich et al 2012). The role of PRRs in IBD has already 
been mentioned. 
The development of the chronic inflammation seen in IBD seems to follow on from an 
acute inflammatory response and typically has two distinct phenotypes (Wyllie et al 
2015). A Th1 or Th17 dominated response activates macrophages to release 
cytokines such as TNF-a, IL-1b and IL-6. Whilst there is an overlap between Th1 and 
Th17 responses, the former is typically associated with macrophage mediated Crohn’s 
like lesions and Th17 with a neutrophil dominated or autoimmune response. Both can 
develop granulomas, formed from aggregates of the inflammatory cells. A Th2 
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dominated response has two types: IL-4 and IL-3 trigger a humoral response usually 
seen in UC, with mucosal production of IgG and/or IgE; IL-5 triggers an eosinophilic 
infiltration observed in allergic disorders and eosinophilic esophagitis. 
Compared to controls the proportions of Treg and TH17 cells are altered in patients with 
IBD (Eastaff-Leung et al 2010). The numbers of circulating Treg cells are significantly 
lower in the peripheral blood of adult patients with CD (5.88x103/ml; p = 0.002) and UC 
(5.16x103/ml; p = 0.006) compared with controls (8.08x103/ml). For cases and controls 
the upper limit of the confidence interval for the proportion of circulating Treg cells was 
0.47 to 0.55%, whilst the lower limit was 0.012% and 0.003% in CD and UC compared 
to 0.121% in controls. In contrast, the proportion of pro-inflammatory TH17 cells was 
found to be higher in patients with CD than corresponding controls (0.36% to 1.25% 
vs 0.1% to 0.49%), as was the absolute number of these cells (7.67x103/ml vs 
15x103/ml; p = 0.0012). They were also significantly increased in UC. These findings 
demonstrate a shift from a TH17 to Treg ratio of 1:1, seen in healthy controls, to an 
excess of pro-inflammatory cells.  
A monoclonal antibody to TNF-a (Infliximab) is recommended by NICE for the 
treatment of IBD (NICE 2010; NICE 2015). Infliximab increases the proportion of CD4+ 
cells with a Treg phenotype in patients with IBD (2.9% vs 4.4%; p = 0.003) and the 
capacity of Treg cells isolated from the peripheral blood of these patients to suppress 
the proliferation of allogenic responder CD4+ T (Teff) cells in vitro (28% vs 66%; p = 
0.04) (Boschetti et al 2011). This shows that disease remission is associated with a 
down regulation of the Th1 response and an increase in Treg cells. 
Circulation	of	immune	cells	
Over forty years ago it was found, using radioactively labelled lymphocytes in rats, that 
naïve lymphocytes trafficked to secondary lymphoid tissue, whereas activated 
lymphocytes preferentially trafficked to mucosal tissue (Gowans et al 1964). The 
passage of lymphocytes from vessels into the tissues involves a series of ligand-
specific binding steps including loose tethering, firm adherence and then passage 
across the endothelium (Butcher 1991). Variations in the expression of selectins and 
integrins, triggered by activation of lymphocytes, determine which cells enter which 
tissue and facilitates a system to guide the trafficking of leucocytes (Habtezion et al 
2016). 
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a4b7 is the receptor for the human mucosal addressin cell adhesion molecule-1 
(Madcam-1) (Erle et al 1994), selectively expressed in intestinal venules (Briskin et al 
1997). It is expressed by lymphocytes that have been exposed to antigen in the gut of 
rodents and humans, the latter being demonstrated in an ingenious experiment by 
Kantele et al (1999). Subjects were exposed, orally or parenterally, to antigen. 
Lymphocytes from subjects exposed to the oral antigen showed reduced proliferation 
in response to the same antigen when the a4b7+ cells were depleted. Lymphocytes 
from subjects that had been exposed to the antigen parenterally also responded, but 
the response was unaffected by the depletion of a4b7+ cells. This supports the 
hypothesis that lymphocytes exposed to antigen in the gut enter the peripheral 
circulation and express a4b7, making this an antigen useful in the identification of 
lymphocytes activated in the gut. Clinical trials of an antibody to a4b7, Vedolizumab, 
have demonstrated some success in treating both CD and UC (Behm et al 2009; 
Cherry et al 2015). Expression of its receptor Madcam-1 is increased in CD and 
UC (Briskin et al 1997) and, interestingly, this receptor-ligand pair has a role in 
recruitment of haematopoietic stem cells into bone marrow in mice (Katayama et al 
2004). 
IBD has a number of extra-intestinal manifestations (Vavricka et al 2015) affecting the 
skin (erythema nodosum, pyoderma gangrenosum), eyes (uveitis and episcleritis) and 
mouth (apthous ulcers and periodontitis). The liver is also affected, manifesting as 
autoimmune hepatitis or primary sclerosing cholangitis (PSC). Liver invading T 
lymphocytes express the gut-specific chemokine CCL25 which promotes a4b7 binding 
to Madcam-1 on the hepatic endothelium and gut activated T cells may mediate 
PSC (Eksteen et al 2004) as well as the other extra-intestinal manifestations of 
IBD (Adams et al 2006).  
The	development	and	maintenance	of	bone	
Physical	structure	of	bone	
The structural components of bone fall into two categories: cortical and cancellous. 
Cortical bone refers to the thicker, denser, outer portion of bone which itself has three 
regions: an outer periosteal layer, an inner endosteal layer, and a layer between those 
consisting of the Haversian canal system carrying blood vessels through the cortical 
bone. Cancellous bone refers to that contained within the cortex. It consists of 
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trabeculae, a honey-comb like network of bone which forms a structure more open 
than that of cortical regions.  
Cellular	elements	of	bone	
Osteoblasts (OBs) are derived from mesenchymal stem cells under the guidance of 
specific genes (Datta et al 2008). Runt-related transcription factor 2 (Runx-2, also 
known as Cbfa1) is a key element in their development, with its absence in mice 
resulting in a phenotype with no osteoblasts (Komori et al 1997; Otto et al 1997). 
Expression of RUNX2 is promoted by bone morphogenetic proteins (BMPs) and 
wingless-ints (WNTS): genetic inactivation of the WNT b-catenin results in the 
formation of chondrocytes rather than osteoblasts (Day et al 2005), and BMP2 
increases expression of Runx-2 (Lee et al 1999; Lee et al 2003). WNTs also mediate 
the effects of LRP5, a low-density lipoprotein (Mao et al 2001). It is the locus for 
osteoporosis-pseudoglioma syndrome with low bone formation (Gong et al 2001) and 
mice lacking this gene have reduced bone formation independent of Runx2 (Kato et al 
2002). Interestingly, humans lacking the gene sclerostin (which binds to LRP5) have 
excessive bone formation which shows it is potentially able to up- and down-regulate 
osteogenesis (Lewiecki 2014). These observations highlight the importance of WNTS 
in regulating OB function (Glass et al 2007). 
Osteoblasts have three different functional phenotypes. Most commonly they are 
recognised as the cells able to form osteoid and mineralise it with hydroxapatite. They 
also go on to become osteocytes, embedded within the bone, and bone lining cells 
which cover the surface of bone. Together, these two subtypes mediate bone 
maintenance and repair. The role of OBs is to synthesise bone matrix by producing 
and mineralising an organic matrix (Florencio-Silva et al 2015). The organic matrix is 
formed from numerous proteins secreted by the osteoblasts: these include collagen 
type I, non-collagenous proteins (osteocalcin, osteonectin, bone specific protein II, and 
osteopontin), and proteoglycans. Mineralisation is initiated by matrix vesicles released 
from specific regions of the osteoblast membrane. Osteoblasts produce large amount 
of alkaline phosphatase (ALP) which converts pyrophosphate into phosphate (Yadav 
et al 2011), whilst annexins enable uptake of calcium into the matrix vesicle (Kirsch et 
al 2000). These two ions are then nucleated to form hydroxyapatite, released into the 
organic matrix when the vesicle ruptures (Florencio-Silva et al 2015) and propagating 
through it (Marotti et al 1972; Boivin et al 2002). Interestingly, whilst chondrocytes do 
not change into osteoblasts they have a capacity to mineralise during the later stages 
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of their hypertrophic phase: both mineralising and non-mineralising chondrocytes 
release vesicles, but those in mineralised cartilage have much stronger alkaline 
phosphatase (ALP) activity and annexins present in their membrane (Kirsch et al 
1997). 
Osteoclasts (OCs) are derived from the haematopoietic stem cell line (Datta et al 
2008). Whether a promyeloid precursor becomes an OC, a macrophage or a dendritic 
cell is determined by the presence of specific factors and/or receptors. It was the 
discovery of a cell surface receptor, its ligand, and an inhibitory secreted factor 
common to these cellular relatives that generated a large amount of interest in the 
development of OCs and their interactions with OBs. In a short period of time three 
research groups separately reported interactions between the ligand receptor activator 
of nuclear factor kappa β (RANKL) expressed by osteoblasts and T cells, its receptor 
on osteoclasts (RANK), and a decoy receptor (osteoprotegerin, OPG) involved in T 
cell signalling, dendritic cell (DC)/T cell signalling and the regulation of osteoclast 
development (Anderson et al 1997; Simonet et al 1997; Wong et al 1997; Lacey et al 
1998). Membrane bound and soluble RANKL is produced by OBs and, in combination 
with colony stimulating factor 1, induce human peripheral blood mononuclear cells to 
differentiate into OCs (Lacey et al 1998). OPG has the opposite effect, stopping the 
development of OCs from spleen cells and protecting ovariectomised rats against bone 
loss (Simonet et al 1997). 
The sequence of cellular events by which OCs resorb bone has been termed the 
resorption cycle (Vaananen et al 2000). OCs migrate to a specific area of bone where 
their plasma membrane becomes tightly attached forming a sealed-off zone. Within 
this sealing zone projections extend from the OC into the bone, forming the ruffled 
border, and acidic vesicles release hydrochloric acid which dissolves the 
hydroxyapatite. Proteolytic enzymes, including matrix metalloproteinases, are then 
able to cleave collagen. The released elements are then taken up and released 
through the functional secretory domain at the opposite surface of the cell, into the 
extra-cellular space. 
Whilst initial ossification of bone is primarily mediated by OBs, after chondrocytes have 
built the cartilage skeleton, the processes of modelling and remodelling guide 
respectively the overall shape and maintenance of bone (Langdahl et al 2016). The 
RANKL system is involved in both these processes (Boyce et al 2008), but it is not the 
  Page	15	
only factor and separation of these two cell types by time and location means additional 
processes are required (Sims et al 2015). 
Bone	development	
Bone develops by endochondral ossification (EO) and intramembranous ossification 
(IO). EO is the primary process by which bones of the appendicular skeleton (made up 
of long bones) and the axial skeleton (including vertebrae) develop 
longitudinally (Cadet et al 2003), with chondrocytes forming an initial cartilage skeleton 
which is subsequently mineralised by osteoblasts. IO is the process by which sesamoid 
bones e.g. the patellar, and the craniofacial (or dermal) bones grow. It is also how 
cortical bone develops on the outer periosteal layer of bone throughout the skeleton, 
producing radial growth of long bones and vertebrae. IO does not involve a cartilage 
skeleton and ossification occurs directly from condensations of pre-osteogenic 
mesenchymal cells (Percival et al 2013), although a cartilage phase has been identified 
in some bones (Nah et al 2000; Abzhanov et al 2007). This section will focus on EO 
rather than IO as it is the predominant ossification process in long bones and 
vertebrae. 
The	cartilage	skeleton	
Undifferentiated mesenchymal stem cells (MSCs) reside in a region of the growth plate 
known as the resting zone (van der Eerden et al 2003), formed from a condensation 
that develops early in fetal development (Hall et al 2000). The MSCs move out of this 
resting zone and differentiate into chondrocytes which proliferate and secrete an 
extracellular matrix (ECM). The ECM produced at this stage consists of type II 
collagen, and other proteins including aggrecan (a proteoglycan) and hyaluronan (a 
glycosaminoglycan) (Heinegard 2009). These combine with other proteins in the ECM 
to provide the growth plate with stability. As the chondrocytes mature they stop 
proliferating, start to hypertrophy and change their secretory profile (Mackie et al 2011). 
In the early stages of hypertrophy chondrocytes start to secrete collagen type X, rather 
than type II (Karsenty et al 2002), and matrix metalloproteinases which remodel the 
ECM (van der Eerden et al 2003). This remodelling helps form the cartilage skeleton 
and facilitates angiogenesis which is necessary for mineralisation (Blumer et al 2008). 
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Figure 1-4 Overview of development of a bone by endochondral ossification. (A) The cartilage model of 
the future bone.(B) A periosteal bone collar has formed and formation of the primary centre of ossification 
has been initiated. (C) The primary centre of ossification is starting to expand towards the ends of the 
cartilage model. (D) The secondary centres of ossification have formed at each end of the bone, leaving 
a cartilaginous growth plate between primary and secondary centres of ossification. (E) Skeletal maturity 
has been achieved, with complete replacement of the growth plate cartilage by bone. The only cartilage 
remaining is the articular cartilage at the ends of the bone. Reproduced with permission (Mackie et al 
2011). 
Mineralisation	
Ossification centres are the regions where osteoblasts mineralise the cartilage 
skeleton converting it into mature bone. Primary ossification centres can be seen in 
the mid-shaft of human fetal long bones from 9 completed weeks of gestation (Bagnall 
et al 1982). Secondary centres can be seen in the distal femoral epiphyses as early as 
29 weeks, although most appear around 35 weeks (Pryse-Davies et al 1974). Their 
development is dependent on a blood supply (Colnot et al 2004). 
Cartilage is avascular, and whilst that is thought to be true of the growth plate 
investigators have identified blood vessels supplying it (Tonna 1961; Wirth et al 2002). 
Although these vessels are dismissed as a transient phenomenon, it is accepted that 
as chondrocytes proliferate and move away from the resting zone they become 
increasingly hypoxic. This increases expression of HIF-1a, a member of the hypoxia 
induced factor gene family (Robins et al 2005). HIF-1a has a role in ensuring 
chondrocytes produce the cartilage skeleton, with its deletion resulting in abnormal 
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cartilage formation in-vivo and in-vitro (Amarilio et al 2007), but is also necessary for 
angiogenesis (Maes et al 2012). 
A number of studies demonstrate that angiogenesis is necessary for mineralisation. 
Sections of cartilage skeleton, explanted into renal tissue to provide a de-novo blood 
supply, have shown that ossification is dependent on vascular invasion (Colnot et al 
2004). Vascular endothelial growth factor (VEGF), an important mediator of 
angiogenesis, has been shown as necessary for both formation of ossification 
centres (Maes et al 2002) and trabecular bone (Gerber et al 1999). The growth of blood 
vessels, arising from the perichondrium and invading the cartilage, deliver pre-
osteoblasts which produce the mature skeleton (Colnot et al 2004; Maes et al 2010). 
When there is a lack of differentiated osteoblasts (OBs), as seen in the Cbfa1 gene 
knockout mouse, a cartilage skeleton forms but does not mineralise (Komori et al 1997; 
Otto et al 1997). 
Bone	modelling	
Modelling alters the overall shape of the bone with OCs resorbing bone on the 
endosteal surface whilst OBs lay down new bone on the periosteal surface (Clarke 
2008; Baron et al 2013). This physical separation (see Figure 1-5) may explain why 
their activities are not considered coupled as they are in the process of remodelling. 
However, there has been less investigation of modelling, and this may in part reflect a 
misconception that it only occurred during childhood. Adults who take up tennis after 
the age of 25, when modelling was thought to have stopped, still show evidence of 
changes in bone shape (Kontulainen et al 2003). Interestingly, the continuation of 
appositional growth into adulthood had already been noted in bone from autopsy 
subjects decades ago (Epker et al 1966). There is also evidence that modelling occurs 
within the cancellous portion of bone, altering trabecular structure in the iliac crest of 
adults (Kobayashi et al 2003). It may be disruptions to this system that explain changes 
in the bone structure of those affected by IBD, only seen with pQCT and bone biopsy 
but not DXA (Burnham et al 2007; Dubner et al 2009; Ward et al 2010). 
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Figure 1-5 Bone modelling and remodelling. On the left is modelling with osteoclasts and osteoblasts on 
separate bone surfaces, on the right is remodelling with both cell types on the same bone surface. 
Reproduced with permission (Baron et al 2013). 
Bone	remodelling	
Remodelling is the process by which the body maintains the quality of bone and 
responds to mechanical stress. It is primarily mediated by osteoblasts (OBs) and 
osteoclasts (OCs), acting within the basic multicellular unit (BMU). In remodelling, 
unlike modelling, the actions of OCs and OBs are linked as the two cell types form the 
basic multicellular unit (Sims et al 2008), although the observation that during 
childhood bone mass increases and then steadily declines in adulthood (Lips et al 
1978) shows that their actions are not necessarily balanced over time. However, in an 
elegant study by Eriksen et al, the chronology of resorption and formation were 
mapped out in healthy individuals (Eriksen et al 1984a; Eriksen et al 1984b). They 
showed that there was an initial resorptive phase of 8 days with increased numbers of 
OCs, and a formation phase of over 135 days when OBs dominate. As can be seen in 
Figure 1-6 these two phases are temporally distinct and separated by a “mononuclear 
phase” with an influx of mononuclear cells. These are thought to be haematopoietic in 
origin and are present at a period when pre-osteoblasts start to appear.  
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Figure 1-6 Smoothed curves showing the total remodelling period derived from resorption and formation 
curves. The remodelling period is subdivided into osteoclastic resorption phase (I, 8 days), mononuclear 
resorption phase (II, 36 days), pre-osteoblastic phase (Ill, 9 days), initial mineralization lag time (IV, 15 
days), and mineralization phase (V, 130 days). Reproduced with permission (Eriksen et al 1984a). 
OBs and osteocytes, through RANKL and OPG, start the process of remodelling by 
initiating the development of OCs and stimulating their resorptive activity (Pivonka et 
al 2008). Osteocytes seem able to detect mechanical loading and the development of 
damage, and their apoptosis triggers site specific resorption by OCs (Verborgt et al 
2002; Noble et al 2003; Mann et al 2006). Osteocytes may trigger the release of OC 
precursors from the bone marrow via processes reaching into it (Kamioka et al 2001). 
Chemoattractants such as osteocalcin and collagen fragments, released from the 
bone, also mobilise OC precursors (Malone 1982). Bone lining cells, covering the bone 
surface, release collagenase which exposes the mineralised matrix (Hauge et al 2001). 
The BMU, when initiated, develops a blood supply (Michael Parfitt 2006). This certainly 
delivers OCs, and possibly also OBs (Eriksen et al 2006; Sacchetti et al 2007). OCs 
then trigger bone formation by OBs. There is a reversal phase mediated by 
mononuclear phagocytes, and the release of growth factors - insulin like growth factor, 
fibroblast growth factor, transforming growth factor b and bone morphogenic 
proteins (Sims et al 2008). However, bone formation by OBs can be triggered by the 
presence of pits alone (Gray et al 1996; Dalby et al 2006). 
Bone	turnover	
OBs and OCs overall activity can be quantified by measuring bone turnover markers, 
substances released by the cells into the blood stream. In adults, where remodelling 
is the predominant process, their measurement can predict risk of reduced bone 
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mineral density and fracture. In children bone development and modelling is greater 
but, whilst in neither of these the actions of OBs and OCs are linked, measurement of 
bone turnover does have a role in assessing bone health (Rauchenzauner et al 2007).  
Osteoclasts	
Collagen, one of the main constituents of bone, has hydroxypyridium crosslinks. One 
of these, called deoxypyridinoline (DPD), bridges several collagen peptides to provide 
additional stability. When bone is resorbed, DPD is released into the circulation and 
the urine (Seibel 2000). Serum levels of DPD have been shown to correlate well with 
bone resorption (Eastell et al 1997). 
Crosslinking is necessary for the formation of collagen and involves specific molecular 
regions, one of which is the carboxy-terminal telopeptide (Seibel 2000). Measurement 
of the carboxy-terminal telopeptide of type I collagen in urine, released when bone is 
resorbed, has been found to correlate with other markers of bone resorption (Gorai et 
al 1997). 
Osteoblasts	
Osteocalcin (also known as bone-gla-protein) is a marker of osteoblast activity which 
is expressed late in the differentiation of osteoblasts (Stein et al 1990). It is secreted 
by osteoblasts to form bone, but is also secreted into the circulation (Ingram et al 
1994). Osteocalcin is considered a useful clinical marker of bone formation (Neve et 
al 2013).  
In bone, collagen is synthesised by osteoblasts in the form of pre-collagen. These 
molecules can be identified by the presence of a specific amino-terminal propeptide – 
PINP (Merry et al 1976). Measurement of PINP in the serum correlates with other bone 
formation markers, and the value of these measurements has increased with the 
introduction of newer assays which demonstrate a better correlation with bone 
formation (Seibel 2000). 
Alkaline phosphatase (ALP) is a ubiquitous enzyme in the human body which is found 
in a range of different cell types. Although its precise function is not clear (Harris 1990), 
its absence is associated with abnormal bone development. ALP has been shown to 
be an effective marker of bone formation (van Straalen et al 1991). 
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Bone	health	in	inflammatory	bowel	disease	
Growth	
At diagnosis, children with Crohn’s disease (CD) have significant reductions in their 
height, with disease severity seemingly the primary determining factor (Griffiths et al 
1993; Hildebrand et al 1994). This is typically ascribed to problems with malnutrition, 
and may explain why targeted enteral nutrition improves growth (Morin et al 1980; 
Kirschner et al 1981; Belli et al 1988). An additional mechanism is the effect of the 
immune response. In a mouse model of IBD lower growth was seen with increased IL-
6 and reduced IGF-1, and administration of IGF-1 improved growth (Ballinger et al 
2000). It is estimated that inflammation explains 30-40% of growth failure. TNF-a may 
also affect growth of the cartilage skeleton by inhibiting the differentiation of 
chondrocytes, as seen in studies using rodent chondrocytes. Supporting this is the 
observation that Infliximab, a monoclonal antibody to TNF-a, improves growth (Walters 
et al 2007); although this effect may be due to a reduction in inflammatory cytokines 
and/or improving absorption of nutrients which would occur with disease remission. 
Corticosteroids have a negative effect on linear growth, but when used in the treatment 
of CD growth does improve (Griffiths et al 1993; Hildebrand et al 1994). This indicates 
that any negative effect of steroids may be outweighed by improvements in nutrient 
absorption and reductions in inflammation. Thus, whilst final adult height is reduced 
not all studies show a significant reduction (Alemzadeh et al 2002; Herzog et al 2014). 
Perhaps ameliorating the slowing of growth is a delay in puberty, giving greater time 
for growth (Hildebrand et al 1994).  
However, as was discussed previously, growth and mineralisation are distinct 
processes. The final common pathway for deficits on growth is the impact of the 
disease on the growth plate (Ballinger et al 2001). Mineralisation, and bone mineral 
density, is mediated by the action of osteoblasts. Whilst chondrocytes influence 
mineralisation there are other biological pathways which could have greater effect. For 
example, whilst IL-6 may inhibit chondrocytes which in turn reduces mineralisation by 
OBs, the direct effect of IL-6 on osteoblasts may have a far greater effect. 
Bone	mineral	density	
Low bone mineral density in IBD is well described in the literature, and the aim of this 
thesis is to better understand why it occurs. Assessment of bone mineral density 
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(BMD) in clinical care has been made possible by the development of dual X-ray 
absorptiometry (DXA). Meaningful interpretation of measurements requires an 
understanding of the techniques and terminology used.  
DXA is well established as a non-invasive method for measuring the mineral density 
of bone in adults. It calculates the bone mineral density (BMD) based on attenuation 
of a beam of low dose radiation. As with standard X-rays bones can be identified as 
areas that are distinct from the surrounding soft tissues (see Figure 1-7). The 
absorption in those areas is measured and the bone mineral content (BMC) calculated. 
BMC is then expressed as g/cm2 (areal bone mineral density, aBMD) by dividing the 
BMC by the projected area of the bone. Studies using cadavers have established the 
relationship between absorption of X-rays and BMC, with absorption being greater in 
more mineralised bone (Ho et al 1990; Edmondston et al 1993). 
	
Figure 1-7 Example images of DXA. The left panel shows a whole-body image with the skeleton visible, 
the right panel shows a higher magnification view of the lumbar spine with image recognition software 
identifying individual bones. 
In adults BMD is reported as a T-score which reflects the number of standard 
deviations from the mean of a reference population of young, healthy adults. The WHO 
identifies an individual as having osteoporosis when their BMD T-score is greater than 
2.5 standard deviations (SDs) below the mean (Kanis 2002), a value associated with 
an increased risk of fracture (Marshall et al 1996). In children, the measurement of 
BMD by DXA is more complicated. DXA uses a 2-dimensional image of 3-dimensional 
structure and, even if they have the same BMC, a smaller bone will have an apparently 
lower BMD (Binkovitz et al 2008). Also, during puberty, regional growth of bones differs 
in boys and girls (Bass et al 1999; Bradney et al 2000). This means SDs must be 
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adjusted for age and sex, in which case they are referred to as z-scores (Gafni et al 
2004). 
Studies in adults with IBD have found reduced BMD (Schulte et al 1998; Ardizzone et 
al 2000; Schoon et al 2000; Jahnsen et al 2004; Leslie et al 2008). In CD 36% to 55% 
of patients are osteopaenic, and 7% to 50% are osteoporotic. In UC 32% to 67% of 
patients are osteopaenic and 7% to 18% are osteoporotic. These findings have been 
confirmed in case controlled studies, although some find no difference between CD 
and UC (Silvennoinen et al 1995; Lamb et al 2002) whilst one a reduction in only 
CD (Jahnsen et al 1997). Fracture risk can be increased by as much as 40% (Bernstein 
et al 2000). This was not confirmed in a similar study (Loftus et al 2002), but screening 
often identifies asymptomatic fractures (Klaus et al 2002; Stockbrugger et al 2002) and 
the incidence of fracture may be underestimated. 
Case reports describe severe bone disease and fractures in children with CD (Semeao 
et al 1997; Thearle et al 2000) and UC (Lucarelli et al 2006), but population studies 
find that fracture rates in children with CD are not increased (Persad et al 2006; 
Kappelman et al 2011). Studies utilising DXA have shown reductions in BMD in 
children with IBD but problems with methodology and definitions bring their findings 
into question.  
Semeao et al (1999) measured lumbar spine BMD Z-scores in patients 5 to 25 years 
of age with Crohn’s disease and found that 70% were osteopenic and 38% 
osteoporotic, but there are two problems with this study. Definitions were based on Z-
scores (adjusting for age and sex only) of less than -1 for osteopenia and less than -2 
for osteoporosis and The International Society for Clinical Densitometry (ISCD) now 
state that these diagnoses can no longer be made based on DXA alone (Kalkwarf et 
al 2014). Semeao et al (1999) also found that “BMD increased with age” despite 
correcting for bone age which could have occurred because they didn’t account for 
changes in bone size. Because of the way DXA measures BMD as a bone’s size 
increases, even if the true mineral density remains unchanged, the apparent BMD will 
be greater (Binkovitz et al 2008). This problem has been demonstrated in clinical 
studies. Ahmed et al (2004) measured lumbar and total body BMD in children with CD 
and UC. Results were compared to a reference database which included bone 
area (van der Sluis et al 2002). Ahmed et al (2004) found the adjustment for bone area 
(a measure of bone size) reduced rates of osteopenia from 65% to 22%, and 
osteoporosis from 45% to 4%. Walther et al (2006) also found lower rates of 
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osteoporosis and osteopenia (40% and 13% respectively) when they used they used 
an established method, recommended by Kroger et al (1992), to adjust BMD for bone 
size. Also, when measuring BMD by DXA, greater amounts of muscle and fat will 
increase absorption of X-rays and, hence, the apparent BMD (Bolotin 2007). A study 
by Burnham et al (2004) measured total body BMC and found a 26% reduction in 
patients with CD, but this difference disappeared when adjusted for lean body 
mass (Burnham et al 2004). 
Given these findings and their methodological difficulties it is difficult to be sure that 
the BMD of children with IBD, other than in a few individual patients, is reduced. 
Another way of measuring BMD is peripheral quantitative computed tomography 
(pQCT). The advantage of this is that it provides an image of the bone structure which 
is unaffected by surrounding tissues, and can measure independently the proportion 
of cortical (outer) and trabecular (inner) bone, unlike the composite absorption image 
of a DXA (see Figure 1-8). This modality has shown reductions in BMD in children with 
newly diagnosed CD compared to that of healthy age, sex- and race-matched 
children (Dubner et al 2009). They found that the tibial trabecular volumetric BMD in 
children with CD was, on average, on the 10th percentile. They also found an increase 
in the endosteal dimensions and a marginal reduction in the periosteal surface, which 
reflects a thinning of the outer cortical bone and in previous studies was associated 
with greater bone fragility. These findings are supported by a study describing bone 
biopsies taken from children newly diagnosed with IBD, although they found only 
reductions in cortical bone width of 23% with no reduction in trabecular bone (Ward et 
al 2010). Also, it may be that the overall shape of the bone is affected, given the 
observation of changes in proximal femur geometry in children with IBD (Burnham et 
al 2007). 
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Figure 1-8 Dimensional reconstruction of bone imaged by pQCT. The image shows that this modality 
enables assessment of both bone volume and its mineral density. Open access article (Cheung et al 
2013). 
Therefore, whilst bone does appear to be affected in children with IBD, both in terms 
of mineralisation and structure, this has not been shown to affect short term fracture 
risk. However, childhood is an important time for bone mineral accrual and 
development of peak bone mass (Bailey 1997). The observation that children with IBD 
do not achieve their full height (Sawczenko et al 2006) and have a compromised peak 
bone mass (Laakso et al 2014) may explain the finding of juvenile onset of CD being 
associated with lower BMD in later life (Mauro et al 2007) and, potentially, an increased 
risk of fracture. 
Bone	turnover	
Bone turnover (or bone metabolism) refers to the process of resorption and formation, 
and bone turnover markers are elements released into the blood which reflect the rate 
at which these two processes are occurring (Seibel 2000). Greater bone formation 
would be expected in children who are growing. In adults, whose BMD reduces with 
age, greater bone resorption would be expected. However, both formation and 
resorption markers are higher in children (Rauchenzauner et al 2007) indicating higher 
overall bone metabolism. Their measurement in patients with IBD, either monitoring 
changes over time or compared with appropriate controls, show that affected 
individuals have changes in the activity of osteoblasts and osteoclasts and that pattern 
of change is different in adults and children. 
A study recruited 34 adult patients newly diagnosed with IBD over a one year period 
and measured their BMD by DXA and the bone turnover markers deoxypyridinoline (a 
measure of osteoclast activity) and osteocalcin (a measure of osteoblast 
activity) (Lamb et al 2002). They found significant reductions in BMD when compared 
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to controls with irritable bowel syndrome, no difference in levels of osteocalcin (8.6 vs 
7.7µg/L; p = 0.6105), but a significant increase in urinary deoxypyridinoline (7.66 vs 
5.70nmol/mmol creatinine; p = 0.0163). This suggests that increased bone resorption 
was the cause of their lower BMD. 
Dresner-Pollak et al (2000) measured serum osteocalcin, bone-specific alkaline 
phosphatase (a measure of osteoblast activity), urinary NTx (a measure of osteoclast 
activity) and BMD by DXA in 36 patients with IBD. There was no control group and 
measurements of bone turnover markers were related to changes in BMD over a 24-
month period. It was found that initial urinary NTx levels were inversely correlated with 
changes in BMD, although only at the lumbar spine and not at the femoral neck. 
Patients with a urinary NTx in the highest quartile exhibited the lowest increase in spine 
BMD. No correlations between BMD and serum levels of osteocalcin or bone-specific 
alkaline phosphatase were observed. This shows that increases in urinary N-
telopeptide crosslinked type 1 collagen (NTx, a marker of osteoclast activity) can 
predict low BMD in adult patients with IBD. 
Of note, the treatment of CD patients with infliximab has been shown to reduce levels 
of urinary NTx, and increase the levels of the bone formation markers bone-specific 
ALP, osteocalcin and pro-collagen type 1 N-terminal propeptide (P1NP). Franchimont 
et al (2004) recruited 71 patients with CD who were treated for the first time with 
infliximab over a six-week period. Prior to treatment, bone turnover markers indicated 
an increase in resorption and a decrease in bone formation compared to controls. After 
treatment, levels of bone turnover markers normalised, with all the individual markers 
being significantly different.  
Although these findings suggest that bone resorption is the primary driver of bone loss 
in adults with IBD, bone biopsies of patients with IBD found primarily a reduction in 
bone formation (Croucher et al 1993). However, the authors acknowledge that the 
assessment of resorption is less clear than that of formation, and does not necessarily 
reflect the balance of bone turnover. The measurement of bone turnover in adults can 
be used to predict fracture risk independently of actual BMD (Garnero 2000; Kitatani 
et al 2003). 
In children with IBD the pattern of change in bone turnover markers is different. 
Sylvester et al (2006) measured bone turnover markers in paediatric patients that were 
newly diagnosed with CD before being started on steroids. The findings demonstrated 
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that although markers of bone resorption were no different from controls, markers of 
bone formation were significantly reduced (see Table 1-2). In a follow up study, these 
markers improved with treatment (Sylvester et al 2007). Whitten et al (2010) also found 
reductions in ALP, but these weren’t significant whilst an increase in bone resorption 
markers was. The authors point to the work of Sylvester et al (2006) having more peri-
pubertal children, a period of life when bone turnover markers change (Cadogan et al 
1998) which may explain the differences. 
These data suggest that bone formation is reduced in paediatric CD. This is different 
to the findings in adults with IBD who predominantly exhibit an increase in bone 
resorption. Sylvester et al (2006) also found that the reduction in bone formation 
markers positively correlated with levels of the pro-inflammatory cytokine interferon 
gamma (IFN-g). Based on this they suggest that activated T cells might mediate the 
reduction. Although this is a reasonable proposition, it could be argued that levels of 
IFN-g are a simplistic measure of what is a complex, predominantly cell-mediated, 
process. 
	
Table 1-2 Changes in bone turnover markers in children newly diagnosed with Crohn’s disease. The 
table presents data published by Sylvester et al (2006). 
Does	the	immune	system	cause	low	BMD	in	IBD?	
Whilst the magnitude of the problem and the risk of fracture is difficult to quantify, 
especially so in children, the body of evidence presented above shows that IBD has a 
negative impact on bone metabolism. Understanding why this occurs is important in 
managing the condition. 
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Disease severity and/or duration have been identified as risk factors for low BMD (de 
Jong et al 2003; Sylvester et al 2006; van Hogezand et al 2006; Paganelli et al 2007; 
Sylvester et al 2007; Lopes et al 2008), although this is not a universal finding (Bartram 
et al 2006; Pappa et al 2006). There is also improvement in BMD with 
treatment (Franchimont et al 2004; Dubner et al 2009). However, whilst this association 
would be consistent with prolonged exposure of the bone to pro-inflammatory 
cytokines and cells affecting bone metabolism, other possible explanations need to be 
considered. 
Those with more severe disease also have greater problems with nutrition, and this 
has been suggested as a cause of reduced BMD (Dubner et al 2009; Abraham et al 
2014). One mechanism is a reduction in calcium and vitamin D, but studies have not 
supported this. Calcium and parathyroid hormone levels in patients with IBD are 
normal (Leslie et al 2008; Abraham et al 2014), calcium intake does not correlate with 
BMD (Lopes et al 2008), and supplementation does not improve BMD (van 
Bodegraven et al 2014) even when combined with vitamin D (Bernstein et al 1996; 
Benchimol et al 2007) or calcitonin (Pappa et al 2011). Vitamin D levels are reduced 
in those with IBD (Leslie et al 2008; Abraham et al 2014) but do not correlate with low 
BMD (Silvennoinen 1996; Silvennoinen et al 1996; Jahnsen et al 2002; Sentongo et al 
2002; Pappa et al 2006). Reductions in body mass index (BMI), reflecting nutritional 
status, are associated with reductions in BMD (Siffledeen et al 2004; Bartram et al 
2006; Sylvester et al 2007; Cohran et al 2008; Lopes et al 2008). But it may be that 
the reasons for this association are factors such as patients with less fat and lean 
tissue absorbing less of the DXA machines X-rays reducing the apparent BMD, as was 
discussed in the earlier section. 
Those with more severe disease also use more steroids, and in children their use has 
been shown to increase the risk of fracture (van Staa et al 2003). Low BMD in IBD is 
often ascribed to the use of steroids, and a range of studies in adults (Silvennoinen et 
al 1995; Jahnsen et al 2004; Siffledeen et al 2004; Bartram et al 2006; van Hogezand 
et al 2006; Abraham et al 2014) and children (Lopes et al 2008; Ward et al 2010; 
Laakso et al 2014) support this. But other studies do not find steroid use to be 
associated with reductions in BMD (Bartram et al 2006; Pappa et al 2006; Walther et 
al 2006; Paganelli et al 2007; Sylvester et al 2007). In fact, low BMD is often present 
at diagnosis patients with IBD (Ghosh et al 1994; Habtezion et al 2002; Lamb et al 
2002; Gupta et al 2004; Harpavat et al 2005; Walther et al 2006) preceding use of 
steroids and in some cases improving with treatment (Dubner et al 2009). A 
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comparison of the effects of steroids in children with IBD and nephrotic syndrome (an 
immune mediated condition in which the kidneys leak substantial amounts of protein) 
found that despite equivalent steroid doses the impact on BMD was greater in the IBD 
group (Leonard et al 2004) and it also affected geometry (Burnham et al 2007), which 
may be modulated by IL-6 (Kriel et al 2010). Therefore, whilst steroids appear to affect 
BMD via an effect on bone shape, steroids do not completely explain the finding of low 
BMD in IBD.  
Osteoimmunology	–	when	the	immune	system	talks	to	the	bone	
Osteoimmunology refers to interactions between the immune system and bone. As the 
clinical studies presented above imply, in IBD and other inflammatory disorders the 
immune dysregulation appears to be associated with low BMD. However, causation 
cannot be assumed to be due to a number of potential factors affecting BMD in IDB 
patients. What the clinical data does indicate is that whilst in adults there is an increase 
in osteoclast mediated bone resorption, in children there is a reduction in osteoblast 
mediated bone formation. The findings discussed below describe the published 
literature in relation to laboratory based studies which have examined the effects of 
the immune system on bone. 
Effect	of	soluble	elements	
An investigation as to whether humoral factors mediate low BMD in IBD was 
undertaken by Hyams et al (1997). Fetal rat parietal bones were cultured in serum from 
healthy paediatric controls, and paediatric patients with CD and UC. Incubation in CD 
serum resulted in a lower dry weight and calcium content, altered bone 
histomorphometry as exhibited by a disorganised mineral and osteoid, and distended 
and misshapen osteoblasts (see Figure 1-9). This effect was subsequently found to be 
reduced by the presence of IL-6 blocking agents (Sylvester et al 2002). The same 
group also looked at the effects of serum from patients with CD on rat osteoblast 
cultures, rather than whole bone. They found that whilst nodule formation and protein 
expression was reduced, proliferation and viability were unaffected. Blocking of IL-6 
did not alter the observed effects (Varghese et al 2002). These findings highlight the 
complex interactions between humoral elements of the immune system and bone 
metabolism, also found when looking at the effect of individual cytokines. 
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Figure 1-9: Light micrographs showing the effect of soluble immune factors on bone. Fetal rat parietal 
bones were treated with a 1:100 dilution of serum from a control patient (A) and patients with ulcerative 
colitis (B) and Crohn's disease (C). In A, the mineralised matrix (M) is covered with a thin layer of osteoid 
(arrow), which is covered by a thick layer of flattened osteoblasts (ob) and preosteoblasts. In B, no osteoid 
is apparent and a thick, darkly stained layer of matrix (arrow) covers the mineralised bone (M). The 
osteoblast layer (ob) is not as compact, and the osteoblasts are ovoid in shape. In C, little mineralised 
matrix (M) is found and it is uneven. Osteoid (arrows) is prevalent, and the osteoblasts (ob) are misshapen 
and plump with little organisation. Reproduced with permission (Hyams 1997). 
TNF-a	
Tumour necrosis factor-a (TNF-a) is a member of the TNF superfamily of 19 ligands 
and 29 receptors (Aggarwal et al 2012). This family has diverse roles within 
mammalian bodies with their pro-inflammatory actions mediated, at least in part, by 
activation of the transcription factor nuclear factor-kB. TNF-a was first isolated from 
the conditioned supernatants of human promyelomonocytic cell line HL-60. Whilst it 
has a role in the proliferation of B-cells it has also been implicated in a range of 
diseases and the effects of this pro-inflammatory cytokine on bone are well 
established.  
TNF-a has been shown to inhibits the differentiation of rat calvarial osteoblasts and 
their production of mineralised nodules (Gilbert et al 2000). This has also been seen 
with murine OBs and is mediated by the p55, or type 1, receptor through inhibition of 
Cbfa1 DNA binding (Abbas et al 2003). Cbfa1, also known as Runx-2, is a key 
osteoblast differentiation factor. The p55 pathway has a role in apoptosis but a further 
study on OBs, from p55 knockout mice, confirms whilst the receptor is necessary to 
mediate the reductions in differentiation there was no evidence of apoptosis (Gilbert et 
al 2005). 
During the life of an osteoblast the response to TNF-a can change. The response of 
murine mesenchymal stem cells (MSCs) and mature OBs to TNF-a were 
compared (Sidney et al 2014). MSCs seemed unaffected with no reduction in nodule 
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formation or alkaline phosphatase activity, and there was no impact on their viability. 
Primary OBs became less viable, and their ALP activity and nodule formation were 
reduced. This highlights that observations in MSCs cannot simply be applied to primary 
OBs. This principle may help explain why in human MSCs TNF-a inhibits the Runx-2 
pathway, as seen with murine OBs, whilst ALP activity and mineralisation were 
increased (Ding et al 2009). 
Whilst the effects of TNF-a on OBs is variable it consistently increases OC activity and 
bone resorption. Human peripheral blood mononuclear cells incubated with 
macrophage colony stimulating factor (M-CSF) form OCs after 10 days, and in the 
presence of TNF-a there were greater numbers of OCs (Kudo et al 2002). This was 
independent of the RANKL pathway as the addition of OPG did not affect numbers. 
There was also more resorption which could be due to greater OC number and/or OC 
activity. The blocking of TNF-a reduced both the number of OCs and resorption whilst 
the blocking of IL1a reduced resorption but not OC number suggesting that TNF-a 
primarily affect OC number with greater resorption activity requiring IL1a. 
IL-17	
The DNA signature for IL-17 was identified in 1993 with the identification of its role in 
inflammation recognised shortly after (Zenobia et al 2015). Ten years later it was 
shown to be produced by a developmentally distinct subset of CD4+ helper cells, now 
known as Th17 cells. They have since been shown to have roles in a range of 
inflammatory disorders but also in protective antimicrobial immunity. 
Rat calvarial cells showed reduced bone formation in the presence of IL-17 with 
reductions in ALP, nodule formation, and expression of the osteogenesis related genes 
osteocalcin and osterix (Kim et al 2014). The healing of defects created in the calvaria 
was also inhibited by the presence of IL-17. In contrast to these findings IL-17 
increases the osteogenic capacity of human MSCs (Huang et al 2009) through 
increasing proliferation and subsequent differentiation into OBs expressing ALP (rather 
than chondrocytes or adipocytes). There was also increased expression of genes for 
ALP and Runx2. 
A co-culture system of mouse haematopoietic cells and primary OBs was used to 
investigate the effects of IL-17 (Kotake et al 1999). The presence of IL-17 increased 
formation of OCs and dentine resorption showing its potential to reduce bone mineral 
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density. IL-17 also increased expression of the gene for osteoclast differentiation factor 
(ODF, or RANKL), found on the membrane of OBs and necessary for OC formation: 
separation of OBs from haematopoietic cells by a transwell insert and the presence of 
a soluble decoy receptor for ODF both reduced IL-17 induced OC formation.  
In a study using bone explants from human patients with rheumatoid arthritis the 
blocking of either TNF-a or IL-17 inhibited production of IL-6 and reduced production 
of c-terminal peptide (CTX), produced by the breakdown of type 1 collagen, indicating 
reduced bone resorption (Chabaud et al 2001). However, there was significant 
variation in the eight patient sample responses. Inhibition in the presence of either 
TNF-a and IL-17 was only 50% for IL-6 in 25% of samples and for CTX in only 38% of 
samples. This may explain why combined blockade of both TNF-a and IL-17 increased 
inhibition overall and indicate that, despite having the same clinical phenotype, the 
underlying immune process may differ between patients.  
IFN-g	
The interferons (IFNs) were first identified as cytokines able to interfere with viral 
replication (Schroder et al 2004).  IFN-g is the only type II IFN and is produced by a 
range of cell types, including T cells, B cells and natural killer cells. It was originally 
called macrophage activating factor and triggers anti-tumour effects, orchestrates 
leucocyte attraction, and regulates B cell function. 
IFN-g null mice have been shown to have a 45% reduction in bone volume compared 
to controls (Duque et al 2011). There were reductions in Runx-2 and osteopontin (an 
acidic phosphoprotein produced by OBs with a role in bone formation) gene 
expression, the mineral apposition rate, and OC number, indicating reduced bone 
formation rather than increased resorption.  
However, reflecting the complexity of immune pathways, IFN-g can indirectly increase 
OC number. A different group isolated OC precursors from the same IFN-g null mouse 
and incubated them in culture media from T-cells activated by antigen presenting cells 
from wild type mice (Gao et al 2007). The addition of IFN-g to this system, in which OC 
precursors won’t respond to IFN-g resulted in a threefold increase in OC number. They 
go on to look at the effects of IFN-g on resorption in T-cell deficient mice in whom it 
had no effect on resorption, and bone-loss mouse models in whom it did increase 
  Page	33	
resorption. This suggests that the pro- and anti-osteoclastogenic effects of IFN-g on 
bone resorption are altered by underlying disease processes. 
The effects of IFN-g on OBs is also complex. In a study using cultured human OB-like 
cells IFN-g decreased proliferation but increased ALP activity and production of 
osteocalcin (Gowen et al 1988). TNF-a had the reverse effect with greater proliferation 
but reduced ALP activity and osteocalcin production. Also, whilst using a combination 
of IFN-g and TNF-a, there are differences in the response of MSCs and OBs (Sidney 
et al 2014). MSCs show a limited reduction in nodule formation but no reduction in ALP 
activity or viability whilst OBs are significantly reduced in all three aspects. 
IL-4	and	IL-13	
IL-4 is considered an anti-inflammatory cytokine produced by Th2 cells and has been 
shown to suppress the production of IFN-g by mononuclear cells (Peleman et al 1989). 
It is closely related to IL-13 the genes for both being found on chromosome 5 of mice, 
and shares receptor components (Hilton et al 1996). IL-13 inhibits inflammatory 
cytokine production by human monocytes (Minty et al 1993) and regulates B cell 
function by inducing production of IgM and IgG (McKenzie et al 1993). Therefore, whilst 
in direct comparison they have differing effects on T cell function, unlike the other 
cytokines discussed in this section they are considered anti-inflammatory (Minty et al 
1997). 
Mice overexpressing IL-4 show reduced bone formation (Lewis et al 1993) with 
development of a kyphosis and showing reductions in cortical thickness, trabecular 
mass and bone strength. Reductions in ALP, osteocalcin and OB number were seen; 
as were reductions in tartrate resistant acid phosphatase (TRAP, a marker of OC 
activity). Cortical bone mass is also reduced by a lack of IL-4 (Silfversward et al 2007). 
Compared to wild type mice, IL-13 knockout mice had normal bone structure whilst 
male IL-4/IL-13 knockout mice did not. 
In a single cell culture system IL-13 can potentially effect OBs, but is less potent than 
IL-4 (Frost et al 2001). Both reduced OB proliferation whilst increasing ALP activity, IL-
4 doing so at much lower doses. They also increased expression of IL-6. Other studies 
have shown that IL-4 suppresses the formation of OCs from monocytes incubated with 
M-CSF and RANKL, and OC activity with reduced resorption and inhibition of TRAP 
expression (Moreno et al 2003; Mangashetti et al 2005). A direct effect of IL-13 on OCs 
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has not been shown but it can increase expression of OPG by endothelial cells, the 
conditioned media of which inhibited the functional activity of OCs as measured by an 
unusual fluorophore-releasing assay (Stein et al 2008). 
Effect	of	cellular	elements	
The effect of soluble elements of the immune system on bone have been studied 
extensively, both in terms of bone formation and resorption. With regard to the effect 
of cellular elements of the immune system on BMD, interactions between lymphocytes 
and osteoclasts have been well studied. There is an understandable focus on the 
RANKL system, as discussed earlier, but two specific studies show that the balance of 
regulatory and pro-inflammatory lymphocytes could influence bone metabolism. 
Sato et al (2006) generated Th1, Th2, and Th17 and lymphocytes and included them 
in an assay for osteoclast differentiation and function. They found that whilst Th1 and 
Th2 cells inhibited osteoclastogenesis, Th17 cells promoted it by increasing the 
numbers of osteoclasts. They found that IL-17 was an important mediator of this effect, 
and that the method of producing osteoclasts (RANKL/MCSF or culture with 
osteoblasts) had some influence on the outcome. 
Interestingly, whilst Sato et al (2006) found no effect of Treg cells on 
osteoclastogenesis Zaiss et al (2007) found they markedly reduced osteoclast 
formation. These differences may be due to differences in the methods used, but 
perhaps of note is that Sato identifies Tregs on CD25 expression alone whereas Zaiss 
confirms their phenotype based on expression of FOXP3. Therefore, Sato may have 
had a combination of regulatory and inflammatory lymphocytes in the population and 
not just Tregs.  
These demonstrate the potential for lymphocyte populations to increase bone loss in 
inflammatory conditions and reduce it as the immune dysregulation is brought under 
control. 
Conclusion	
Patient’s with IBD have changes in their bone metabolism, affecting the mineral density 
and possibly leading to a greater risk of fracture. Reduced BMD in IBD is likely to be 
multifactorial but there is convincing evidence that the chronic inflammation seen in 
IBD, and other autoimmune disorders, makes a significant contribution. Soluble 
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elements clearly play a role, and in adults there is an established molecular pathway 
(RANKL/RANK/OPG) mediating interaction between lymphocytes and osteoclasts 
leading to the increased bone resorption seen in older IBD patients. 
This mechanism cannot be applied to children. Whilst they do have reductions in bone 
mineral density it is associated with reductions in bone formation rather than increased 
resorption. This probably reflects the processes of bone growth and development that 
are predominating, and that process is primarily mediated by osteoblasts. When this 
thesis began, although the effect of soluble elements had been studied, there was very 
little published research looking at the effects of immune cells on osteoblasts.  
Mucosal immunity in health and IBD involves cells of the adaptive and innate immune 
system. Locally, CD4+ lymphocytes are the main orchestrators in a variety of guises 
including Treg and Th17 phenotypes. Systemically, the trafficking of gut activated 
immune cells expressing the gut homing integrin a4b7 potentially mediate the extra-
intestinal effects of IBD. This thesis aims to investigate the potential for gut activated 
immune cells, focussing on CD4+ lymphocytes, to have a negative impact on bone 
formation.  
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Hypothesis	
The reductions in BMD seen in children with Crohn’s disease are, at least in part, 
mediated by interactions between osteoblasts and activated lymphocytes that have 
migrated from gut mucosal tissue to the bone. 
Aims	
This study has two aims. The first is to investigate the effects of lymphocytes, and their 
secreted factors, on the osteoblast like osteosarcoma cell line Saos-2. The second is 
to look for associations between the relative proportions and activation status of 
lymphocytes, including those expressing the gut-activation marker a4b7, in children 
with Crohn’s disease, and changes in their BMD measured by DXA. 
 
Objectives	
• Isolate peripheral blood mononuclear cells from healthy volunteers 
• Investigate the effects of these cells and their secreted factors on Saos2:  
o Proliferation 
o Alkaline phosphatase activity 
• Recruit a cohort of paediatric patients undergoing endoscopy for clinical 
reasons and collect samples from patients from patients diagnosed with 
Crohn’s disease and those with no identifiable bowel pathology 
• Develop a method for the isolation of immune cells from paediatric endoscopic 
gut biopsy samples 
• For these groups: 
o Collect peripheral blood and gut biopsy samples and measure relative 
proportions and activation status of lymphocytes in the gut and 
peripheral blood using flow cytometry 
o Collect data on the level of selected markers of bone turnover in 
peripheral blood and urine 
o Measure bone mineral density of patients with Crohn’s Disease using 
dual-energy X-ray absorptiometry  
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2 Materials	and	Methods	
The experimental work undertaken for this thesis consisted of two parts. A series of in 
vitro experiments studied specific interactions between immune cells and Saos-2 cells, 
and a comparative in vivo study compared peripheral blood immune cell phenotypes 
and bone metabolism in children with inflammatory bowel disease to those of healthy 
controls. 
In	vitro	study	of	the	influence	of	immune	cells	on	the	proliferation	and	alkaline	
phosphatase	activity	of	Saos-2	cells	
The aim of the in vitro experimental work described in this section is to investigate the 
effects of lymphocytes, and their secreted factors, on the proliferation and alkaline 
phosphatase activity of the osteoblast like osteosarcoma cell line Saos-2.  
Saos-2	cells	
The osteoblast-like osteosarcoma cell Saos-2 was used for these experiments (see 
Figure 2-1), and kindly provided by Professor Alison Gartland of The University of 
Sheffield’s Mellanby Bone Centre. The establishment of the cell line was first described 
in 1977 (Fogh et al 1977). It was subsequently shown to have several osteoblast 
characteristics including high levels of alkaline phosphatase (ALP) and the ability to 
generate a calcified bone-like matrix (Rodan et al 1987). These features were of 
particular interest as reductions in serum alkaline phosphatase (Sylvester et al 2006) 
and bone mineral density (Harpavat et al 2005) have been found in children that were 
newly diagnosed with Crohn’s disease.  
Other osteosarcoma cell lines (TE85, U2OS and MG63) show very little alkaline 
phosphatase activity (Murray et al 1987; Pautke et al 2004). It is also important to note 
that Saos-2 cells show a more mature osteoblast phenotype than U2OS and MG63, 
consistently producing osteocalcin, bone sialoprotein, decorin, and procollagen-
1 (Pautke et al 2004). These proteins are considered characteristic of osteoblasts.  
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Figure 2-1: Light micrograph of Saos-2 cells (20x magnification). 
Maintenance	of	Saos-2	
Saos-2 cells were maintained in Nunc T75 flasks with Dulbecco’s Modified Eagle 
Medium (D-MEM) containing GlutaMAXä, 4500mg/L D-Glucose and sodium pyruvate 
(GIBCO #31966-021). Medium was supplemented with 10% v/v foetal bovine serum 
(GIBCO #10270-106), 100units/ml penicillin and 100µg/ml streptomycin (BioWhittaker 
#DE-17-602E).  This will subsequently be referred to as bone cell medium (BCM).  
Cells were initially seeded at 1x106 per flask and split once they reached 70-80% 
confluence, usually on day 3 or 4. To split cells, flasks were washed twice with 
phosphate buffered saline (PBS) to remove medium and incubated with 2.5 ml of 
trypsin/EDTA solution (GIBCO #25200-056) for 5 minutes at 37°C. Having ensured 
that all cells were detached from the base of the flask, 10 ml of BCM was added to 
stop the enzyme activity. The cell suspension was transferred to a 25 ml Universal 
container, and after centrifugation at 300g for 5 minutes, the supernatant was 
discarded and the cells re-suspended in 1 ml of BCM. Viable cells were then counted 
on the basis of trypan blue dye exclusion (0.4% w/v, Sigma #T8154) using a 
haemocytometer. 
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Peripheral	blood	mononuclear	cells,	lymphocytes	and	their	isolation	
Whole blood comprises erythrocytes, leucocytes and plasma. The cellular components 
of blood derive from multi-potential hematopoietic stem cells (see Figure 2-2) that, in 
adult humans, reside in the bone marrow.  During haematopoiesis these stem cells 
develop into erythrocytes (predominantly red blood cells), myelocytes and 
lymphocytes (leucocytes or white blood cells). Leucocytes consist of two populations: 
granulocytes and mononuclear leucocytes. Granulocytes are polymorphonuclear cells 
with stainable cytoplasmic granules. They include neutrophils, basophils and 
eosinophils; all of which derive from a myeloid progenitor. Mononuclear leucocytes 
have a single nucleus and lack the stainable granules of the polymorphonuclear cells. 
This population includes lymphocytes and lymphoid dendritic cells (derived from a 
lymphoid progenitor), but also monocytes and myeloid-dendritic cells (derived from a 
myeloid progenitor). 
 
Figure 2-2: The haematopoietic cell line. This diagram shows the development of the various blood cell 
types from a common, multipotential hematopoietic stem cell. HSC – haematopoietic stem cell, LT – long 
term, ST – short term, CLP – common lymphoid progenitor, CMP – common myeloid progenitor, MEP – 
megakaryocyte-erythroid progenitor, GMP – granulocyte-macrophage progenitor. Reproduced with 
permission (Sankaran et al 2015). 
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Lymphocytes consist of three subtypes of white blood cell: natural killer (NK) cells, T 
cells and B cells. T and B cells are the main components of the adaptive immune 
system recognising non-self-antigens, co-ordinating the immune response and 
maintaining memory of previously-encountered antigens. B cells mature in the bone 
marrow and produce antibody in response to foreign antigen. T cells mature in the 
thymus providing adaptive, cell-mediated immunity. They are an essential part of the 
immune system; however, if they become reactive to self-antigen autoimmune disease 
such as inflammatory bowel disease develops. Lymphocytes, like any cell, express 
proteins on their cell surface which allow them to carry out their functional roles. The 
use of fluorescently labelled antibodies to specific protein structures enables 
identification of cell type, and provide information as to their functional status (see later 
section). 
Mononuclear cells can be isolated from whole blood by centrifugation on density 
gradient media (see Figure 2-3). This approach was first described using a 
combination of sodium metrizoate and a polysaccharide (Boyum 1968) which is 
produced commercially as LymphoprepÔ. However, this process had been found to 
alter the relative proportions of lymphocytes, including reductions in the number CD8+ 
cells (Renzi et al 1987), possibly due to the aggregation of erythrocytes. There was 
also a concern that the ionic charge on the metrizoate could be toxic to cells (Axis 
Shield News Bulletin). Therefore, an alternative preparation using isohexol 
(Nycodenzä), lacking the ionic charge, was introduced in 1982 (Axis Shield News 
Bulletin). A revised protocol, also by Boyum, used this modified form and was 
published later (Rickwood 1983).  
 
Figure 2-3: Separation of peripheral blood mononuclear cells (PBMCs) using density gradient 
centrifugation. 
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The isolation of specific lymphocytes subsets (such as CD4+ T cells) can be achieved 
by incubating a cell suspension with an antibody to a specific cell-surface protein which 
is conjugated to either a fluorescent flurophore or a metal oxide micro-bead. Where a 
flurophore has been used, cells can be separated using a flow cytometer (see later 
description). If metal-oxide beads are used then cells can be isolated using a 
magnet (Tomlinson et al 2013). Whilst the former enables more complex cell 
identification, the use of micro-beads can be cheaper and faster. 
Micro-beads and magnets can be used in two ways (see Figure 2-4). For the first, 
labelled cells pass through a column containing metallic beads within a magnetic field. 
The labelled cells adhere to these metallic beads, and the unlabelled pass through. 
For the second, a magnetically-labelled cell suspension is placed in a conical tube. 
When placed in a magnet, the magnetically labelled cells “attach” to the tube edges, 
and remain in the tube when it is inverted. 
 
Figure 2-4: Two methods of magnet based cell isolation. In both methods cells of interest are magnetically 
labelled with antibody. In column based separation the suspension passes through a column of larger 
beads within a magnetic field, and magnetically labelled cells are retained within the column. In tube based 
separation the cell suspension is placed within a magnet and magnetically labelled cells remain in the 
tube when the tube is inverted. 
A	 B	 C	
1	 2	 3	
Column	based	separa4on	
Tube	based	separa4on	
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The outcome of both these methods is the same in that labelled cells are removed. 
However, the cell surface proteins to which the micro-beads bind will usually have a 
functional role, and the presence of the micro-bead may affect its function and/or future 
labelling. This makes the labelled cells unlikely to be of use in experiments. It also 
means the cell markers that are labelled depends on whether the aim is to deplete or 
enrich a specific population e.g. CD4+ cells. Positive selection can be used to isolate 
a specific population. The micro-beads are bound by antibody to CD4+ cells, and after 
passing through the magnet only non-CD4+ cells will remain. Negative selection can 
be used to enrich a specific cell population. The micro-beads bind to cell surface 
markers that are not expressed on CD4+ cells (CD8, CD14, CD15, CD16, CD19, CD36, 
CD56, CD123, TCRγ/δ, and CD235a), and after passing through the magnet only 
CD4+ cells will remain. 
Isolation	of	peripheral	blood	mononuclear	cells	from	whole	blood	
Ethical approval to obtain whole blood from healthy volunteers was given by the 
University of Sheffield Research Ethics Committee (SMBRER116; related documents 
in appendix). All participants gave informed consent. PBMCs were isolated from blood 
by density gradient centrifugation. Peripheral blood was collected into EDTA 
anticoagulant (BD Biosciences Vacutainer™ tubes, BD Biosciences, Oxford, UK), 
transferred to a 25 ml Universal container and diluted 1:1 with 0.9% v/v NaCl (Sigma-
Aldrich #S57653). The diluted blood was then layered onto Nycoprep™ 1077 (Axis-
Shield #1114550) at a ratio of 2:1 (blood: Nycoprep™) ensuring that a clear blood/ 
Nycoprep™ interface was maintained. Samples were then centrifuged at 400g for 30 
min at room temperature, with no brake. This resulted in separation of the blood 
constituents, as outlined in Figure 2-3. 
The mononuclear cell layer at the interface was harvested, transferred into a second 
container, diluted 1:1 with sterile phosphate buffered saline (PBS; Oxoid #BR0014G) 
and centrifuged at 600g for 10 minutes. The supernatant was discarded and the cell 
pellet was washed twice with RPMI growth medium (BioWhittaker #BE12-115F) 
supplemented with 10% v/v foetal calf serum (Sigma #M5905), 100 units/ml penicillin 
and 100µg/ml streptomycin (BioWhittaker #DE-17-602E). Viable cells were then 
counted on the basis of trypan blue dye exclusion (0.4% w/v, Sigma #T8154) using a 
haemocytometer. 
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Isolation	of	lymphocytes	subsets	from	a	PBMC	population	
Lymphocyte subsets were isolated using magnetic cell sorting. For the initial 
experiments, a negative selection CD4+ T Cell Isolation Kit (Miltenyi Biotech, Bisley, 
UK) was used following their recommended protocol. All volumes discussed are per 
107 cells. Aliquots of the PBMC cell suspension were centrifuged at 300g for 5 minutes 
and the supernatant removed. The cell pellet was re-suspended in 40 μL of PBS with 
2% v : v mouse serum (staining buffer, SB), 10μL of Biotin-Antibody cocktail was added 
and after mixing well was incubated for 10 minutes at 4-8°C. A further 30μL of buffer 
was added followed by 20μL of Anti-Biotin Microbeads, the suspension mixed well and 
incubated at 4-8°C for 15 minutes. Cells were again washed in SB at 10-20 times the 
labelling volume, centrifuged at 300g for 10 minutes and the supernatant aspirated. 
Viable cells were counted on the basis of trypan blue dye exclusion and were re-
suspended in buffer at 500μL per 108 cells. A MACS Column was placed in the 
magnetic field of a MACS Separator and the column rinsed with ice-cold buffer. The 
cell suspension was then applied to the column and allowed to pass through collecting 
the effluent. Three volumes of buffer were subsequently applied to ensure optimal 
efficiency of cell isolation. The cell suspension was washed twice with PBS, the cells 
re-suspended in RPMI and viable cells were counted on the basis of trypan blue dye 
exclusion using a haemocytometer.  
For the second set of experiments, EasySep™ cell enrichment and isolation kits were 
used following the manufacturers recommended protocol (StemCell Technologies, 
Manchester, UK). A CD4+ enriched cell population was generated using a negative 
selection kit (#19052) and a CD4+ depleted cell population was generated using a 
CD4+ T cell positive selection kit that would bind and extract CD4+ cells (#18052), 
allowing other cell types to pass through. PBMCs were suspended in Robosep™ buffer 
at a concentration of 108 cells/ml and the appropriate antibody cocktail added. After 
incubation for 15 minutes at room temperature, magnetic particles which bind to the 
antibodies were added, followed by a further period of incubation. The cell suspension 
was gently pipetted into round bottom polystyrene tubes and placed directly into a 
magnet field. After 5 minutes, the suspension was poured off, and any cells bound to 
magnetic particles remained within the tube, leaving a suspension that was either 
enriched or depleted for CD4+ T cells. 
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Influence	of	supernatants	from	activated	immune	cells	on	the	growth	of	Saos-2	
cells	
Activation	of	lymphocytes	
In vivo activation of T cells occurs when antigenic peptides are presented on the major 
histocompatibility complex (MHC, or human leucocyte antigen, HLA, in humans) of 
antigen presenting cells (APCs) to appropriately specific receptors on responding T 
cells. A signal is transduced via the T Cell Receptor (TCR) complex which includes the 
CD3 protein (Roitt 1996). Full T cell activation requires the concomitant delivery of 
essential co-stimulatory signals from the APC, in the absence of which T cells can 
become non-responsive (anergic).  
In vitro stimulation of T cells can be achieved in several different ways. T cells can be 
activated using the lectin protein concanavalin-A (ConA), which activates T cells by 
binding mannose on the cell surface. The cross-linking of surface carbohydrates 
induces polyclonal activation in a manner which is antigen and MHC/HLA-
independent (Palacios 1982). The binding of specific mAbs to the CD3 component of 
the TCR, concomitant with binding to CD28 and the consequential delivery of essential 
co-stimulatory signals, is sufficient to activate T cells (Levine et al 1997). This approach 
could be considered as being more physiological than ConA co-stimulation. ConA also 
requires the presence of monocytes to be effective (Hedfors et al 1975), and if a T cell 
population is purified (for example a CD4+ rich population), ConA will not activate 
cells (Hedfors et al 1975; Palacios 1982). 
Generation	of	activated	immune	cell	supernatants	
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy volunteers, 
from which CD4+ lymphocytes were subsequently isolated using the Miltenyi CD4+ T 
Cell negative isolation kit. Immune cell populations were centrifuged at 300g for 5 
minutes, the supernatant discarded and the cell pellet re-suspended in BCM at 1x106 
cells/ml. 1ml of the cell suspension was transferred to wells of a 24 well culture plate 
(Corning #CLS3524) and 1x106 Miltenyi Treg Suppression Inspector Beads (Miltenyi 
#130-092-909 subsequently referred to as stimulatory beads) added. These beads are 
coated with mAbs to CD3 and CD28 and their interaction with T cell populations mimics 
antigen-induced activation processes. Plates were incubated for 4 days at 37°C with 
5% v/v CO2, at which point the medium was removed and the centrifuged to remove 
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cells. The supernatant containing secreted factors from the activated PBMCs was 
stored at -80°C for future use.  
Culture	of	Saos-2	cells	in	supernatants	from	activated	cells	
Saos-2 cells (105 per well) were incubated for 5 days with supernatants from activated 
PBMC populations (50%, 25%, 12.5%, and 6.25% v/v with BCM) in a total volume of 
500µl per well (BCM alone as control), after which the medium was removed and 
stored at -80°C for later cytokine analysis. Cell numbers were assessed for each of the 
5 days. For this, 200µl of 0.25% trypsin with EDTA (Invitrogen #25200-056) was added 
to each well and incubated for 5 min at 37°C. BCM (300µl) was added to each well 
and pipetted vigorously to ensure all cells were removed. Cells were counted using a 
Beckman Coulter Vi-CELL™ automated cell counter. 
Analysis	 of	 cell	 phenotype,	 functional	 status	 and	 enumeration	 using	 flow	
cytometry	
Flow cytometry was used to assess the phenotypic and functional status of immune 
cells in the in vitro and clinical studies. Additional techniques, relying on the ability of 
flow cytometry to accurately identify cell types, enabled counting of cells that could not 
be separated following co-culture.  
How	a	flow	cytometer	works	
A typical flow cytometer uses hydrodynamic focusing to organise particle suspensions 
into a single stream. It does this by enclosing the central channel, through which the 
sample is injected, in an outer sheath of faster flowing fluid (see Figure 2-5). When the 
faster fluid (sheath fluid) flows past the end of the central channel, drag focuses the 
particle suspension into a single stream within the sheath fluid (Spielman et al 1968; 
Shuler et al 1972).  
Each particle then passes through one or more beams of laser light of different 
wavelengths. As light is incident upon the cell, it is diffused and measurement of the 
light at different angles reflects cell characteristics. Light at around a 20° to that of the 
light source is called forward scatter (FSC), and its intensity reflects the cell size. At 
90°, called side scatter (SSC), the light profile reflects granularity or density. The data 
from each cell (events) can then be plotted on a dot plot of SSC against FSC (see 
Figure 2-6). 
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Figure 2-5: Schematic demonstrating hydrodynamic focussing. Particles moving within an inner sheath 
(shown in green) inside an outer sheath (shown in blue) of faster moving fluid. Where the two fluid streams 
meet, the particles are focused into a single stream. This enables analysis of individual cells. 
 
Figure 2-6: Representative flow cytometry scatter dot plots of immune cells and Saos-2 cells. Panel A - 
resting lymphocytes are the small and comparatively agranular. Panel B - when activated, lymphocytes 
enlarge and become more granular. Panel C - although Saos-2 cells are larger and more granular than 
resting lymphocytes, there is some overlap with activated lymphocytes. 
When fluorescent molecules (fluorophores) are exposed to light of the appropriate 
wavelength, energy is absorbed and the molecule is excited. The energy of the excited 
electrons decays and is re-emitted as light at a different wavelength. The flow 
cytometer can control the frequency of light which it delivers to cells that are either 
directly or indirectly labelled with fluorescent molecules using a panel of defined 
wavelength lasers and this allows cell features and / or the expression of antigens to 
be determined. Fluorescent molecules are conjugated to monoclonal antibodies 
(mAbs) that recognise cell-associated antigens of interest (see Figure 2-7). 
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Figure 2-7: Fluorescent labelling of cell surface molecules for analysis by flow cytometry. The diagram on 
the left shows a cell bearing a surface molecule, in this case CD4. Cells have been incubated with a mAb 
to which the fluorescent molecule Qdot 605 has been conjugated.  Cells which do not express CD4 emit 
a signal in the region indicated by the red peak on the histogram plot. Cells expressing CD4+ would re-
emit the light which would be detected and shown by the blue peak to the far right of the histogram. 
Lymphocyte	surface	markers	
PBMC preparations contain sub-populations of cells that express a variety of 
molecules on their surface. Most of these have a role in enabling specific functions of 
that cell, but they can also be used to identify phenotypic and functional aspects of the 
cell. The Cluster of Differentiation or Cluster Designation (CD) system attributes 
specific numbers to internationally-agreed target molecules (Roitt et al 1996).  
CD4 identifies T helper cells that either positively or negatively influence the immune 
response via interactions with other immune cells. CD8 identifies cytotoxic T cells that 
can kill virally infected cells (Bierer et al 1988; Roitt et al 1996). These molecules 
interact with MHC class II and MHC class I molecules that are expressed on the 
surface of APCs and thereby regulate and target the antigen presentation process to 
individual T cell sub-populations. CD4 interacts with MHC class II, predominantly found 
on antigen presenting cells (APCs). CD8 interacts with MHC class I which is expressed 
on all nucleated cells in the body.  
CD19 is expressed on all B cells and some types of DC. It is a member of the 
immunoglobulin superfamily and forms a transmembrane signalling complex with 
CD21, CD81 and CD225 and acts as a response regulator for B cell development, 
activation and differentiation (Tedder et al 1994; Roitt et al 1996). B cells produce 
antigen specific immunoglobulins (Ig), this being increased when exposed to the 
appropriate antigen. This can be mediated by direct binding of antigen to the Ig in the 
  Page	48	
membrane, although the presentation of the antigen on MHC class II to CD4+ cells is 
a far greater stimulus.  
CD45, also known as the leucocyte common antigen, is present on all cells of the 
haematopoietic cell line (Thomas 1989). It is used to identify immune cells in 
experiments where they are co-cultured with Saos-2. 
CD69 and CD25 are early and late markers of lymphocyte activation respectively. 
CD25 (the alpha chain of the IL-2 receptor) is also constitutively expressed (at high 
levels) on a resting population of CD4+ cells that have become known as CD4+CD25high 
immunoregulatory T cells (Treg cells). IL-2 plays a central role in the clonal expansion 
of activated lymphocytes, and binds to the IL-2 receptor (IL-2R) (Minami et al 1993). 
IL-2R has three chains with the a chain named CD25. CD69 has a role in the early 
stages of T cell and B cell activation and is one of the earliest antigens expressed after 
activation by several cell types (Cosulich et al 1987; Testi et al 1989). 
Characterisation	and	identification	of	cells	by	flow	cytometry	
Viability	
Antibodies to specific cell markers can non-specifically bind to dead cells. Exclusion of 
dead cells from the analysis is therefore important when measuring cell populations by 
flow cytometry. Of course, analysing dead cells is of value when determining potentially 
cytotoxic responses.  Identifying dead cells can be achieved using several approaches, 
one of which involves amine reactive viability dye (ViD). The dye can penetrate 
damaged cell membranes and react with amine groups in the cell cytoplasm forming 
a stable, fluorescent product. They do react with surface amine groups, but the total 
binding capacity is minimal relative to that of the cytoplasm. For these experiments, a 
dye excited by blue fluorescence with an ultraviolet emission spectrum was used 
(LIVE/DEADâ Invitrogen #L23105). 
Their effectiveness in identifying dead cells has been demonstrated (Perfetto et al 
2006), but how it identifies dead cells was investigated. PBMCs were incubated in 
increasing concentrations of hydrogen peroxide for 30 minutes, after which they were 
washed twice in phosphate buffered saline (PBS). Cells were incubated with the ViD 
for 30 minutes before being washed again with PBS. Cells incubated with propidium 
iodide (PI) and Annexin V were used as a comparison. PI identified dead cells by 
penetrating the cells membrane and binding to its DNA. Annexin V identifies apoptotic 
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cells by binding to phosphotidylserine, expressed on the surface of cells undergoing 
this process. 
	
Figure 2-8: Representative histograms of viability staining with propidium iodide, Annexin and and amine 
reactive dye. Row 1 – scatter plots of FSC and SSC for cells incubated in increasing concentrations of 
hydrogen peroxide, with the lowest concentration in A and the highest in C. Row 2 - histograms of the 
viable group shown in 1B stained with differing dyes Row 3 – histograms of the non-viable group shown 
in 1B stained with differing dyes. On histograms unstained controls are red, stained samples blue. 
Figure 2-8 summarises the findings. Row 1 shows that as cells become non-viable 
their size and granularity change, leading to a change in position on the scatter plot. 
Row 2 shows the “viable” population in panel 1B, with the three dyes confirming they 
are mostly viable cells. Row 3 shows the “non-viable” population in 1B, with the three 
dyes confirming the lack of viable cells. This suggests that the FSC/SSC does identify 
a significant proportion of non-viable cells. In addition, when staining for flow cytometry, 
isotype controls will detect some non-specific binding.  
A	 B	 C	
1	
2	
3	
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Fluorescent	labelling	of	cell	surface	markers	
Fluorescent labelling of cell surface markers enables the identification of specific cell 
populations (e.g. CD4+ lymphocytes) and their functional status (e.g. expression of 
CD25 reflecting activation status). The cell surface marker of interest and its pattern of 
fluorescence influence how the output is interpreted and reported. 
It is possible for antibodies to non-specifically bind to cells and result in ‘false positives’. 
This possibility is monitored by including non-specific, isotype-binding controls, in all 
staining procedures. These controls are immunoglobulins of the same species that are 
labelled with the same fluorochrome, but which have been demonstrated not to bind 
to any antigens on the target cell populations. These could be mAbs having specificity 
to haptens (small irrelevant molecules) or antigens that are expressed by another 
species. More recently, the concept of fluorescence minus one (FMO) controls which 
replace the need for isotype controls for multiparameter staining panels has 
superseded the use of isotype controls. 
	
Figure 2-9: Representative examples of staining for CD4 and CD69 expression. The scatter plots (with 
FSC-A on the Y axis) from left to right compare the appearance of the unstained, isotype control and 
stained cells. At the far right the same data are presented as overlaid histograms: red (unstained), blue 
(isotype control) and green (stained). 
Figure 2-9 compares the fluorescence produced by CD4+ cells, and expression of 
CD69. When fluorescently labelled the phenotypic marker CD4 produces a distinct 
population. Cells are considered simply as being either CD4 positive or CD4+ negative, 
and this is also true for CD8 and CD19. For the activation marker CD69 no distinct 
population is produced, but there is an increase in fluorescence from the stained cells. 
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A similar pattern is seen for CD25. Both CD25 and CD69 can be measured by either 
the proportion of cells that are positive (as a percentage) and the intensity of 
expression. Both are important parameters providing insight into the amount of a given 
antigen that is expressed and, in the case of activation antigens, the degree of 
activation.  
Identification of phenotypic markers using fluorescent labelling does not always 
produce a distinct population. An example of this is the integrin a4b7, which was used 
to identify immune cells that have been activated within the gut mucosa, and which 
was used for the in vivo study. Identification of a4b7+ cells is described later. 
Enumeration	of	cell	populations	
A flow cytometer can record the total number of events / cells / particles that pass 
through the laser beam. This information alone cannot be used to calculate the 
absolute number of cells in a sample because the total volume of the suspension 
analysed is not recorded by the instrument which was used in the current study, and 
so it is only possible to calculate the relative number of cells in each population. 
However, an absolute cell number can be determined by ensuring the sample volume 
is accurate and adding a known number of microbeads such as Countbrightä Absolute 
Counting Beads (Invitrogen #C36950).  When analysed, the volume of suspension, 
and hence the number of cell events, can be calculated using the following formula. 
 
 
Where 
A = number of cell events 
B = number of bead events 
C = assigned bead count of the lot (beads/50µl) 
D = volume of sample (µl) 
=	A		
B	
x	 C	
D	
Concentration	of	sample	as	cells/µl	
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Co-culture	of	immune	cells	with	Saos-2	cells	
Series	1	–	influence	of	immune	cells	on	the	growth	of	Saos-2	cells	
The primary aim of these experiments was to investigate the effect of activated immune 
cells on the growth of Saos-2 cells. Four independent variables were included: immune 
cell type (PBMCs or CD4+ lymphocytes), immune cell number relative to the number 
of Saos-2, activation status and contact status. The dependent variables were Saos-2 
number and changes in activations status of immune cells (based on the expression 
of CD25 and CD69). 
Experimental	setup	
	
Figure 2-10: Set up for co-culture experiments. Upper Panel - grid shows the layout of the variables within 
the experiment. All wells contained 105 Saos-2 cells. Lower Panel - representative well including Saos-
2, lymphocytes and the transwell insert. 
Saos-2 cells (105 cells in 500µl BCM) were added to wells of a 24-well culture plate 
(Corning #CLS3470). Resting and polyclonally activated immune cells were added to 
the wells at ratios of 1, 2, 4 and 8 immune cells : 1 Saos-2 cell. To establish the effects 
of immune cell activation on the growth of Saos-2 cells, immune cells were activated 
using Miltenyi Treg Suppression Inspector Beads (Miltenyi #130-092-909 subsequently 
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referred to as stimulatory beads) at an immune cell:bead ratio of 1:1. These beads are 
coated with mAbs to CD3 and CD28 and their interaction with T cell populations mimics 
antigen-induced activation processes. To establish the effects of cell-cell contact and 
secreted factors on the observed effects, 0.4µm pore polyester transwell membrane 
inserts (Corning #CLS3470) were used. These provide a physical separation between 
the Saos-2 growing on the base of the well and immune cells within the insert, whilst 
allowing the passage of secreted factors such as cytokines. The details of this are 
provided in Figure 2-10. Control wells with Saos-2 alone, immune cells alone and 
immune cells with stimulatory beads were included. For these experiments, cultures 
were incubated for 4 days at 37°C with 5% v/v CO2.  
Collection	of	cells	from	the	culture	wells	
Medium was collected from the wells and the transwell inserts at the end of the 
experimental period and centrifuged at 300g for 5 minutes. Supernatants were 
collected and stored at -80°C, and the cell pellet was re-suspended in BCM. 
Saos-2 cells were harvested by incubating each well with 200µl of 0.25% v/v trypsin 
with EDTA (Invitrogen #25200-056) for 5 min at 37°C. Medium (300µl) was added and 
vigorously pipetted to ensure the Saos-2 were completely removed from the base of 
the well. The removal of cells was confirmed visually using a standard light microscope. 
Following centrifugation, cell pellets were combined with the cells isolated from the 
medium of the corresponding well and washed twice in BCM.  
Cells in the Saos-2 and immune cell control wells were counted to give an estimate of 
maximum cell numbers in the co-culture wells for fluorescent staining. Cells were re-
suspended in PBS with 10% v/v FBS and 2% v/v mouse serum at a concentration of 
1x106 cells/100µl in preparation for fluorescent staining.  
Preparation	of	samples	for	flow	cytometry	analysis	
After incubating at room temperature for 15 min in staining buffer with mouse serum, 
samples were separated into aliquots of 250,000 cells to provide unstained, isotype 
and stained samples for comparison. Details of the fluorescently-conjugated mAbs 
used are shown in Table 2-1. Appropriate isotype controls were included in every 
experiment. 
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Table 2-1: Fluorescent antibodies used in the co-culture experiments.  
Samples were incubated with mAbs for 30 minutes at 4°C, after which samples were 
washed once in staining buffer. Unstained and isotype samples were re-suspended in 
200µl of staining buffer, and stained samples were re-suspended in 350µl of staining 
buffer. Samples were kept in the dark on ice and analysed by flow cytometry (BD 
Biosciences LSRII). Countbrightä Absolute Counting Beads (50µl), Invitrogen 
#C36950) were added to stained samples immediately prior to analysis. Data were 
acquired using BD Biosciences FACSDivaä software and analysed using FlowJo™ 
analysis software (v8.8.6, Tree Star).  
The gating strategy is shown in Figure 2-11. Row 1 shows identification of viable cells. 
1A is unstained, 1B is stained and includes the counting beads. In 1C the population 
“cells” are confirmed as viable. In 1D the population “non-viable” shows a proportion 
of those cells have taken up the LIVE/DEAD stain. Row 2 shows the identification of 
haematopoietic cells expressing CD45. In 2A, a population of cells consisting of both 
immune cells and Saos-2 are identified. 2B shows that population after staining with 
the isotype control, and 2C shows that same population after staining with a 
fluorescently labelled antibody to CD45. A distinct population of CD45+ cells can be 
seen. 2D shows the CD45+ cells identified on the original scatter plot and identified as 
lymphocytes. 3A-D shows the identification of the lymphocyte subsets CD4+ and CD8+, 
with isotype and stained scatter plots. 4A and B shows similar scatter plots for CD19+. 
4C and D are histograms identifying cells expressing CD25 and CD69.  
Fluorphore	 mAB	 Clone	 Concentra2on	(1x106	cells/100µl)	 Catalogue	number	
Qdot	605™		 an,-CD4			 S3.5	 1µl	 Invitrogen	#Q10008		
Qdot	705™		 an,-CD8		 3B5	 1µl	 Invitrogen	#Q100509		
Alexa	Fluor™		 an,-CD19		 HIB19	 20µl	 Biolegend	#302226		
APC-Cy7™		 an,-CD69		 FN50	 0.5µg	 Biolegend	#310914		
PE-Cy7™		 an,-CD25		 HI30	 0.5µg	 Ebioscience	#25-0259-42		
Paciﬁc	Blue™		 an,-CD45		 BC96	 0.25µg	 Biolegend	#304022		
Ultraviolet	 LIVE/DEAD®	 N/A	 1µl	 Invitrogen	L23105	
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Figure 2-11: Representative flow cytometry plots demonstrating the gating strategy for the co-culture 
experiments. Row 1 – identification of viable cells using UV LIVE/DEAD: A Unstained B stained with 
counting beads present C histogram of cells of interest (red line unstained, blue fill stained) D histogram 
of presumed non-viable cells (red line unstained, blue fill stained) Row 2 – identification of haematopoietic 
cells A scatter plot B “All cells” unstained C “All cells” stained for CD45 D CD45+ cells shown on the scatter 
plot Row 3/4 – identification of lymphocyte subsets and their expression of activation markers 3A/B 
Isotype control and stained for CD4+ 3C/D Isotype control and stained for CD8+ 4A/B Isotype control and 
stained for CD19+ 4C histogram of CD25 expression (red isotype control, purple stained sample) 4D 
histogram of CD25 expression (red isotype control, purple stained sample). 
Series	2	–	influence	of	immune	cells	on	the	ALP	activity	of	Saos-2	cells	
The primary aim of these experiments was to investigate the effect of immune cells on 
alkaline phosphatase (ALP) activity. Three independent variables were considered: 
cell type (PBMCs, a CD4+ enriched population, and PBMCs depleted of CD4+ 
lymphocytes), cell number, and activation status. The primary dependent variable was 
ALP activity, but growth of Saos-2 cells was also studied. 
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ALP is present in both immune cells and Saos-2 cells, and therefore the two cell types 
were separated by transwell inserts in all conditions. Immune cells were added 24 
hours after the Saos-2 cells, thereby allowing them time to adhere. A CD4+ lymphocyte 
depleted population was included to further investigate any potential role of these cells 
in mediating observed effects on Saos-2 cells. 
Experimental	setup	
Peripheral blood mononuclear cells were isolated as described earlier, from which 
three populations were generated: PBMCs, CD4-enriched and CD4-depleted. Saos-2 
cells (105 cells in 500µl of BCM) were added to wells of a 24-well culture plate (Corning 
#CLS3470). After 48 hours, 0.4µm pore polyester transwell membrane inserts (Corning 
#CLS3470) were placed in each well, to which immune cells were added at ratios of 
0.6, 1, 3 and 6 immune cells: 1 Saos-2 cell. Immune cells were activated using Miltenyi 
Treg Suppression Inspector Beads (Miltenyi #130-092-909 subsequently referred to as 
stimulatory beads) at an immune cell: bead ratio of 1:1. Control wells with Saos-2 
alone, immune cells alone and immune cells with stimulatory beads were included. 
Cultures were incubated for 4 days at 37°C with 5% v/v CO2.   
Counting	of	Saos-2	cells	and	analysis	of	lymphocytes	by	flow	cytometry	
Techniques used here are carried out in the same way as for series 1, unless described 
otherwise. Immune cells were aspirated from the transwell inserts by pipette and 
prepared for analysis by flow cytometry. Saos-2 cells were harvested from the wells 
using trypsin, and counted using an automated cell counter.  
Measurement	of	alkaline	phosphatase	activity	
Alkaline phosphatase (ALP) is a glycoprotein that, in humans, has the protein moiety 
encoded by four different gene loci: tissue non-specific (or liver/bone/kidney), 
intestinal, placental and placental-like (Harris 1990). Whilst it is found in serum, it is 
primarily a membrane-bound protein. Release from the membrane may be mediated 
by a phosphatidylinositol phospholipase which changes its structure from tetra- to di-
meric (Hawrylak et al 1988). As discussed previously, it is strongly expressed by Saos-
2. ALP activity can be measured using the substrate p-nitrophenyl phosphate (PNPP), 
which ALP converts to a soluble end-product (p-nitrophenyl; PN) which absorbs light 
in the 405nm range (Thompson et al 1991). ALP activity reflects the amount of ALP, 
which in turn indicates the cells ability to form a mineralised matrix. With greater ALP 
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activity, more of the soluble end-product PN is produced, and more light is absorbed 
(see Figure 2-12). 
	
Figure 2-12: Diagram showing the chemical changes as p-nitrophenylphosphate (PNPP) is converted to 
p-nitrophenyl (PN). The increase in concentration of PN causes a change in colour which reduces the 
light passing through and increases absorption of light. 
Because ALP is membrane bound, the cells needed to be harvested without the use 
of trypsin as this would remove it from the membrane. Instead, the cells were lysed in 
situ using water and freeze-thaw cycles. The enzymatic activity of ALP in the different 
experimental conditions was normalised to cell number by measuring the DNA using 
the Quant-iT™ PicoGreen® dsDNA Assay Kit (ThermoFisher Scientific #P7589). 
PicoGreen® is a sensitive fluorescent nucleic acid stain for quantitating double-
stranded DNA. It is sensitive to even small amounts of DNA, and so contamination with 
all other sources of DNA must be excluded.   
Once the experiment was complete, medium was removed from the wells, and the 
remaining cells washed twice with PBS. DNA-free water (0.5 ml) was added to each 
well and three freeze-thaw cycles undertaken. For each cycle, cells were frozen at -
80°C for 45 minutes and then thawed for 15 minutes whilst being agitated on a shaker. 
This produced a cell lysate retaining ALP. 
Concentra)on	of	p-nitrophenylphosphate	
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A buffered solution of PNPP was made by dissolving 10 mg of PNPP (Sigma P4744) 
in 0.2 ml of 1M TRIS, 0.05 ml of 0.2 M MgCl2, and 10 ml of DNA-free water and 
adjusting the pH to 8.0-8.3 (termed ALP substrate). Equal volumes of cell lysate and 
ALP substrate were added to wells of a 96-well plate, including control wells, with DNA-
free water being substituted for cell lysate in controls. Absorbance was measured at 
405nm using a multi-functional microplate reader (BMG FLUOstar Galaxy™). This was 
measured immediately and at 5-minute intervals up to 25 minutes.  
The PicoGreen® reagents were prepared per the manufacturer’s recommended 
protocol. The kit comes with a TE buffer consisting of 10 mM Tris-HCl and 1 mM EDTA 
at a pH of 7.5. Samples of each cell lysate were diluted 10 times with the TE buffer in 
a 96-well plate. A standard DNA solution, provided with the kit, was used to provide a 
series of wells with a known concentration of DNA to be used as a standard curve. 
Appropriate volumes of PicoGreen®, diluted in the TE buffer, were added to the cell 
lysate samples and the standard DNA solutions. After 1 to 2 minutes, fluorescence 
was measured using the BMG FLUOstar Galaxy™ at an excitation of ~480nm and 
emission of ~520nm. DNA content was calculated by comparing the measured 
fluorescent output of the cell lysate samples, minus the reading from the control wells, 
and comparing it to the standard curve.  
In	vivo	study	of	immune	cell	status	in	children	with	inflammatory	bowel	disease	
and	their	association	with	bone	metabolism	
The aim of this in vivo study was to investigate potential associations between the 
relative proportions and activation status of lymphocytes in children with Crohn’s 
disease and changes in BMD measured by DXA. 
Participants	and	investigative	rationale	
Children aged 4-16 years of age having an endoscopy for investigation of 
gastrointestinal symptoms were recruited. Ethical approval for this study was obtained 
from the Sheffield Research Ethics Committee (08/H1308/275). All participants gave 
informed consent. Peripheral blood (13 ml) was collected into EDTA anticoagulant (BD 
Biosciences Vacutainer™ tubes, BD Biosciences, Oxford, UK) for analysis by 
multicolour flow cytometry. Gut biopsies (10 per participant) were taken using standard 
size paediatric biopsy forceps (Boston Scientific, Radial Jaw, 2.4mm: Cat no 1340). 
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Patients were fasted for their general anaesthetic, and their second void urine sample 
of the day was collected into a plain universal container. 
In those with no macroscopic inflammation, 10 biopsies were taken from the colon and 
the last part of the ileum: 2 ileal, 2 caecal, and 2 each from the ascending, transverse 
and descending regions of the colon. In patients with evidence of IBD, biopsies were 
predominantly taken from inflamed areas of bowel, including the upper GI tract. The 
reason for this approach was to focus on a comparison of inflamed and non-inflamed 
tissue. This does mean that any differences may reflect the changing location of the 
biopsy, rather than a pathological process. However, a more consistent approach to 
biopsy location could potentially limit the option of focusing on inflamed areas of bowel, 
potentially missing the sampling of areas of greater inflammation. An additional 
limitation to achieving consistent regional biopsies was that in some cases the 
technical difficulties of endoscopy meant that specific areas could not be biopsied. 
Isolation	of	lymphocytes	from	endoscopic	mucosal	biopsies	
Lymphocytes were isolated from the peripheral blood using the same method as for 
the in-vitro experiments. Isolation of lymphocytes from mucosal tissue is an established 
technique with physical (Clancy 1976) and enzymatic (Bull et al 1977) methods 
described in the 1970s, and used extensively since to study mucosal immunology. At 
the time of undertaking this work most studies seemed to use enzymes to isolate 
immune cells from resected sections of gut, but with no detailed descriptions of an 
approach to isolation from the smaller pinch biopsies taken with an endoscope some 
optimisation of a technique for isolation was necessary.  
The most recent and comprehensive description at the time used two combinations of 
enzymes to release cells from the epithelial and lamina propria layers (Weigmann et 
al 2007) which is necessary given the fundamental differences in the lymphocyte 
populations normally found in those two compartments. The enzymes do digest cell 
surface proteins (Abuzakouk et al 1996; Van Damme et al 2000) affecting analysis by 
flow cytometry. Mechanical isolation methods potentially overcome this problem but 
may isolate lower numbers of cells (Bland et al 1979) which could also affect analysis 
given the size of the biopsies. After this work was completed a publication supported 
and described the use of enzymatic digestion, rather than mechanical, for the isolation 
of lymphocytes from endoscopic gut biopsies (Carrasco et al 2013).  
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Optimisation of the isolation technique is described in chapter 4, but the following basic 
aspects will be covered here. The initial enzymes were those used by Weigmann et 
al (2007) who used two different solutions in their protocol: a pre-digestion solution to 
release epithelial cells, and a digestion solution to release cells from the lamina propria. 
They also used a percoll gradient and passed digested tissue through a cell strainer, 
both of which were tried. Although an adequate cell yield was achieved there was loss 
of cell surface proteins so the effects of the individual enzymes were investigated using 
isolated PBMCs.  
Enzymes	used	for	the	release	of	lymphocytes	from	mucosal	gut	biopsies	
Pre-digestion solution: 
  Hanks Balanced Salt Solution (Sigma #H6648)  
  5mM EDTA (GIBCO #15575-020)  
  1mM DTT (Sigma #D0632)  
Digestion solution:  
  Phosphate buffered saline (PBS) 
  0.05% w/v collagenase type IV (Worthington #LS004186) 
  0.05% w/v DNase 1 (Worthington #LS002004)  
  0.3% w/v dispase (Roche #04942078001) 
Ethylenediaminetetraacetic	acid	(EDTA)	
Ethylenediaminetetraacetic acid (EDTA) is a polyamino-carboxylic acid. It is a 
chelating agent with the ability to bind to, and sequester metal ions. Within mucosa, 
the epidermal layer is bound to the underlying connective tissue by basal epithelial cell 
hemidesmosomes, cell-substrate adhesion junctions (Stepp et al 1990). Incubation of 
oral mucosa in EDTA makes separation of the epithelium from connective tissue 
possible, and it was suggested this could occur because attachment requires the 
presence of metal ions which are removed by the EDTA (Scaletta et al 1971). 
Dithiothreitol	(DTT)	
Dithiothreitol (DTT) is a disulfide reducing agent. Its use in mucosal digestion appears 
to have been serendipitous. When rat skin samples were incubated in a buffer 
containing DTT it resulted in easier detachment of the epidermis from the dermis. The 
basement membrane remained attached to the epidermis when mechanical separation 
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was combined with incubation in DTT, but to the dermis with mechanical separation 
alone. The authors were unsure of the mechanism for this (Epstein et al 1979). 
Collagenase	
Collagen is an important constituent of connective tissue. There are at least 27 
forms (Eyre 2004), with type I being the most abundant protein in the human body (Di 
Lullo et al 2002). Although the structure of collagen has been studied since the 1930s, 
a complete understanding has only recently been described (Orgel et al 2006) and is 
shown in Figure 2-13. Polypeptide chains, called a chains, have a left-handed helical 
structure. Three a chains then wind together forming a right-handed triple helix known 
as the collagen molecule. Three collagen molecules then further combine to form a 
super-super coil, again a right-handed helix, or sub-fibril. Sub-fibrils then combine to 
form fibrils. 
 
Figure 2-13: The structure of collagen. This shows the alpha chain and its formation into a triple helix 
known as the collagen molecule. Reproduced with permission (Orgel et al 2006). 
Collagenases are endopeptidases (enzymes that break peptide bonds of non-terminal 
amino-acids) which cleave the triple helical region of the collagen molecule (Gross et 
al 1974). Collagenase is available in several forms, and one with a low tryptic activity 
is suggested in the paper by Weigmann et al (2007), as this is thought to have less of 
an effect on surface proteins. For these experiments, Worthington’s collagenase type 
IV (Worthington #LS004186) was used. 
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Dispase	
Dispase is a neutral protease isolated from culture filtrates of Bacillus polymyxa. It has 
been found to act on fibronectin and type IV collagen, but not laminin or type I 
collagen (Stenn et al 1989). It has also been used in this protocol, as it is thought to 
reduce cell clumping without affecting cell viability (Weigmann et al 2007). 
Deoxyribonuclease	(DNAse)	
Deoxyribonuclease (DNAse) was first described as early as 1903 and crystallised by 
Kunitz in 1950 (Kunitz 1950a; Kunitz 1950b). Its primary role is the breakdown of DNA, 
although it has also been found to reduce viscosity of mucous secretions in patients 
with cystic fibrosis (Shak et al 1990). It is this latter effect that may explain its use to 
reduce cell clumping (Weigmann et al 2007). 
Percoll®	density	gradients	
Percoll® density gradient medium enables the separation of cells from tissue based on 
their density. In this instance, it is intended to separate lamina propria cells from other 
cell types and debris. The density of the Percoll® solution (GE Healthcare #17-0891-
01) was adjusted from 1.13 to 1.124 g/ml. For this, a solution of 1.5M NaCl was made 
by adding 4.38 g of NaCl (Sigma #57653) to 50 ml of double distilled water. 1.82 ml of 
the 1.5M NaCl solution (density 1.058 g/ml) was then added to 20 ml of the Percoll® 
solution, based on the following calculation taken from an Amersham laboratories 
product sheet: 
Vx = Vo ((Po – Pi)/(Pi – P10)) thus   Pi = (VoPo + VxP10)/(Vx + Vo) 
Where   Vx  = volume of diluting medium (ml) 
  Vo  = volume of undiluted Percoll® (ml) 
  Po  = density of Percoll® (1.13 g/ml) 
  P10  =  density of 1.5M NaCl (1.058 g/ml) 
  Pi = density of solution produced (g/ml) 
The 1.124 density Percoll® was then mixed with PBS to produce a 40% v/v solution 
(8.4 ml Percoll® and 11.6 ml PBS) and an 80% solution (8 ml Percoll® and 2 ml PBS). 
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Effect	of	digestive	enzymes	on	the	expression	of	cell	surface	markers	
To identify which component was having the greatest effect, the influence of enzymes 
on cell surface antigen expression was investigated. For this, PBMCs were isolated 
from the blood of healthy volunteers (as described above). Cells were incubated in 
RPMI growth medium (BioWhittaker #BE12-115F) supplemented with 10% v/v foetal 
bovine serum (GIBCO #10270-106), 100units/ml penicillin and 100µg/ml streptomycin 
(BioWhittaker #DE-17-602E) and concanavalin A (5µg/ml) overnight at 37°C with 5% 
v/v CO2 at a concentration of 1x106 cells/ml. Cells were then transferred to medium 
without the ConA for a further 24 hours.  
Digestion enzymes were made up at concentrations corresponding to those used in 
the biopsy sample digestion process: 
Pre-digestion enzymes in HBSS 
  EDTA    5mM 
  DTT    1M 
Digestion enzymes in PBS 
  Collagenase type IV  0.1% and 0.01% w/v 
  Dispase   0.3% and 0.03% w/v 
  DNase    0.05% w/v 
 
PBMCs were incubated in the enzyme solutions for 1 hour at 37°C. Cells were then 
washed twice with PBS, re-suspended in SB with 2% v/v mouse serum and incubated 
for 15 minutes at 4°C. Cells were then incubated with appropriate concentrations (as 
shown in table) of the following mAbs for 30 minutes at 4°C: Qdot™ 605-conjugated 
anti-CD4, PerCP/Cy5.5™-conjugated anti-CD8, Alexa Fluor™ 700 (AF700)-
conjugated anti-CD19, PE/Cy7™-conjugated anti-CD25, APC-conjugated anti-CD69, 
PE-conjugated anti-a4 integrin, FITC-conjugated anti-b7 integrin. Samples were 
washed with excess SB and re-suspended in SB. Samples were kept on ice in the dark 
and analysed within 4 hours. 
Fluorescent	staining	of	isolated	cells	
Most of the cell surface markers of interest were the same as for the co-culture studies: 
CD4, CD8, CD19, CD25 and CD69. However, the expression of the a4b7 integrin was 
additionally investigated, as a4b7 is a marker of lymphocytes in the peripheral 
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circulation that have been exposed to antigen in the gut (as discussed in the 
introduction). This required separate fluorescent antibodies for a4 and b7. 
Fluorescent	antibodies	
PBMCs were isolated from peripheral blood using the same method as described for 
the in vitro experiments. Development of the technique for isolation of cells from the 
mucosal biopsies is described in chapter 4. For both, once isolated, the cells were 
fluorescently labelled as described for the in vitro studies.  
Two fluorescent antibody panels were used for these experiments. In the development 
of the technique for isolation of cells from mucosal samples the panel in Table 2-2 was 
used for the first three patient samples. An improved antibody panel was determined, 
shown in Table 2-3, which enabled a fluorescent labelling of a single sample of cells 
whilst identifying all the necessary cell surface markers.  
	
Table 2-2: Table of mAbs, used initially for the in vivo study, and their corresponding fluorophors. 
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), Alexa Fluor™ 700 
(AF700), quantum dot (Qdot™), cyanine dye (Cy7™).  
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Table 2-3: Table of mAbs, used for most of the in vivo study, and their corresponding fluorophors. 
Fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), Alexa Fluor™ 700 
(AF700), quantum dot (Qdot™), cyanine dye (Cy7™). 
Viability	
It is necessary to identify viable cells when using fluorescent labelling, and this is 
especially true for cells isolated from gut mucosa biopsies since they are subjected to 
both physical and chemical disruption. Figure 2-14 shows scatter plots for cells isolated 
from peripheral blood, and the gut epithelial and lamina propria layers. For both gut 
cell populations, the scatter plot is much more widely distributed than that of the 
PBMCs. Viability staining shows that both the lymphocyte population, and the larger 
and more granular cells further out on the scatter plot, are in fact viable.  
Fluorphore	 mAB	 Clone	 Concentra2on	(1x106	cells/100µl)	 Catalogue	number	
Qdot	605™		 an,-CD4			 S3.5	 1µl	 Invitrogen	#Q10008		
Qdot	705™		 an,-CD8		 3B5	 1µl	 Invitrogen	#Q100509		
Alexa	Fluor™		 an,-CD19		 HIB19	 20µl	 Biolegend	#302226		
APC-Cy7™		 an,-CD69		 FN50	 0.5µg	 Biolegend	#310914		
PE-Cy7™		 an,-CD25		 HI30	 0.5µg	 Ebioscience	#25-0259-42		
FITC™	 an,-β7	 FIB27	 0.25µg	 Biolegend	#121010		
PE™	 an,-α4		 9F10	 5µl	 Biolegend	#304303		
Ultraviolet	 LIVE/DEAD®	 N/A	 1µl	 Invitrogen	L23105	
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Figure 2-14: Scatter plots for cells isolated from the peripheral blood, gut epithelium and gut lamina 
propria. Histograms reflect viability staining: open red is unstained, filled blue is the stained “lymphocyte” 
population, filled orange is the “other cell types” population.  
Identification	of	lymphocyte	subsets	and	their	activation	status	
Enzyme	digestion	assays	
Figure 2-15 shows the gating strategy for the enzyme digestion assays. Panel 1-A 
identifies the activated lymphocyte population, and panel 1-B identifies the viable cells. 
Identification of CD4+, CD8+ and CD19+ cells, and their expression of CD25 and CD69, 
were carried out in keeping with the co-culture experiments.  
Identification of a4b7+ cells is complicated by the single integrin requiring two separate 
fluorescent labels. Whilst an antibody to a4b7 has been produced, it is not 
commercially available. There are antibodies to human forms of both a4 and b7, but 
since both can also be expressed with other integrins e.g. as a4b1, both must be 
labelled to accurately identify a4b7+ cells. Therefore, when identifying those cells a 
scatter plot of each labels fluorescence is created. On the basis of the isotype control 
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the scatter plots is divided into 4 sections: a4-b7-, a4+b7-, a4-b7+ and a4b7+. This can 
be seen in panel 2-D of Figure 2-15. 
	
Figure 2-15: Gating strategy for the enzyme digestion assay. Panel 2 - A - for this viability stain red filled 
histogram reflects unstained cells and blue fill reflects stained. Panel 2 – B and C - for the activation 
marker histograms red fill reflects isotype control and blue fill reflects labelled cells. 
Patient	samples	
The gating strategy for identifying lymphocytes in the peripheral blood, gut epithelium, 
and lamina propria of patients are shown in Figures 2-16 to 2-18. Whilst in the PBMC 
preparation there is a clear lymphocyte population, the cells isolated from the gut are 
more diverse and the lymphocyte population less clear. Therefore, for both mucosal 
epithelium (MEL) and lamina propria (LP) cells, the lymphocyte subsets were identified 
from all events on the scatter plot. It was then possible to identify CD4+, CD8+ and 
CD19+ lymphocytes on the original scatter plot. This was then used to locate the 
lymphocyte gate for subsequent assessment of relative proportions.  
1	
2	
A	 B	 C	 D	
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Figure 2-16: Gating strategy for peripheral blood lymphocytes in the in vivo study. Panel 1B - open red 
histogram represent unstained cells, and the blue filled histogram stained cells. Panels 3A to B - open 
red histogram represents the isotype control and filled blue the fluorescently labelled cells.  
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Figure 2-17: Gating strategy for epithelial lymphocytes. Panel 1A - scatter plot of all cells isolated from 
the epithelial layer. Panel 1B - populations identified in B2-3 shown on the original scatter plot, identifying 
the location of the lymphocyte population. Panel 1C - open red histogram represents unstained cells, 
whilst the filled blue represents stained cells. Panels D2 and 3 – open red histograms where open red 
represents the isotype control and filled green the fluorescently labelled cells. Panels 5A and B – open 
red histograms represent the isotype control and filled purple the fluorescently labelled cells. 
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Figure 2-18: Gating strategy for lamina propria lymphocytes. Panel 1A - scatter plot of all cells isolated 
from the epithelial layer. Panel 1B - the populations identified in B2-3 shown on the original scatter plot, 
identifying the location of the lymphocyte population. Panel 1C – open red histogram represents unstained 
cells, whilst the filled blue represents stained cells. Panels D2 and 3 – open red histograms represent the 
isotype controls whilst filled green represent the fluorescently labelled cells. Panels 5A and B – open red 
histograms represent the isotype control and filled purple the fluorescently labelled cells. 
Measurement	of	bone	turnover	markers	
Bone metabolism refers to activity of osteoblasts and osteoclast activity in terms of 
formation and resorption of bone. Organic compounds released by these processes 
can be measured in blood and urine, and used to assess bone metabolism (as 
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discussed in the Introduction). Analysis of bone turnover markers in blood and urine 
was carried out by the Bone Analysis Laboratory of the University of Sheffield and the 
biochemistry laboratory at Sheffield Teaching Hospitals NHS Trust. Details of the 
methods used are given below.  
Type	1	procollagen	amino-terminal	propeptide.		
Bone primarily consists of type 1 collagen which is derived from type 1 pro-collagen 
synthesised by fibroblasts and osteoblasts. Type 1 pro-collagen has amino (N) and 
carboxy (C) terminal extensions (both propeptides) that are removed during the 
conversion of pro-collagen to collagen. The propeptide with amino terminal extensions, 
also known as P1NP, is most commonly measured. Once released and has entered 
the blood stream thermal degradation effects convert the trimeric form to monomeric.  
Serum levels were measured using an Elecsys total P1NP assay (Roche #03141071), 
utilising electrochemoluminescence. For this immunoassay, serum is incubated with a 
biotinylated monoclonal P1NP-specific antibody, a ruthemium labelled monoclonal 
P1NP-specific antibody and streptavadin-coated micro-particles. The biotin labelled 
antibody binds to the streptavidin of the micro-particle. The P1NP molecule then binds 
to two types of antibody: one bound to a micro-particle, the other bound to a ruthenium 
molecule. The complex can be isolated by application of a magnet allowing non-bound 
molecules to be removed. Application of voltage then induces chemoluminescence by 
the ruthenium complex [Ru(Bpy)3]2+, with the molecule being regenerated by 
tripropylamine (TPA). The luminescence was measured using a Cobas E411 
automated immunoassay analyser. 
Osteocalcin	
Osteocalcin is the most important non-collagen protein in bone matrix. It is a bone-
specific, calcium binding protein which is dependent on vitamin K. It is synthesised by 
osteoblasts in response to vitamin D3. Osteocalcin is assimilated into bone, and 
released into the blood stream where it can be measured. 
Serum osteocalcin levels were measured using an Elecsys™ N-MID osteocalcin assay 
(Cobas #12149133). This method utilises electrochemoluminescence as described 
above for the measurement of P1NP, the only difference being the use of a 
biontinylated monoclonal osteocalcin specific antibody. 
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N-telopeptide	of	type	1	collagen	
N-telopeptide of type 1 collagen, NTx, is a marker of bone resorption and increases 
when there is increased osteoclast activity.  
Patients were starved overnight, prior to their endoscopy, and their second urine 
sample of the day collected. Samples were analysed for NTx, corrected for the urine 
creatinine level to account for any dilution effect, by the biochemistry laboratory of 
Sheffield Teaching Hospitals NHS Foundation Trust using a competitive immunoassay 
(Vitros #680 0030). In brief, greater concentrations of NTx in the urine reduce the 
binding of luminogenic substrates and decrease the amount of light emitted. 
Wells are coated with a synthetic NTx peptide able to bind a mouse monoclonal anti-
NTx antibody conjugated to a horseradish peroxidase (HRP). HRP generates 
luminescence by catalysing the oxidation of a luminol derivative, and the effect is 
prolonged by the addition of an electron transfer agent. The sample is added to the 
peptide coated wells with the HRP-conjugated antibody. The greater the concentration 
of NTx in the urine sample the less HRP will bind to that on the well. The liquid portion 
is removed, thus discarding the HRP bound to the urinary NTx leaving only that bound 
to the synthetic NTx peptide which remains within the well. The luminescence reagent 
(containing the luminol derivative and electron transfer agent) is added to the well 
generating luminescence proportional to the amount of HRP bound to the well. This, 
in turn, is inversely proportional to the concentration of NTx in the urine sample. The 
concentration of NTx will be affected by the how much urine the subject has produced, 
thus results are corrected for the concentration of creatinine in the urine. 
Measurement	of	BMD	by	DXA	
As discussed in the introduction, dual X-ray absorptiometry (DXA) provides a non-
invasive method of measuring bone mineral density (BMD). One important aspect of 
its use in children is that it expresses the measured BMD per unit area, which for 
smaller bones leads to an underrepresentation of the bones true mineral content (see 
earlier discussion). A more accurate value for BMD would be expressed per unit of 
volume, and so several different methods have been used to calculate the volume of 
bone from its projected area.  
13 patients with confirmed IBD had a DXA scan within 3 months of their enrolment into 
the study. DXA scans were obtained using the GE Healthcare Lunar iDXA. Volumetric 
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BMD (vBMD) was calculated using the method of Carter as described in the Alphabet 
Study (Crabtree et al 2017). In this study 3598 children aged 4 to 20 years were 
recruited and their BMD measured by GE-Lunar and Hologic scanners across 7 
centres. The data were used to construct reference values for measures of BMD in 
keeping with the 2013 ISCD recommendations (Kalkwarf et al 2014). They recommend 
that in children with short stature or growth delay (seen in children with IBD) should be 
reported as either bone mineral apparent density (BMAD) or TBLH adjusted for the 
subject height Z-score. For this study BMAD was used as described by Carter et 
al (Carter et al 1992): 
Lumbar spine BMAD (g/cm3) = 
("#$%&"#$'&"#$(&"#$))(+%&+'&+(&+))  
Where Vn is the volume of the nth individual vertebrae = APn1.5 (APn = projected 
vertebral area of the nth vertebra).  
BMCn is the bone mineral content of the nth vertebrae. 
The calculated BMAD of cases was compared to three healthy controls, identified from 
the Sheffield database which contributed to the Alphabet Study, matched for age and 
sex. 
Statistics	
The section describes the statistical tests used to analyse the data presented within 
this thesis. Advice was provided by Maths and Statistics Help (MASH) of the University 
of Sheffield, and Laerd Statistics (https://statistics.laerd.com) an online guide to 
statistics and the software programme SPSS. 
Independent	samples	T-test	
The independent samples T-test is used to determine if a difference exists between 
the means of two independent groups on a continuous dependent variable. It has three 
assumptions in relation to the study design: 
1. There is one dependent variable measured at the continuous level 
2. There is one independent variable that consists of two categorical and 
independent groups 
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3. There is independence of observations 
The dependent variable is usually the outcome measure, and continuous indicates it 
is measured as a scale e.g. the number of Saos-2 cells. The independent variable is 
the aspect of the experiment which is adjusted. An example would be whether the 
Saos-2 cells are cultured in a PBMC or CD4+ lymphocytes activated cell supernatant.  
There are also three assumptions about the data 
4. There should be no significant outliers 
5. The dependent variable should be normally distributed 
6. There is homogeneity of variance 
Any deviation from these three assumptions, and interventions to resolve them, are 
discussed in the results section. Outliers were looked for by inspection of boxplots. 
Normality was assessed by the Shapiro-Wilk test for normality. Whilst it is true that to 
run a T-test data should be normally distributed, the test remains accurate even when 
this assumption is not met (Wilcox 1995). Considered more important is the variance 
of the data, which needs to be similar between the two variables. This is measured by 
Levene’s test of equality of variance. Both normality and variance can be adjusted by 
transforming the data using square function, square root, inverse or log10. 
It was assumed that the experimental data would be normally distributed. This was in 
part because of central limit theorem which argues that with enough observations the 
data will be normally distributed (Läärä 2009). For the in vitro experiments, each well 
of Saos-2 would have many cells, all with very similar characteristics, thus each 
experiment was carried out with a large “population”. T-tests were also used for the 
flow cytometry data as each value was based on analysis of large numbers of 
individual cells. 
ANOVA	
Analysis of variance (ANOVA) has very similar requirements to the independent 
samples T-test, including the need for normally distributed data. It is used when there 
are more than two groups of data to compare because multiple comparisons increase 
the chance of finding a false positive or type 1 error. Thus, it is an omnibus statistic 
reflecting the data overall, rather than comparing the means of each group. It is 
therefore usually followed by post-hoc testing which compares all the groups to each 
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other, such as Tukey’s. This can sometime produce conflicting results with the ANOVA 
finding no difference, but the post hoc test finding one. Given that specific predictions 
were not made for these experiments, when such a conflict occurred the findings of 
the ANOVA were given priority.  
The basic requirements are the same as that of the independent samples T-test (see 
above), except that the number of independent variables is increased which affects 
the type of ANOVA.  
One-way	ANOVA	
This is used when there is one independent variable with two or more categorical 
variables. An example of its use would be to compare the number of Saos-2 cells (the 
dependent variable) each day over a five-day period (one independent variable with 
five groups). The one-way ANOVA would say whether the cells grew overall, and post 
hoc testing would compare the differences between each individual day (a total of ten 
comparisons). When there is more than one independent variable ANOVA can be 
used, but the interpretation becomes more complex. 
Two-,	three-,	and	four-way	ANOVA	
The co-culture experiment investigated the effects of three independent variables on 
Saos-2 growth (or four variables if also considering the type of immune cell population) 
and statistical analysis was carried out using two-, three- and four-way ANOVA. The 
use of multiple ANOVAs is not usual in biological experiments but in this instance made 
it possible to consider the combined effects of all the independent variables on the 
growth of the Saos-2 cells. The effect of each variable could have been quantified 
statistically using a series of T-tests, as used in studies quoted in this thesis (Kawakami 
et al 1997; Yamaza et al 2008), but there are three limitations to this approach.  
The first is the occurrence of type 1 errors resulting from repeated analyses. Whether 
this is a significant issue depends on whether you consider each well of the plate an 
individual experiment or part of a whole experiment. However, biological studies do 
sometimes use a one-way ANOVA rather than a series of T-tests (Rifas 2006; Croes 
et al 2016). Whilst the one-way ANOVA has important differences from a multiple 
ANOVA one shared feature is they both account for multiple analyses and, whilst the 
papers don’t discuss their rationale, this may be why they chose to use ANOVA. 
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The second limitation is that using a series of T-tests only allows consideration of the 
effect of one variable at a time, and if there are two or more “independent” variables 
they may be inter-dependent. For example, in this study it was found that increasing 
the number of resting immune cells increased the growth of Saos-2 cells whilst 
increasing the number of activated immune cells inhibited growth, with both acting in 
a dose dependent manner. Therefore, it is potentially misleading to consider (both 
statistically and mechanistically) the effects of cell number and their activation status 
independently. 
The third limitation then arises is if interactions between the variables assessed by T-
test are determined by a comparison of p values. One group found that 50% of 157 
articles from 5 top ranking journals, where interactions had been assessed, used this 
method (Nieuwenhuis et al 2011). They found what they describe as an erroneous 
approach was most common in cellular and molecular neuroscience, and it potentially 
led to incorrect conclusions in two thirds of all articles.   
Interpretation	of	multiple	ANOVA	analysis	
Whilst multiple ANOVA has advantages it is a more complicated analysis, but this is 
necessary when considering multiple variables and wouldn’t necessarily be considered 
in a series of T-tests.  
Figure 2-19 shows three representative graphs, each with two independent variables. 
One reflected by the y-axis, and has three groups indicated by the data points 
(dependent variables). The other is reflected by the trend lines, and has two groups 
indicated by the line colour (independent variables). 
In graph A the two trend lines (solid blue and green) are parallel which means they 
don’t interact. If the immune cell number is carried on the x axis and the immune cell 
activation status shown by the two solid trend lines, the red dotted line represents the 
average immune cell number and excludes the effect of their activation status. Since 
the lines are all parallel it is possible to statistically analyse the effect of immune cell 
number alone, and is referred to as a “main effect”. 
In graphs B and C, the two trend lines are not parallel indicating an interaction between 
the independent variables, and the red dotted line (or average) no longer reflects either 
of the trend lines. Therefore, the only way to statistically analyse the effect of immune 
cell number, is to make a series of comparisons based on both immune cell number 
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and the activation status. Unhelpfully in these circumstances, despite the analysis 
being more complicated, the analysis is referred to as the “simple main effects”. 
	
Figure 2-19: Representative graphs demonstrating interactions between independent variables. The y-
axis represents the dependent variable, the x-axis one independent variable, and the coloured (solid) 
trend lines the second independent variable. Dashed lines represent the average of the two trend lines. 
Graph A shows no interaction, graph B shows an ordinal interaction, graph C shows a disordinal 
interaction.  
The	Mann-Whitney	U-test	
Whilst described as the non-parametric equivalent to the T-test, the more important 
difference is that it compares the distribution of two populations rather than their 
means. Therefore, the distribution of data does not need to be “normal”, although if the 
distributions are similar then the medians of the two populations can be compared.  
This test was used for statistical analysis of the patient data that were not expected to 
be normally distributed, such as BMD and bone turnover markers.  
Linear	regression	
This test was used to assess relationships between immune cell populations and BMD 
in patients. It produces a value “R” which reflects the strength of the association 
between two variables, the higher the value the stronger the association, and whether 
it is direct or inverse, the latter giving a negative value for R. Linear regression also 
measures how much of the variation is due to the association between the two 
variables. As an example of this, a population of people will have a range of body 
weights. An observational study might find an inverse relationship between exercise 
and body weight, but only explain 10% of the populations variation in body weight.  
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3 In	vitro	results	
Effect	of	immune	cells	and	their	secreted	factors	on	the	growth	and	functional	
activity	of	Saos-2	cells	
The following experiments used immune cells isolated from blood samples provided 
by healthy volunteers. Each experiment was repeated three times on different days 
using blood from different volunteers, but experiments for each donor were not 
replicated. 
Characterisation	of	lymphocyte	populations	and	Saos-2	cells		
Relative	proportions	of	lymphocyte	subsets	in	the	PBMC	and	CD4+	enriched	populations		
The two populations of immune cells were different in respect to their proportions of 
lymphocytes (see Figure 3-1). The enrichment process increased the proportion of 
CD4+ lymphocytes from 45% to 93.5%, with the proportions of CD8+ and CD19+ cells 
being reduced from 24% to 2.9% and 7.6% to 1.1% respectively. The relative 
proportions of lymphocytes were unchanged following activation with Miltenyi Treg 
Suppression Inspector Beads. 
Effects	of	activation	on	the	proliferation	and	phenotype	of	immune	cells	
Cell	number	
A 4-day incubation of immune cells with Miltenyi Treg Suppression Inspector Beads 
increased numbers of PBMCs (443,333 ± 74,461 resting vs 1,660,000 ± 530,031 
activated) and CD4+ lymphocytes (390,667 ± 87,351 resting vs 1,102,250 ± 475,546 
activated). However, these differences were not statistically significant, primarily due 
to variability in the data (see Figure 3-2). This variability might result from the need to 
use counting beads and the repeated incubation and washing steps that were used for 
the fluorescent staining of the cells for flow cytometric analysis, during which cells are 
lost. 
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Figure 3-1: A comparison of the relative proportions of lymphocytes within a PBMC and a CD4 enriched 
population, and the effects of polyclonal activation. Panel A - the proportion of lymphocytes in a PBMC 
population before and after activation with Miltenyi Treg Suppression Inspector Beads. Panel B -  the 
proportion of lymphocytes in a CD4+ enriched population before and after activation with Miltenyi Treg 
Suppression Inspector Beads. Data are derived from three independent experiments, from three donors 
with no technical repeats, and are presented as means ± 1 standard error. 
	
Figure 3-2: Effect of polyclonal activation on the proliferation of lymphocytes in PBMC and CD4+ enriched 
immune cell populations. The graphs compare incubation over a 4-day period in medium alone (resting) 
with the addition of with Miltenyi Treg Suppression Inspector Beads (activated). Data are derived from three 
independent experiments, from three donors with no technical repeats, and are presented as means ± 1 
standard error. 
Size	and	granularity	
Changes in forward scatter (FSC) and side scatter (SSC), describing respectively the 
size and granularity of cells, have previously been shown to correlate with 
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activation (Webster et al 1995). In these experiments, visible changes in the side and 
forward scatter of the activated lymphocyte populations were apparent (Figure 3.3). 
Activation with Miltenyi Treg Suppression Inspector Beads increased the FSC and SSC 
of cells, and could be visualised using dot plots (Figure 3-3, panel A) or histograms 
(Figure 3-3, panel B). Numerical values for SSC and FSC were generated to allow 
statistical comparison. Activation with Miltenyi Treg Suppression Inspector Beads 
statistically increased the FSC and SSC of PBMCs and CD4+ populations (Figure 3-3, 
panels C and D). 
	
Figure 3-3: Effects of polyclonal activation on the FSA and SSC of lymphocytes. Panel A - representative 
scatter plots of resting and activated PBMCs illustrating the effects of activation with Miltenyi Treg 
Suppression Inspector Beads on FSC and SSC, with the lymphocytes population highlighted. Panel B - 
overlay histograms comparing the SSC and FSC of the resting (blue) and activated (red) lymphocytes. 
Panels C and D - Numerical values for SSC and FSC. Data are derived from three independent 
experiments, from three donors with no technical repeats, and are presented as means ± 1 standard error. 
Influence	of	activation	with	Miltenyi	Treg	Suppression	Inspector	Beads	on	the	expression	
of	the	activation	markers	CD69	and	CD25	
In these experiments, incubation of PBMCs with Miltenyi Treg Suppression Inspector 
Beads increased both the percentage of cells expressing CD25 and CD69 and the 
overall intensity of their expression (see 
Figure 3-4). This was seen across all the lymphocyte subsets (CD4+, CD8+ and 
CD19+), but only the increases in percentage of positive lymphocytes were statistically 
significant. Apart from expression of CD25 by CD19+ B cells, the increases in 
fluorescent intensity were not statistically significant. However, the fluorescent intensity 
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of CD69 expression increased by a factor of approximately 1.5, whereas the 
expression of CD25 increased by a factor of up to 12, depending on the subset (5.9 
for CD4+ T cells, 12 for CD8+ T cells and 4 for CD19+ B cells). 
What these experiments do not demonstrate is the variation of expression over the 4-
day incubation period, and since CD69 is considered an early activation marker the 
intensity may change over that period. What can be seen is that all three subsets up-
regulated their expression of both activation antigens, and that appears to be greater 
for CD25 than CD69, at least at the 4-day time-point. 
	
Figure 3-4: Effect of polyclonal activation on the expression of CD25 and CD69 by lymphocyte subsets 
within a PBMC population. Panel A – percentage of lymphocyte subsets expressing CD25 and CD69 * p 
< 0.001 ** p = 0.001 + p = 0.003. Panel B – fluorescent intensity of CD25 expression by lymphocyte 
subsets § p = 0.006. Panel C – fluorescent intensity of CD69 expression by lymphocyte subsets. 
Comparing panels B and C, there is a more marked difference in expression of CD25 between resting 
and activated cells, than for CD69. Data are derived from three independent experiments, from three 
donors with no technical repeats, and are presented as means ± 1 standard error. 
A similar pattern was seen for the CD4+ cells in a population which was enriched for 
these cells. As shown in 
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Figure 3-5, activation with Miltenyi Treg Suppression Inspector Beads induced 
statistically significant increases in the expression of CD25 (6.6% vs 73.4%; p = 0.013) 
and CD69 (1.4% vs 64%; p = 0.002), when measured as the percentage of positive 
cells. Activation also induced a statistically significant increase in the intensity of CD25 
expression (3550.7 vs 46104; p < 0.001), but not the intensity of CD69 expression 
(1449.0 vs 2334.7; p = 0.344), at least at this 4-day time-point. 
Expression	of	the	Major	Histocompatibility	(MHC)	antigens	by	Saos-2	cells	
Major histocompatibility antigens / clusters (MHCs) are expressed on the surface of 
many human tissue cells. Whereas MHC (human leukocyte antigen, HLA in the 
humans) class I is expressed on all nucleated cells in humans, MHC class II expression 
is more restricted and is selectively expressed on antigen presenting cells (APCs) such 
as dendritic cells (DCs), monocytes/macrophages and B cells, as well as on certain 
populations of activated cells such as activated T cell populations and endothelial cells. 
MHC class II interacts with CD4 on T cells and, if this is allogeneic to the responding 
T cell, then potent T cell activation can be triggered. This process is known as the 
mixed lymphocyte reaction (MLR) if the triggering and responding cells are 
lymphocytes isolated from genetically dissimilar donors, and underpins the potent early 
rejection response that can be observed following organ transplantation. Given that  
	
Figure 3-5: Effects of polyclonal activation on the expression of CD25 and CD69 by CD4+ lymphocytes in 
PBMC and CD4+ enriched populations. Panel A - percentage of lymphocytes positive * p = 0.013 ** p = 
0.002. Panel B - fluorescent intensity + p < 0.001. Statistical significance of differences in the PBMC 
population are not repeated here. Data are derived from three independent experiments, from three 
donors with no technical repeats, and are presented as means ± 1 standard error. 
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MHC (HLA) class II expression on Saos-2 cells could therefore be a potent trigger of 
T cells in the co-culture experiments, it was important to determine the expression of 
HLA class I and class I by the Saos-2 cells. 
As the histograms in Figure 3-6 show, the Saos-2 cells expressed MHC class I but not 
MHC class II. Although the absence of MHC class II removes one potential 
confounding factor with regards to their potential ability to activate CD4+ lymphocytes, 
the presence of MHC class I could provide a mechanism by which CD8+ lymphocytes 
in the PBMC preparations are influencing the measure of proliferation of the Saos-2, 
in that CD8+ T cells could lyse Saos-2 target cells via the recognition of HLA class I. 
Although the frequency of cells that have the potential to kill Saos-2 cells would be 
expected to be extremely low and so the level of killing would be minimal, the possible 
influence of such responses on the measurements made and the interpretation of the 
data needs to be appreciated. 
	
Figure 3-6: Representative fluorescence histograms showing the expression of MHC class I and II by 
Saos-2 cells. MHC class I (left panel – fluorescein [FITC] fluorophore), but not MHC class II (right panel – 
phycoerythrin [PE] fluorophore), expressed by Saos-2 cells. Red histograms represent isotype controls, 
blue histograms represent stained cells. 
Effect	of	supernatants-derived	from	activated	immune	cell	populations	on	the	
growth	of	Saos-2	cells		
The aim of these experiments was to determine the effects of factors secreted by 
PBMCs or CD4+ lymphocytes on the growth of Saos-2 cells. For these experiments, 
PBMCs or CD4+ lymphocytes were incubated with Miltenyi Treg Suppression Inspector 
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Beads in bone cell media (BCM) for four days, after which the cells and beads were 
removed to leave the activated cell supernatant (ACS). Saos-2 cells were then cultured 
for 5 days in fresh medium with increasing concentrations of the supernatant. 
Growth	profile	of	Saos-2	cells	
Before undertaking experiments looking at the growth of Saos-2 cells, their growth in 
bone cell medium (BCM – as described in Methods and Materials) was studied. This 
was undertaken to establish their proliferation profile over the course of the 
experiments and identify lag and plateau phases.  
	
Figure 3-7: Saos-2 growth characteristics under normal culture conditions. Panel A - number of Saos-2 
cells on days 1 to 5 when cultured in BCM; dashed red line indicates a theoretical population reaching its 
size limit. Panel B - cell number relative to that of the day before. Data are derived from three independent 
experiments, from three donors with no technical repeats, and are presented as means ± 1 standard error. 
The solid blue line of the graph in panel A in Figure 3.7 shows the absolute number of 
Saos-2 cells on each of the 5 days of the culture period. Cell numbers increased 
steadily over that period with no apparent lag or plateau phase. On day 5, the Saos-2 
cells were still in a phase of growth, thereby indicating that culture periods of up to 5 
days would be appropriate to assess the influence of any potential factor using kinetic-
based analyses. If, for example, growth reached a plateau on day 3 (as indicated by a 
dashed red line on panel A in Figure 3-7) this could not be done. Panel B in Figure 3-7 
plots the cell number relative to that of the day before, showing rate of growth on each 
day, and was calculated by dividing the cell number on day x by that of the day before. 
The relative number, although varying between 1.17 and 1.88, was not significantly 
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different for each day (t-test, p>0.05), thereby supporting the conclusion that the cells 
were in a steady growth phase. 
Effect	of	activated	PBMC	and	CD4+	cell	supernatants	on	the	proliferation	of	Saos-2	cells	
This analysis compared the number of Saos-2 cells after 5 days of culture in different 
concentrations of activated cell supernatants (ACS; 0-50% v/v) derived from activated 
PBMCs or CD4+ lymphocytes. ACS from activated PBMCs (ANOVA; p = 0.017) and 
CD4+ lymphocytes (ANOVA; p = 0.028) similarly inhibited the proliferation of the Saos-
2 cells in a dose-dependent manner (Figure 3-8). Since only the concentration of ACS 
is seen to affect Saos-2 number, data were analysed using a one-way ANOVA. 
Although inhibition of proliferation was seen at a 6% v/v concentration, the inhibitory 
effect only reached statistical significance at a 50% v/v concentration for both media 
preparations, when compared to the medium alone control (PBMC 527,500 vs 275,317 
p = 0.015; CD4 485,150 vs 213,000 p = 0.021). 
	
Figure 3-8: Effect of supernatants from polyclonally activated PBMCs and CD4+ lymphocytes on the 
growth of Saos2 cells. Saos2 cells were cultured in medium alone or increasing concentrations of 
activated cell supernatant (ACS) for 5 days, at which time cell numbers were determined. Both forms of 
ACS dose-dependently inhibited the proliferation of Saos-2 cells, with the inhibitory effect becoming of 
statistical significance at 50% v/v for both ACS types. * p = 0.015 + p = 0.021. Data are derived from three 
independent experiments, from three donors with no technical repeats, and are presented as means ± 1 
standard error. 
The influence of ACS on the number of Saos2 cells was also determined on each day 
of the 5-day culture period (Figure 3-9). Both ACS types had a negative impact on the 
numbers of Saos-2, with the effects being visible as early as day 1 or 2. These 
observations indicate that cell number (the dependent variable) is potentially 
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influenced by the two variables, time and ACS type, and so the data were analysed 
using two-way ANOVA. Although these are independent variables the growth curves 
indicate that their effects may be inter-dependent (called an interaction). As discussed 
in the Materials and Methods, this influences the statistical analysis. In brief, if the two 
variables interact then their effects must be considered individually (known as the 
simple main effects). 
The two-way ANOVA comparing the PBMC and CD4-ACS to their respective controls 
revealed a statistically significant interaction between time and being cultured in ACS 
for both the PBMC-ACS (p = 0.02) and the CD4-ACS (p = 0.02) and the simple main 
effects are reported below for both ACS conditions. 
	
Figure 3-9: Effect of 50% v/v supernatants from polyclonally activated PBMCs and CD4+ lymphocytes on 
the growth of Saos-2 cells. Panel A - the growth of Saos2 cells in the presence of ACS derived for 
activated PBMCs, with no statistical interaction between the variables presence of ACS and time. * p = 
0.017 ** p < 0.001 § p = 0.033 §§ p = 0.022. Panel B - the growth of Saos2 cells in the presence of ACS 
derived from activated CD4+ lymphocytes, with a statistical interaction between the variables presence of 
ACS and time + p = 0.015 ++ p = 0.001. Data are derived from three independent experiments, from three 
donors with no technical repeats, and are presented as means ± 1 standard error. 
Cells grew in control media, the increase reaching significance on day 5 compared to 
day 1 (142,383 vs 527,500; p < 0.001). Saos-2 cells grew in PBMC-ACS (p = 0.009), 
increasing in number significantly by day 4 (87,683 vs 265,583; p = 0.033) through to 
day 5 (87,683 vs 275,317; p = 0.025) compared to day 1. However, they grew more 
slowly than those in the control medium, with significant reductions in the number of 
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Saos-2 cells on days 3 (297,183 vs 157,300; p = 0.017) and 5 (527,500 vs 275,317; p 
< 0.001). 
In the CD4-ACS experiment, the Saos-2 cells grew in the control medium (p < 0.001), 
the increase in cell number compared to day 1 reaching significance on day 4 (117,883 
vs 424,383; p = 0.002) and continuing to day 5 (117,883 vs 485,150; p < 0.001). 
However, in the 50% v/v CD4-ACS, cell numbers increased, but the difference was not 
significant (p = 0.422). This led to significant differences between the two conditions 
on day 4 (424,383 vs 244,933; p = 0.015) and day 5 (485,150 vs 213,000; p = 0.001). 
Despite there being differences in the pattern of statistical significance between the 
two experiments, on inspection the growth profiles appear broadly similar showing 
slower growth in the ACS condition of both experiments, relative to its control, over the 
five-day culture period. Comparing the growth curves of Saos-2 cells in ACS derived 
from activated PBMCs and CD4+ lymphocytes using a two-way ANOVA revealed no 
significant difference between the two conditions. There was growth overall (p = 
0.006), with increased numbers of cells on day 4 (mean difference 142,141; p = 0.016) 
and day 5 (mean difference 131,041; p = 0.030) compared to day 1. 
In summary, these data indicate that ACS derived from both PBMCs and CD4+ 
lymphocytes slows the growth of Saos-2 cells, and this effect is cumulative over time. 
However, no clear difference between the ACS types was demonstrated.  
Series	 1	 -	 influence	 of	 resting	 and	 activated	 immune	 cell	 populations	 on	 the	
growth	of	Saos-2	cells	
The data so far indicate that supernatants from activated PBMCs and CD4+ cells inhibit 
the growth of Saos-2 cells. Although this supports the hypothesis that inflammatory 
processes could affect bone metabolism, more complex cell-mediated processes may 
be involved in vivo. Therefore, a series of experiments were undertaken to investigate 
a series of potential factors: immune cell type i.e. PBMC or CD4+ lymphocyte enriched, 
activated or resting, contact between immune and bone cell, and the relative proportion 
of Saos-2 cells to immune cells. The growth of Saos-2 cells in response to these factors 
was measured, as were changes in the activation status of the immune cells. 
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Identification	of	Saos-2	cells	and	PBMCs	in	mixed	cultures	
One practical problem with this series of experiments was that whilst resting PBMCs 
and Saos-2 cells form distinct populations on FSC vs. SSC plots, activated PBMCs 
become larger, denser, and begin to ‘encroach’ into the light scatter region for the 
Saos-2 population (see Figure 3-10). This makes it difficult to identify the two cell types 
in a mixed population based on their FSC vs. SSC characteristics alone. It was 
therefore necessary to identify cells on the basis of discriminating surface antigen 
expression.  
CD45 is a surface antigen expressed only by cells of the haematopoietic system. 
Osteoblasts are mesenchymal in origin and so do not express this marker. CD45 
expression was therefore selected as a potential cell surface antigen which can 
distinguish the two different cell types in a mixed population, and a Pacific Blue™-
conjugated mAb was used. This approach allowed the two cell types to be identified in 
a mixed population (see Figure 3-11). All the cells in the lymphocyte populations 
express CD45, as the histogram of stained lymphocytes has shifted to the right for the 
stained cells. Saos-2 did not express CD45, as the histograms for the isotype controls 
and stained cells overlay each other. The overlay histograms for one experiment 
(Experiment 3) exhibited some overlap of the Saos-2 and activated lymphocytes with 
regards to Pacific Blue™ fluorescence. The reasons for this are not clear. 
	
Figure 3-10: Representative FSC vs. SSC scatter plots demonstrating the encroachment of activated 
lymphocytes into the light scatter region of Saos-2 cells. 
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Figure 3-11: Representative fluorescence histograms of CD45 expression by lymphocytes and Saos-2 
cells. Resting lymphocytes (column A), activated lymphocytes (column B) and Saos-2 cells (column C) 
with their respective isotype controls. Overlay histograms for the three cells types in each experiment are 
illustrated in Column D.  
Influence	of	resting	and	activated	PBMCs	on	the	growth	of	Saos-2	cells	
Increasing numbers of activated immune cells had a negative effect on Saos-2 growth 
(see Figure 3-12), a finding consistent with the effects of the activated cell supernatant. 
Resting PBMCs had an opposite effect, and the overall effect was to increase the 
growth of Saos-2, which was an unexpected finding. The presence of a transwell insert 
appears to promote the growth of the Saos-2 in both the resting and activated 
conditions. 
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Figure 3-12: Effects of resting and activated PBMCs on the growth of Saos-2 cells. Several factors are 
presented: activation status (resting or activated), contact status (in contact or separated by a transwell 
insert) and PBMC number (ratios are Saos-2 to immune cells e.g. 1:8 represents 100,000 Saos-2 cells 
and 800,000 PBMCs). Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error. 
The data was normally distributed but there was excessive variance (Levene’s test for 
homogeneity of variances, p = 0.002), addressed by carrying out a square-root 
transformation of the data (so that p = 0.088). There was no statistically significant 
interaction between the three independent variables of cell number, activation status 
and contacts status (p = 0.204). However, there were significant interactions between 
each possible pairing of independent variables. 
Two-way	interaction	between	activation	status	and	number	of	immune	cells	
There was a statistically significant interaction between activation status and the 
number of immune cells (p < 0.001) and their effects are shown in Figure 3-13. 
Increasing the number of resting PBMCs increased the growth of Saos-2 cells (p = 
0.024), and at a Saos-2 cell: PBMC ratio of 1:8 the increase was statistically significant 
when compared to control (mean difference -106 [95% CI -198 to -14.7]; p = 0.013). 
Increasing the number of activated PBMCs progressively inhibited the growth of Saos-
2 cells (p < 0.001), and at a Saos-2 cell: PBMC ratio of 1:2 the decrease was 
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statistically significant (mean difference 106 [95% CI 15 to 198]; p = 0.013). At all 
PBMC to Saos-2 ratios there was a significant difference in the number of Saos-2 cells 
in the activated and resting conditions (p < 0.001 for all ratios). 
	
Figure 3-13: The two-way interaction between activation status and PBMC number. *p < 0.001 ** p = 
0.013 + p = 0.05 ++ p = 0.001 (values are Bonferroni adjusted for multiple comparisons; a = 0.05). Data 
are derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error. 
Therefore, in keeping with the finding of an interaction, the effect of cell number is 
dependent on the activation status of the PBMCs. Resting PBMCs promote Saos-2 
growth whilst activated cells are inhibitory, with the latter having a greater overall effect. 
Two-way	interaction	between	contact	status	and	number	of	immune	cells	
There was a statistically significant interaction between contact status and the number 
of immune cells (p = 0.027) and their effects can be seen in Figure 3-14. It shows that 
in the contact condition the presence of PBMCs reduced growth, but increased growth 
when separated by transwell insert.  
Increasing the PBMC number had a statistically significant effect on the growth of 
Saos-2 cells when in contact (p = 0.025), but not in the presence of a transwell insert 
(p = 0.632). Although increasing the number of PBMCs in contact reduced the growth 
of Saos-2 the difference was only statistically significant at a ratio of 2:1 compared to 
control (mean difference 97.588 [95% CI 6.16 to 189]; p = 0.029), but there is no dose 
response apparent. For all PBMC to Saos-2 ratios the presence of a transwell insert 
significantly increased the number of Saos-2 cells. 
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Therefore, it appears that when PBMCs are in contact with Saos-2 they have a 
negative effect on growth, but when separated by a transwell insert the effect is 
positive.  
	
Figure 3-14: The two-way interaction between contact status and PBMC number. * p < 0.001 ** p = 0.008 
+ p = 0.005 p = 0.029 (p values are Bonferroni adjusted for multiple comparisons, a = 0.05). Data are 
derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error. 
Two-way	interaction	between	activation	status	and	contact	status	
There was a statistically significant interaction between the activation status of the 
immune cells and the contact status (p = 0.001).  
As can be seen in Figure 3-15 the presence of a transwell insert significantly increased 
the number of Saos-2 cells in both the resting (mean difference 40.729 [95% CI -80 to 
-1]; p = 0.043) and activated (mean difference -136 [95% CI 175 to 97]; p < 0.001) 
conditions, with the effect being greater in the activated condition. Activated PBMCs 
significantly reduced the number of Saos-2 cells when in contact (mean difference 199 
[95% CI 160 to 239]; p < 0.001), and in the presence of a transwell insert (mean 
difference 104 [95% CI 65 to 144]; p < 0.001). The effect was greatest in the contact 
group. 
This shows that the overall effects of resting and activated PBMCs i.e. positive or 
negative, are not affected by contact status; but Saos-2 number are greater in the 
presence of a transwell insert.  
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Figure 3-15: Two-way interaction between activation status and contact status in the PBMC co-culture. * 
p < 0.001 ** p = 0.043 (values are Bonferroni adjusted for multiple comparisons; a = 0.05). Data are 
derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error.  
Influence	of	resting	and	activated	CD4+	lymphocytes	on	the	growth	of	Saos-2	cells	
The co-culture experiments were repeated using a CD4+ cell-enriched population.  
Figure 3-16 illustrates all three experimental factors and their effect on Saos-2 number 
at the end of the culture period. The findings are like those for the PBMC experiments, 
with resting CD4+ cells seemingly promoting the growth of Saos-2, and activated CD4+ 
cells inhibiting growth. In the activated conditions, the presence of a transwell insert 
appeared to lessen the inhibitory effect. As for the PBMC experiments, data were 
analysed by three-way ANOVA. Although data were normally distributed and there was 
homogeneity of variance, it was square root transformed to be treated in a similar	way 
to the PBMC data.  
There was no statistically significant three-way interaction between cell number, 
activation status and contacts status (p = 0.283). Of three potential two-way 
interactions, activation status/cell number (p < 0.001) and activation status/contact 
status (p = 0.001) were statistically significant. The interaction between contact status 
and cell number was the only non-significant interaction. 
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Figure 3-16: Effects of a CD4+ lymphocyte enriched population on the growth of Saos-2 cells. Three 
factors are presented: activation status (resting or activated), contact status (in contact or separated by a 
transwell insert) and CD4+ lymphocyte enriched population cell number (ratios are Saos-2 cell to CD4+ 
lymphocyte enriched population e.g. 1:8 represents 100,000 Saos-2 cells and 800,000 CD4+ lymphocyte 
enriched population). Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error.  
Two-way	interaction	between	activation	status	and	number	of	CD4+	lymphocytes	
There was a statistically significant interaction between activation status and the 
number of CD4+ lymphocytes (p < 0.001). 
The number of CD4+ lymphocytes significantly influenced Saos-2 cell growth, 
increasing it in the resting condition (p = 0.035) and decreasing it in the activated 
condition (p = 0.002), with an apparent dose response effect (see Figure 3-17). 
However, whilst the difference relative to control reached significance in the activated 
condition at 400,000 Saos-2 cells (mean difference 110.1 [95% CI 8.33 to 211.8]; p = 
0.026) and 800,000 (mean difference 112.0 [95% CI 10.23 to 213.7; p = 0.022), none 
of the differences to control were statistically significant in the resting condition.  
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Figure 3-17: Two-way interaction between activation status and CD4+ lymphocyte number. * p < 0.001 ** 
p = 0.026 + p = 0.022 (values are Bonferroni adjusted for multiple comparisons; a = 0.05). Data are 
derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error. 
A reciprocal analysis of the effect of activation at differing numbers of CD4+ lymphocyte 
enriched population cells found that activation status caused a statistically significant 
difference in Saos-2 cell number at Saos-2 cell: CD4+ lymphocyte enriched population 
cell ratios of 1:2 and above.  
Therefore, in keeping with the finding of an interaction, the effect of cell number is 
dependent on the activation status of the CD4+ lymphocyte enriched population with 
resting cells seemingly promoting Saos-2 growth and activated cells inhibiting it. This 
is similar to finding for the PBMCs. 
The	two-way	interaction	between	activation	status	and	contact	status	
There was a statistically significant interaction between the activation status of the 
CD4+ lymphocyte enriched population cells and the contact status (p = 0.001) shown 
in Figure 3-18. 
For the resting CD4+ lymphocytes presence of a transwell insert resulted in a non-
significant increase in the growth of Saos-2 cells (mean difference -16 [95% CI -59.710 
to 27.830]; p = 0.466), but a significant increase in the growth of Saos-2 cells in the 
activated condition (mean difference -120.652 [95% CI -164.423 to -76.882]; p < 
0.001).  
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Figure 3-18: Two-way interaction between activation status and contact status in the CD4+ lymphocyte 
enriched population co-culture * p < 0.001 ** p = 0.008 (values are Bonferroni adjusted for multiple 
comparisons; a = 0.05). Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error. 
The reciprocal analysis found that for both cells in contact, and those separated by a 
transwell insert, activation depleted cell numbers significantly. In the contact condition, 
activation numbers fell by 165 (95% CI 121 vs 208; p < 0.001), whereas in the transwell 
condition they fell by 60 (CI 16 to 104; p = 0.008). 
The	two-way	interaction	between	contact	status	and	cell	number	
There was no statistically significant interaction between contact status and the 
number of CD4+ lymphocyte enriched population cells. On inspection of the graph in 
Figure 3-19, contact appears to reduce Saos-2 cell numbers relative to control, and 
the presence of a transwell insert increases Saos-2 cell number. 
In both the contact and transwell groups, there was no statistically significant difference 
in proliferation compared to their respective controls. However, there are visible 
differences between the two groups on each day. They reach statistical significance at 
100,000 (197 vs 282; p = 0.017), 200,000 (192 vs 259; p = 0.017) and 800,000 (159 
vs 263; p = 0.004). 
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Figure 3-19: Two-way interaction between contact status and CD4+ lymphocyte number. * p = 0.017 ** p 
= 0.004 (p values are Bonferroni adjusted for multiple comparisons, a = 0.05) Data are derived from three 
independent experiments, from three donors with no technical repeats, and are presented as means ± 1 
standard error. 
Comparison	of	the	effect	of	PBMCs	and	CD4+	lymphocytes	on	the	growth	of	Saos-2	cells	
The purpose of this section is to bring together the results of the two co-culture 
experiments. The experiments were, independently, complex and considered several 
inter-dependent variables. The statistical analysis reflects this, with it not being 
possible to discuss the effects of each independent variable due to interactions 
between them. It is also desirable to compare the effects of PBMCs and CD4+ 
lymphocytes on the growth of Saos-2 cells. Figure 3-20 repeats all the graphs in 
Figures 3.12 to 3.19, placing them next to each other for comparison. The patterns for 
each corresponding graph appear similar, indicating that there is little difference in the 
effect of PBMCs and CD4+ cells on Saos-2 cell growth. Table 3-1 summarises the 
statistical analyses and, whilst there are differences, the effects are broadly similar.  
The two immune cell subtypes were compared. A T-test established that there was no 
statistically significant difference between the PBMC and CD4+ lymphocyte enriched 
population controls (68,117 vs 58,060; p > 0.05). After this, a series of two-way 
ANOVAs were carried out comparing the groups. Excessive variance in the data 
precluded 4- and 3- way ANOVA, despite square root transformations (maintained for 
consistency with the previous analyses). There were no statistically significant two-
way interactions, although interactions are seen in the graphs (see Figure 3-21). 
Comparing the effects of PBMCs and CD4+ lymphocyte enriched population cells on 
Saos-2 number, a difference was only seen in the activated contact group (45 vs 82; 
p = 0.008), for all others there was no significant difference. 
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Figure 3-20: Comparison of data patterns in the PBMC and CD4+ lymphocytes experiments. The graphs 
are those seen in Figures 3.12-19, repeated here to enable comparison of data patterns between the two 
immune cell populations. 
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Figure 3-21: Direct comparisons of the effects of PBMCs and CD4+ lymphocyte enriched population cells 
on Saos-2 proliferation. Y axes are the square root of Saos-2 number and X axes the number of immune 
cells. Data are derived from three independent experiments, from three donors with no technical repeats, 
and are presented as means. Error bars are not included due to overlap precluding meaningful 
interpretation. 
	
Table 3-1: Summary of the findings from both three-way ANOVAs. It shows the six combinations of the 
three variables, and their outcome in the PBMC and CD4 conditions.  
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Effect	of	Saos-2	cells	on	the	activation	status	of	lymphocytes		
Whilst the primary aim of this experiment was to look at the effects of immune cells on 
Saos-2 cell growth, using flow cytometry it was also possible to investigate the 
reciprocal effects of Saos-2 cells on the activation status of immune cells.  
Effect	of	Saos-2	cells	on	expression	of	activation	markers	by	lymphocytes	within	a	PBMC	
population	
Within the PBMC population it was possible to examine changes in expression of CD25 
and CD69 by CD4+, CD8+ and CD19+ lymphocytes (see Figure 3-22). Expression of 
activation markers, as measured by the percentage of cells positive, within both the 
resting and activated conditions, follows a similar pattern for all three lymphocyte types. 
In the resting conditions, Saos-2 cells induce expression of activation markers, 
whereas in the activated condition the reverse is seen, with Saos-2 cells inhibiting 
expression. 
	
Figure 3-22: Influence of Saos-2 cells on the expression of CD25 and CD69 by CD4+, CD8+ and CD19+ 
lymphocytes within a PBMC population. Expression of markers is measured on the basis of the 
percentage of cells positive (left), and the intensity of expression (right). The upper graphs show the 
findings in the resting PBMC populations, the lower graphs the findings in the activated condition. Data 
are derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means. Error bars are not shown due to their overlap precluding meaningful interpretation. 
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When measured by intensity of the fluorescent signal, expression of CD25 follows the 
same pattern as when measured by the percentage of cells positive. The expression 
of CD69 measured by fluorescent intensity is not affected by the increasing number of 
immune cells, and is markedly lower than that of CD25 (see Figure 3-22). This may be 
because CD69 is an early activation marker and the intensity of expression reduces 
over the 4-day period, although this does not explain why the percentage of cells 
expressing CD69 is still affected by Saos-2 number. It may be that different activation 
pathways are triggered. 
Activation	of	CD4+ve	lymphocytes	within	a	PBMC	population	
Figure 3-23 show changes in expression of CD25 and CD69 by CD4+ lymphocytes in 
a resting PBMC population, as measured on the basis of fluorescent intensity (FI) and 
the proportion (%) of cells that are positive for the antigen, in relation to the ratio of 
Saos-2 cells to PBMCs and their contact status. In the resting PBMC conditions, an 
increasing number of Saos-2 cells was associated with an increase in expression of 
CD25, as measured by FI and percentage of cells positive. For CD69 expression, there 
was an increase in the proportion of cells expressing the activation antigen, but not the 
intensity of expression. The presence of a transwell insert had no effect.  
In the activated condition, the effect of Saos-2 cell number was less clear (see Figure 
3-24). Although a dose-response effect in relation to the percentage of CD4+ 
lymphocytes that were positive for CD25 and CD69 expression was observed, no 
dose-response effect was seen for the intensity of CD25 and CD69 expression. As for 
the resting PBMC conditions, contact status has no apparent effect. 
A two-way ANOVA was used compare the effect of contact status and Saos-2 cell 
number on the expression of activation markers by CD4+ cells in the resting PBMC 
population, but no statistically significant differences were found. This is surprising 
given the appearance of the data, but large variances within the data, which could not 
be resolved by either square root or log transformations, made establishing differences 
difficult. 
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Figure 3-23: Relationship between ratios of Saos-2 cells to resting PBMCs, and the effect of contact 
status, on expression of CD25 and CD69. A Saos-2: PBMC ratio of 1:8 indicates 1 Saos-2 cell for every 
8 PBMCs. Saos-2 cells appear to induce expression of the activation markers CD25 and CD69 by CD4+ 
lymphocytes, within a population of resting PBMCs. As the proportion of Saos-2 cell increase, there is an 
increase in the percentage of CD4+ lymphocytes expressing CD25 (panel A), CD69 (panel B) and the 
fluorescent intensity of CD25 expression (panel B). The fluorescent intensity of CD69 expression does 
not show the same pattern (panel D). Data are derived from three independent experiments, from three 
donors with no technical repeats, and are presented as means ± 1 standard error.   
	
Figure 3-24: Relationship between ratios of Saos-2 cells to activated PBMCs, and the effect of contact 
status. A Saos-2: PBMC ratio of 1:8 indicates 1 Saos-2 cell for every 8 PBMCs. Saos-2 cells inhibited the 
expression of activation markers by CD4+ lymphocytes in an activated PBMC population, although the 
effect is not as clear as that seen for the resting PBMCs. As numbers of Saos-2 cells increase the 
proportion of cells expressing CD25 (panel A) and CD69 (panel C) is reduced in a dose-dependent 
manner. No effects on the intensity of CD25 (panel B) and CD69 (panel D) were observed. Data are 
derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error. 
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Activation	of	CD4+	lymphocytes	within	a	CD4+	lymphocyte	enriched	population		
Figure 3-25 show the changes in expression of activation markers by resting CD4+ 
lymphocytes in a CD4+ lymphocyte enriched population, in relation to Saos-2 cell 
number and cell contact status. On inspection, a dose-response can be seen for all 
four measures of activation markers i.e. percentage of cells positive and FI. Also, in 
relation to the percentage of CD4+ lymphocytes expressing CD25, the presence of a 
transwell insert appeared to increase CD25 expression.  
	
Figure 3-25: Expression of activation markers by a resting, purified CD4+ cells in a CD4+ lymphocyte 
enriched population is induced by co-culture with Saos-2 cells. Increasing proportions of Saos-2 cells 
(ratios are Saos-2: CD4+ve) resulted in increased percentage of CD4+ cells expressing CD25 (panel A) 
and CD69 (panel C), and the fluorescent intensity of CD25 expression (panel B). Fluorescent intensity of 
CD69 does appear to show an increase in expression, although the differences are not statistically 
significant. Data are derived from three independent experiments, from three donors with no technical 
repeats, and are presented as means ± 1 standard error.  
Figure 3-26 shows the same variables for the activated immune cell condition. 
Associations between activation marker expression and Saos-2 cell number are much 
less clear, and whilst it could be said that all four measures of surface marker 
expression were reduced at a 1:1 ratio of Saos-2 cell : CD4+ lymphocyte enriched 
population cells the simple dose relationship is variable. In fact, expression of surface 
markers is initially increased (for all except the percentage of cells positive for CD25). 
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Although there are differences between the groups in contact and the groups where a 
transwell insert is present, a clear relationship is difficult to describe.  
Two-way ANOVA was used compare the effect of contact status and Saos-2 cell 
number on expression of activation markers by CD4+ cells in the resting CD4+ 
lymphocyte enriched population. A Log10 transformation of the data resolved the high 
variance, and there were no two-way interactions. At a CD4+ lymphocyte enriched 
population : Saos-2 cell ratio of 1:1 there was an increase in the percentage of cells 
positive for CD25 (0.542 vs 1.438; p = 0.002) and CD69 (-0.11 vs 1.38; p = 0.029), and 
an increase in the FI of expression of CD25 (3.54 vs 4.55; p = 0.015). Although for 
most measures contact status had no effect, the presence of a transwell insert 
increased the percentage of CD4+ cells that expressed CD25 (mean difference -0.263 
[95% CI -0.521 to -0.005]; p = 0.046). 
	
Figure 3-26: Effect of Saos-2 cells on expression of CD25 and CD69 by purified population of polyclonally 
activated CD4+ lymphocytes. Saos-2 cells had no effect on expression of activation markers. There were 
no clear differences in the percentage of those positive for CD25 (panel A) or CD69 (panel C), or in 
fluorescent intensity of CD25 (panel B) or CD69 (panel D). Data are derived from three independent 
experiments, from three donors with no technical repeats, and are presented as means ± 1 standard error.  
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Summary	of	findings	
Saos-2	growth	
These findings show significant effects of immune cells on the growth of Saos-2 cells. 
There is no strong evidence to suggest a difference between the effects of PBMCs and 
CD4+ lymphocytes on the growth of Saos-2 cells. Activation of immune cells has a 
consistently negative impact on the growth of Saos-2 cells, seen in both the PBMC 
and CD4+ lymphocyte enriched population conditions. The effect of a transwell insert 
overall was to increase Saos-2 cell number, although the effect appears greatest in 
the activated conditions. Cell number does appear to be important, with both resting 
and activated immune cells showing evidence of a dose-response effect. However, the 
effect of contact does not appear to be affected by cell number. 
Effect	of	Saos-2	cells	on	the	activation	of	status	if	lymphocytes	
These findings demonstrate an effect of Saos-2 cells on the activation status of 
lymphocytes. Increasing numbers of Saos-2 cells activated resting immune cells. 
Although a dose-response effect was seen in both PBMCs and CD4+ lymphocytes, 
only in the latter did that reach statistical significance. Inspection of the graphs of 
expression of CD25 and CD69 by activated immune cells does suggest that with 
increasing numbers of Saos-2 cells there is a slight reduction activation. This more 
apparent in the PBMC population than in the CD4+ lymphocyte population, but neither 
reached statistical significance.   
Series	 2	 -	 influence	 of	 resting	 and	 activated	 immune	 cell	 populations	 on	 the	
alkaline	phosphatase	activity	of	Saos-2	cells	
The aim of these experiments was to further investigate the influence of PBMCs and 
a CD4+ lymphocyte enriched population on the growth and function of Saos-2 cells. 
Functional aspects of Saos-2 cells include alkaline phosphatase (ALP) activity and 
mineralisation. Functional studies require the Saos-2 cells to be growing, however 
previous experiments indicate that higher numbers of activated lymphocytes inhibit 
growth. Therefore, changes to the experimental design for these experiments were 
made.  
Firstly, all the experiments use transwell inserts as even small numbers of activated 
immune cells were shown to dramatically inhibit growth in the earlier experiments. 
Furthermore, keeping cells separate during culture enabled the analysis of ALP activity 
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as all cells contain ALP. An additional consideration was the time at which to add 
immune cells. Doing this at the start of the experiment means they are introduced 
before the Saos-2 have adhered, therefore it could be said that two processes – 
adherence and proliferation – are being assessed. Waiting 48 hours before adding the 
immune cells allows the adherence and growth of Saos-2 cells to be established, 
thereby excluding any potential effect of treatment on adherence indirectly influencing 
measures of ALP generation. With regards to cell numbers, ratios between 6:1 to 0.6:1 
were used (immune cell : Saos-2 cell). 
Preparation	of	CD4+	enriched	and	CD4+	depleted	cell	populations	
For these experiments, a population which had been depleted of CD4+ cells was used, 
in addition to the PBMC and CD4+ enriched populations. The CD4+ enriched population 
was isolated using a negative CD4 selection kit designed to remove as many CD4- 
cells as possible, leaving a suspension of CD4+ cells. The CD4+ depleted population 
was generated using a positive selection CD4+ selection kit which binds CD4+ cells to 
the magnetic beads. For these experiments the “waste” population, depleted of CD4+ 
cells, was used. The purity and content of the different cell preparations are illustrated 
in Figure 3-27 and Figure 3-28. 
Figure 3-28 illustrates that the enrichment was effective, resulting in a population with 
over 90% CD4+ cells. The CD4+ depletion reduced the proportion of CD4+ cells from 
55% to 30%, and increased the relative proportion of CD8+ cells from 30% to over 
60%. However, the expectation from the CD4+ depletion was to remove all CD4+ cells. 
One reason this may not have happened is that the positive selection kit was not 
designed to do this. It is designed to produce a pure population of CD4+ using positive 
selection.  
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Figure 3-27: Representative histograms of identification of lymphocyte subsets. They show differing 
proportions of CD4+ and CD8+ cells in PBMCs (top row), CD4+ enriched (middle) and CD4+ depleted 
(bottom). The PBMC population contains more CD4+ than CD8+, and the CD4+ enriched contains no 
CD8+ cells. The CD4+ depleted population still contains CD4+ cells, but the proportion is altered, relative 
to the CD8+. CD19+ cells are absent in all populations, for reasons that are currently unclear. 
	
Figure 3-28: Relative proportions of lymphocytes subsets in three populations in PBMC, CD4+ enriched 
and CD4+ depleted preparations. 30% of the cells in the CD4+ depleted population are CD4+. Data are 
derived from three independent experiments, from three donors with no technical repeats, and are 
presented as means ± 1 standard error.  
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Effect	of	PBMCs,	CD4+	enriched	and	CD4+	depleted	cell	populations	on	Saos-2	cells	
Growth	
After 5 days of co-culture with PBMCs, CD4+ enriched and CD4+ depleted cell 
populations, the Saos-2 cells were counted using an automated cell counter. Results 
presented in Figure 3-29 show that, with increasing numbers of resting immune cells, 
the growth of Saos-2 cells initially increases, and then begins to fall. This decline in 
growth only falls below that of controls following culture with resting PBMCs, and 
remained higher than the untreated controls following culture with the CD4+ enriched 
and depleted populations (Figure 3-29). 
	
Figure 3-29: Effect of increasing numbers of resting PBMCs, CD4+ enriched and CD4+ depleted cell 
populations on the growth of Saos-2 cells. Ratios are Saos-2 cells : immune cells. Data are derived from 
three independent experiments, from three donors with no technical repeats, and are presented as means 
± 1 standard error. 
Although culture with activated PBMCs, CD4+ enriched and CD4+ depleted cell 
populations influenced the growth of Saos-2 cells, the effects were variable and 
quantitatively small (Figure 3-30). Analysis by three-way ANOVA found that any 
apparent differences in either the resting or activated conditions were not statistically 
significant. 
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Figure 3-30: Effect of increasing numbers of activated PBMCs, CD4+ enriched and CD4+ depleted cell 
populations on the growth of Saos-2 cells. Ratios are Saos-2 cells : immune cells. Data are derived from 
three independent experiments, from three donors with no technical repeats, and are presented as means 
± 1 standard error. 
Alkaline	phosphatase	activity	
Alkaline phosphatase activity is a useful measure of Saos-2 cell function, given its 
importance in bone formation by osteoblasts. Resting and activated PBMC and the 
CD4+ enriched populations increased ALP activity in a dose-dependent manner 
(Figure 3-31). 
Data were analysed by three-way ANOVA on the basis of three factors: immune cell 
number, immune cell type and activation status. There were no outliers (as determined 
by inspection of boxplots), and although the data were normally distributed, they were 
Log10 transformation to reduce variance. There was a significant three-way interaction 
found (p < 0.001). This was followed up with simple two-way interactions, which 
describe the interactions between two factors at all levels of the third factor e.g. the 
presence of an interaction between activation and immune cell type for the different 
immune cell numbers. This is slightly different to the three-way ANOVA analysis of the 
original co-culture data, for which the two-way interactions (not defined as “simple”) 
would, for example, compare two factors with no reference to the third. 
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Figure 3-31: Effect of increasing numbers of activated PBMCs, CD4+ enriched and CD4+ depleted cell 
populations on ALP activity of Saos-2 cells. Panel A – resting immune cells. Panel B – activated immune 
cells. Ratios are Saos-2 cells : immune cells. Data are derived from three independent experiments, from 
three donors with no technical repeats, and are presented as means ± 1 standard error. 
Activation status and cell number had a significant interaction in the CD4+ depleted 
condition (p < 0.001), but not in the PBMC or CD4+ enriched experiments. Cell type 
and activation status had a significant interaction for all immune cell numbers (p < 
0.001). Cell type and cell number had a significant interaction in the activated 
conditions (p < 0.001), but not in the resting conditions.  
Simple	two-way	interaction:	the	effect	of	cell	number	relative	to	cell	type	and	activation	
status		
There was a significant overall effect of cell number on ALP activity in both the CD4+ 
enriched and CD4+ depleted populations, regardless of activation status. Changes in 
ALP activity induced by culturing with PBMCs were not significant. The detailed 
comparisons for cell number, that were statistically significant in relation to cell type 
and activation status, are summarised inFigure 3-32. 
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Figure 3-32: Influence of CD4+ enriched and CD4+ depleted populations on ALP activity in Saos-2 cells 
showing only those comparisons that had statistical significance. Panel A – ALP activity increases with 
the number of resting CD4+ enriched cells * p = 0.012 Panel B - ALP activity increases with the number 
of resting CD4+ depleted cells. ** p = 0.008. Panel C - ALP activity increases with the number of resting 
CD4+ depleted cells + p = 0.001 (p values are Bonferroni adjusted for multiple comparisons, a = 0.05). 
Data are derived from three independent experiments, from three donors with no technical repeats, and 
are presented as means ± 1 standard error. 
Cell number of the resting (p = 0.019) and activated (p = 0.043) CD4+ enriched 
populations influenced ALP activity. Pairwise comparisons revealed that the only 
significant difference in ALP activity was seen for the 600,000-cell resting condition 
when compared to control (mean difference -0.421 [95% CI -0.784 to -0.058]; p = 
0.012). The individual comparisons for the resting CD4+ enriched population cell 
number are not shown in Figure 3-32. For the CD4+ depleted population, cell number 
overall affected ALP activity in the resting (p = 0.018) and activated (p < 0.001), but as 
can be seen in Figure 3-32 the detailed comparison reveals they are more marked in 
the activated group. 
Simple	two-way	interaction:	the	effect	of	activation	status	relative	to	immune	cell	type	
and	number	
The activated CD4+ depleted population increased ALP activity (p < 0.001) an effect 
not seen with the other two cell types. Detailed analysis showed significant increases 
in ALP activity in the activated condition relative to the resting at all cell numbers, with 
evidence of a dose-response effect (see Figure 3-33). 
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Simple	two-way	interaction:	the	effect	of	cell	type	relative	to	immune	cell	number	and	
activation	status	
There was a statistically significant effect of cell type on ALP activity, when the immune 
cells were activated (p < 0.001). Detailed analysis showed that it was the activated 
CD4+ depleted population that affected ALP activity, with significant increases at all 
immune cell ratios compared to the other cell types (see Figure 3-34). However, the 
significant differences in the effects of the resting immune cell populations on ALP 
activity. 
	
Figure 3-33: Influence of resting and activated CD4+ depleted populations on ALP activity. There were no 
significant differences seen in the other conditions p < 0.001 (p values are Bonferroni adjusted for multiple 
comparisons, a = 0.05) Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error. 
	
Figure 3-34: Influence of activated PBMCs, CD4+ enriched and CD4+ depleted populations on ALP activity 
in Saos-2 cells. * p < 0.001 (p values are Bonferroni adjusted for multiple comparisons, a = 0.05) Data 
are derived from three independent experiments with a log10 transformation and presented as means ± 
1 standard error. 
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4 Optimisation	of	lymphocyte	extraction	from	
mucosal	tissue	
Since completing this work a comprehensive method for the isolation of lymphocytes 
from mucosal biopsies has been published (Carrasco et al 2013), at the time of 
undertaking this study no method for their isolation from small biopsy samples had 
been published - a method therefore had to be developed. Given that the isolation of 
lymphocyte populations from gut biopsies required the use of enzymes, a pre-requisite 
to these studies was to demonstrate that the use of these enzymes had no influence 
on the phenotype of the isolated cells. 
Patient	sample	preparation	and	analysis	
Initial	method	
Biopsy samples were collected into a 25ml Universal container containing ice cold 
PBS. The biopsy specimens were transferred from the PBS to 5ml of pre-digestion 
solution, which had been pre-warmed to 37°C, in a 25ml Universal container and 
placed in a water-bath at 37°C with gentle rotation for 20 minutes. The contents of the 
tube were then filtered through a 100µm cell strainer (BD Falcon #352360) and the 
effluent was reserved. The biopsy pieces were incubated in fresh pre-digestion 
solution for 20 minutes, followed by filtering and collection of the effluent, a further two 
times. 
After the third filtering step, the effluent from the pre-digestion stages contained no 
visible cells, and so was discarded. Biopsy pieces were placed in digestion solution, 
pre-warmed to 37°C, and after 20 minutes the solution was passed through a 100µm 
filter. Gentle pressure with a syringe plunger was applied to encourage cell release. 
The tissue readily dissociated and so further digestion steps were not carried out. 
The digested gut biopsy solution was centrifuged for 10 minutes at 500g, the 
supernatant was discarded, the cell pellet re-suspended in cold serum buffer (PBS with 
10% v/v foetal bovine serum (FBS, GIBCO #10270-106) and centrifuged at 300g for 5 
minutes. The cell pellet was re-suspended in 10ml of 40% v/v Percoll® in a 25ml 
Universal container. 5ml of the 80% v/v Percoll® solution was drawn up using a 22g 
needle and a 10ml syringe. This was then introduced under the 40% v/v Percoll® by 
placing the needle end in the base of the tube and gradually depressing the syringe 
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plunger. The 80% v/v Percoll® stayed underneath the 40% and a clear dividing line 
was visible. This was then centrifuged at 1000g for 20 minutes with no brake. Once 
complete, cells at the interface were aspirated using a Pasteur pipette, placed in an 
excess of PBS and centrifuged at 300g for 5 minutes. The cell pellet was added to 5 
ml of RPMI with 10% v/v FBS and kept overnight in an incubator at 37°C. 
The next day cells were counted on a haemocytometer using trypan blue exclusion. 
There were typically a total of 1.5x106 cells, of which more than 95% were viable. Cells 
were suspended in SB with 2% v/v mouse serum (Sigma #M5905) at 1x106 cells/100µl. 
After incubating for 15 minutes at 4°C, fluorescent mAbs were added and incubated 
for a further 30 minutes at 4°C. Cells were then washed in an excess of SB and the 
cell pellet re-suspended in SB for analysis. Unfortunately, the fluorescent signal was 
not clear (see Figure 4-1). 
 
Figure 4-1: Fluorescent signal of the first population of immune cells isolated from gut mucosal biopsies 
using Method 1. Whilst the PBMCs (top row) show a clear peak representing the indicated populations of 
cells (indicated by black bars), but no such defined populations were apparent in the biopsy-derived 
samples (bottom row). 
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Method	2	
At the digestion solution stage, biopsies were for incubated for 40 minutes then 20 
minutes, rather than using 3 x 20 minute incubations. At the end of each digestion 
stage, biopsy pieces were washed over a 40µm cell strainer. After diluting the biopsy 
suspension a lower-force 5 minute 300g centrifugation was undertaken, thereby 
omitting the higher force step. After completing the Percoll® stage, cells were visible at 
the interface, but were only 500,000 in number when counted. This was inadequate 
for staining and may have occurred because the higher force centrifuge step was 
missed.  
Method	3	
Having not seen any cells being released during the pre-digestion stages, only the 
digestion solution was used. After 40 minutes uninterrupted incubation, no breakdown 
of the tissue was seen, as a consequence of which the biopsy samples were incubated 
in pre-digestion solution for 20 minutes. Although incubation in the digestion solution 
did start to break up the tissues only 600,000 cells were present after Percoll® stage 
and analysis was not possible. 
Method	4	
Two patients were recruited on the same day and their samples processed and 
analysed under the same conditions. The method was adjusted to use a different 
incubator with a flat rubber platform. The incubator was not compatible with 25ml 
Universal container and so a 6-well culture plate was used instead. Biopsy specimens 
were placed in the 6-well plate (Corning #3516) with 3 ml of warmed pre-digestion 
solution and placed in an incubator with gentle shaking. After 20 minutes the tissue 
was removed and placed in fresh pre-digestion solution. The used solution was 
transferred to a microfuge tube, centrifuged at 300g for 5 minutes and the resultant 
pellet re-suspended in medium. The tissue underwent 3 x 20 minute incubations in 
pre-digestion solution, followed by 3 x 20 minute incubations in digestion solution using 
this process. Once complete, cells were centrifuged on a Percoll® gradient. Although 
this procedure generated cells that could be analysed by flow cytometry, the surface 
antigens were not reliably maintained and no CD4 or CD8 expression signal was 
visible. CD19 expression was maintained, as was some expression of CD69, albeit of 
very low intensity (see Figure 4-4).  
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Figure 4-2: Fluorescent signals for gut immune cells isolated using Method 4. Although there is a clear 
population of CD19+ cells (middle panel), there is no evidence of a CD4+ or CD8+ population.  
Method	5	
Samples were processed using the same method as for the two individuals whose 
samples were processed using Method 4 above, except that that the concentration of 
collagenase was reduced to 0.01% v/v and that of the dispase to 0.1% v/v. Only 
200,000 cells were isolated and, although they were stained for analysis by flow 
cytometry, no cells were visible. 
Method	6	
The aim of this approach was to minimise the number of transfers between different 
vessels. For this, biopsies were placed in a microfuge tube, to which 1 ml of the pre-
digestion solution was added. Tubes were placed in the incubator at 37°C with 
moderate agitation. After 20 minutes, the tube was shaken vigorously by hand and 
biopsy specimens were allowed to settle. The supernatant looked much cloudier than 
previous attempts and was transferred to a fresh microfuge tube. Pre-digestion 
solution (1 ml) was added to the biopsy specimens and returned to the incubator. The 
supernatant was centrifuged at 300g for 5 minutes and, after discarding the 
supernatant, cells were re-suspended in 1 ml of D-MEM medium. This process was 
repeated for a total of three incubations in pre-digestion followed by digestion solution.  
Although there were sufficient cells for analysis by flow cytometry (including unstained 
and isotype controls), there was no visible fluorescent signal when analysed by flow 
cytometry. 
Method	7	
For this, the process was repeated except this time, on the basis of experiments 
looking at the effects of the various enzymes on the surface markers (see next Section) 
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dispase was not used. This approach yielded 800,000 cells during the pre-digestion 
stage and ultimately sufficient cells for the flow cytometric analysis (including unstained 
and isotype controls) after the digestion stage. Importantly, the expression of surface 
markers (as determined by flow cytometry) was maintained. The data for Methods 6 
and 7 are presented in the Results section. 
Effect	of	digestive	enzymes	on	immune	cell	surface	markers	
In developing the technique for isolation of immune cells from gut biopsy samples the 
effect of digestive enzymes that were required to break down gut tissue and release 
the immune cells was investigated on the expression of surface antigens on resting 
and activated lymphocyte populations was investigated. Expression of CD25 and 
CD69 was increased by incubating isolated PBMC populations in concanavalin A (as 
described in Methods and Materials). Means were compared by independent samples 
T-test. 
Effect	of	digestive	enzymes	on	the	expression	of	lymphocyte	phenotypic	markers	
The treatment of PBMCs with EDTA, dithiothreitol (DTT), deoxyribonuclease (DNAse) 
and 0.1% w/v collagenase had no effect on the percentage of CD4+, CD8+ and CD19+ 
cells (see Figure 4-3). In contrast, treatment of PBMCs with 0.3% w/v dispase reduced  
	
Figure 4-3: Effect of treatment with digestive enzymes on the relative proportions of CD4+, CD8+ and 
CD19+ lymphocyte subsets in activated PBMC preparations. * p = 0.002. Data are derived from three 
independent experiments, from three donors with no technical repeats, and are presented as means ± 1 
standard error. 
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the proportion of CD4+ cells (53% vs 11.9%; p = 0.002), CD8+ (41% vs 24%; p= 0.177) 
and CD19+ (23% vs 6%; p = 0.053), as determined using flow cytometry. Although 
reducing the concentration of dispase from 0.3% to 0.03% reduced this effect, a 
significant reduction in the percentage of CD4+ cells remained (53% vs 15 %; p = 
0.002). 
	
Figure 4-4: Effect of dispase treatment (0.3%, 0.03% w/v) on the relative proportions of CD4+, CD8+ and 
CD19+ lymphocyte subsets in PBMC preparations. * p = 0.002. Data are derived from three independent 
experiments, from three donors with no technical repeats, and are presented as means ± 1 standard error. 
Effect	of	digestive	enzymes	on	the	expression	of	lymphocyte	activation	markers	
The effect of digestive enzymes on expression of CD25 and CD69 by activated PBMCs 
were also studied. As discussed previously, their expression can be measured by the 
percentage of positive cells and the overall fluorescent intensity of expression.  
	
Figure 4-5: Effect of digestive enzyme treatments on the proportion of PBMCs expressing CD25 and 
CD69. * p = 0.008. Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error. 
Dispase (0.3% w/v) reduced the proportion of CD25+ and CD69+ cells (from 75% to 
38% and 84% to 23% respectively, see Figure 4-5). However, only the reduction in the 
proportion of CD69+ was of statistical significance (p = 0.008). Reducing the 
concentration of dispase to 0.03% w/v significantly reduced its effect on the proportion 
of CD25+ and CD69+ cells (23% vs 70.2%; p = 0.015; see Figure 4-6), and its effect on 
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the proportion of CD69+ cells was no longer of statistical significance relative to the 
untreated control. 
	
Figure 4-6: Effect of dispase treatment (0.3%, 0.03% w/v) on the proportion of CD25+ and CD69+ in 
PBMCs. * p = 0.015. Data are derived from three independent experiments, from three donors with no 
technical repeats, and are presented as means ± 1 standard error. 
Although EDTA, dithiothreitol (DTT), deoxyribonuclease (DNAse) and 0.1% w/v 
collagenase had no effect on the intensity of CD25 and CD69 expression, dispase 
treatment did reduce the intensity of expression intensity (see Figure 4-7 and Figure 
4-8). 
	
Figure 4-7: Effect of digestive enzyme treatments on the intensity of CD25 and CD69 expression by 
activated PBMCs. * p = 0.001. Data are derived from three independent experiments, from three donors 
with no technical repeats, and are presented as means ± 1 standard error.   
0	
10	
20	
30	
40	
50	
60	
70	
80	
90	
100	
CD25	 CD69	
Pe
rc
en
ta
ge
	p
os
i.
ve
	
Untreated	
0.3%	dispase	
0.03%	dispase	
*
0	
5000	
10000	
15000	
20000	
25000	
30000	
35000	
40000	
 CD25	  	CD69	
Fl
uo
re
sc
en
t	i
ne
ns
ity
	 Untreated	
EDTA	
DTT	
DNAse	
0.1%	collagenase	
0.3%	dispase	
*	
  Page	120	
	
Figure 4-8: Effect of dispase treatment (0.3%, 0.03% w/v) on the intensity of CD25 and CD69 expression 
by activated PBMCs. * p < 0.001. Data are derived from three independent experiments, from three donors 
with no technical repeats, and are presented as means ± 1 standard error. 
Effect	of	digestive	enzymes	on	the	expression	of	a4	and	b7	integrins	
The a4b7 integrin identifies lymphocytes that have been primed in the gut. Given that 
a single antibody to this surface marker is not commercially available, a combination 
of two separate antibodies was necessary. Expression of both integrins was measured 
on the basis of the proportion of positive cells since the intensity of expression is not 
considered in the published literature, unlike for CD25 and CD69.  
	
Figure 4-9: Effect of digestive enzyme treatments on the proportion of activated PBMCs expressing a4 
and b7 integrins. * p = 0.009. Data are derived from three independent experiments, from three donors 
with no technical repeats, and are presented as means ± 1 standard error. 
Treatment with DTT reduced the expression of both integrins (Figure 4-9), despite it 
not having had any effect on the expression of the other surface antigens that were 
examined in this study. The expression of b7 was also reduced by treatment with 0.1% 
w/v collagenase and 0.3% w/v dispase. Reductions in the concentrations of dispase 
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and collagenase had little or no effect on the reduction in expression of b7 (see Figure 
4-10). 
	
Figure 4-10: Effect of collagenase (0.1%, 0.01% w/v) and dispase (0.3%, 0.03% w/v) treatment on the 
proportion of activated PBMCs expressing b7 integrin. Data are derived from three independent 
experiments, from three donors with no technical repeats, and are presented as means ± 1 standard error. 
Summary	of	findings	
Although the use of digestive enzymes to liberate cells from gut mucosa has the 
potential to affect expression of surface markers, the limited availability of the clinical 
material precluded the use of physical techniques, rather than enzyme digestion. 
Although expression of the integrins was the most sensitive to treatment, their 
expression on circulating lymphocytes (which are not isolated using enzyme digestion) 
is arguably the more important parameter. It should be note that these experiments did 
not examine the effects of enzyme combinations. However, as will be shown, a 
reasonable signal could be obtained from isolated cells. Even if reduced, comparisons 
between patients could still be made. 
	 	
0	
1	
2	
3	
4	
5	
6	
7	
8	
9	
Untreated	 0.1%	collagenase	 0.01%	collagenase	 0.3%	dispase	 0.03%	dispase	
Pe
rc
en
ta
ge
	p
os
i.
ve
	fo
r	b
et
a-
7	
  Page	122	
5 In	vivo	results	
Phenotypic	 characterisation	 of	 intestinal	 and	 peripheral	 blood	 leucocytes	 in	
children	with	Crohn’s	disease,	and	their	relationship(s)	to	bone	metabolism	and	
mineralisation	
The hypothesis of this thesis is that the reductions in bone mineral density (BMD) seen 
in children with Crohn’s disease are, at least in part, mediated by interactions between 
osteoblasts and gut-activated lymphocytes that have migrated from mucosal tissue to 
the bone. The aim of this in vivo study is to look for associations between the relative 
proportions, and activation status of, lymphocytes in children with Crohn’s disease; 
changes in biochemical markers of bone turnover; and changes in measures of BMD 
measured by dual X-ray absorptiometry. 
Children undergoing endoscopy for investigation of gastrointestinal were approached 
with an aim of recruiting 15 with Crohn’s disease and 15 with no identifiable pathology. 
Peripheral blood was taken for measurement of the serum bone turnover markers 
P1NP and osteocalcin, and isolation of peripheral blood mononuclear cells. 10 
gastrointestinal mucosal biopsies were obtained, from which cells were isolated by 
enzymatic digestion. The isolated cells were analysed by flow cytometry to establish 
the proportions of the various phenotypes, and expression of CD25, CD69 and a4b7. 
Finally, confirmed cases of IBD had a DEXA scan to measure their BMD. 
To date there are no published studies investigating the association between 
lymphocyte populations and their cell-surface activation markers with BMD in children 
with IBD. This work has the potential to lead to further studies aiming to identify the 
presence of gut-activated immune cells in the bone of IBD patients, and their effects 
on osteoblasts and bone metabolism. 
The	 impact	 of	 inflammatory	 bowel	 disease	 on	 the	 immune	 cell	 profile	 and	
measures	of	bone	metabolism	
Patient	demographics	
30 patients were recruited in total, 16 controls and 14 cases. Controls were younger 
(9.3 vs 13.4 years; p = 0.003). The cohort consisted of 19 males and 11 females: 10 
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males and 6 females in the control group, 9 males and 5 females in the cases group 
(Table 5-1).  
	
Table 5-1: Samples taken from, and investigations performed, in cases and controls. 
A decision regarding diagnosis, based on mucosal appearances, was made at the time 
of endoscopy. A final diagnosis was made on the basis of histology as part of their 
routine clinical assessment. Of the 14 cases, 10 were new diagnoses of Crohn’s 
disease, 2 were known cases of Crohn’s disease, one was a new diagnosis of 
ulcerative colitis and one a new diagnosis of indeterminate colitis.  
Figure 5-1 and Table 5-2 compare basic clinical data. Patients had a full blood count 
(FBC), and measurements of the erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP) levels and serum albumin levels were taken. Cases had a significantly 
higher ESR (29.33 vs 12.5; p = 0.018). The mean CRP was raised in cases, and 
although this difference was not of statistical significance, values less than 7 are not 
reported which will have affected the statistical analysis. The total white cell count 
(WCC) was similar for the two groups. The proportion of lymphocytes, as a percentage 
of the total white cell count, was significantly lower in cases (32.86% vs 21.65%; p = 
0.022). The total lymphocyte count was lower in cases, although the difference did not 
reach significance (1.81x109/L vs 2.52x109/L; p = 0.053). Serum albumin was 
significantly lower in cases (37.0 vs 42.5; p = 0.002).  
Sample	 Controls	 Cases	
Rou$ne	bloods	 14	 13	
Peripheral	blood	lymphocytes	 8	 12	
Mucosal	epithelial	lymphocytes	 4	 11	
Lamina	propria	lymphocytes	 4	 11	
Serum	bone	turnover	markers	 8	 9	
Urine	bone	turnover	markers	 8	 9	
DEXA	 N/A	 13	
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Figure 5-1: Box and whisker plots comparing the distributions of basic patient data for cases and controls.  
Panel A – age at time of endoscopy higher for cases (p = 0.003) Panel B – ESR raised in cases (p = 
0.018). Panel C = CRP. Panel D - white cell count (WCC) higher in cases. Panel E – lymphocytes as 
percentage of total WCC lower in cases (p = 0.022). Panel F – albumin lower in cases (p = 0.002). Sample 
size as in Table 5-1. 
	
Table 5-2: Comparison of clinical data in cases and controls. Statistically significant findings are 
highlighted in red (a = 0.05). Data are presented as means ± one standard error. 
Phenotypic	characterisation	of	intestinal	and	peripheral	blood	leucocytes	
Immune cells were isolated and the relative proportions of lymphocyte subsets (CD4+, 
CD8+, CD19+) and their expression of CD25 and CD69 were measured as described 
in the Materials and Methods. The presence of lymphocytes expressing a4b7 
(indicating their activation in the gut) was also determined. 
C	B	A
F	E	D
Controls	 Cases	 p	
Age	(years)	 9.30	(0.90)	 13.43	(0.86)	 0.003	
ESR	 12.54	(1.66)	 29.33	(6.63)	 0.018	
CRP	 11.51	(3.19)	 20.62	(4.73)	 0.091	
White	cell	count	(109/L)	 8.27	(0.67)	 9.24	(1.18)	 0.793	
Percentage	lymphocytes	 32.86	(3.41)	 21.65	(3.01)	 0.022	
Lymphocyte	count	(109/L)	 2.52	(0.19)	 1.81	(0.23)	 0.053	
Albumin	 42.54	(0.58)	 37.0	(1.32)	 0.002	
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Mucosal	immune	cell	populations	
Mucosal	lymphocyte	subsets	
The proportions of CD4+ and CD8+ cells are equivalent (15.8% vs 16.2%) within the 
lamina propria (LP) of controls, with the predominant cell type being CD19+ B cells 
(27.8%, Figure 5-2, panel A). In contrast, CD4+ cells predominate in the LP of cases 
relative to CD8+ T cells (26.7% vs 14.6%; p = 0.032) and CD19+ B cells (26.7% vs 
13.6%; p = 0.037). 
	
Figure 5-2: Relative proportions of CD4+, CD8+ and CD19+ lymphocytes subsets within the lamina propria 
and gut mucosal epithelial layer (MEL) of cases and healthy controls. Panel A - proportions of lymphocyte 
subsets with the LP * p = 0.032 ** p = 0.037 Panel B - proportions of lymphocyte subsets with the MEL. 
+ p = 0.002 ++ p = 0.001. Data are presented as means ± 1 standard error, sample size as in Table 5-1. 
The composition of cells within the mucosal epithelial layer (MEL) was distinct to that 
of the LP compartment (Figure 5-2, panel B), with a significantly lower proportion of 
CD4+ cells than either CD8+ cells (27.2% vs 13.9%; p = 0.002), or CD19+ cells (32.6% 
vs 13.9%; p = 0.001) in controls. In cases, the proportion of CD4+ cells is higher (13.8% 
vs 19.2%; not significant), and this is accompanied by a lower proportion of CD8+ cells 
(27.2% vs 24.3%; not significant) and CD19+ cells (32.6% vs 24.2%; not significant).  
In summary, these data indicate that for healthy controls, CD19+ B cells predominate 
within the gut mucosa of healthy controls, with the LP and MEL compartments 
exhibiting differences in the proportions of CD4+ to CD8+ cells. In cases, there is an 
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infiltration of CD4+ cells, primarily (but not exclusively), into the LP. This is 
accompanied by corresponding reductions in the proportions of CD8+ and CD19+ cells. 
However, none of the differences when comparing proportions of each individual 
lymphocyte subset between cases and controls, and within the LP and MEL were 
statistically significant (p > 0.05; Figure 5-1).   
Mucosal	a4b7+	lymphocyte	subsets	
Mucosal lymphocytes expressing a4 and b7 were identified in the LP and MEL of cases 
and controls, and quantified as a percentage of the total number of lymphocytes 
(Figure 5-3).  
	
Figure 5-3: Proportion of mucosal lymphocytes expressing a4b7. A comparison between LP and MEL in 
cases and healthy controls. * p = 0.006 Data are presented as means ± 1 standard error, sample size as 
in Table 5-1. 
There were a greater proportion of a4b7+ lymphocytes within the MEL of controls than 
in the LP (12.7% vs 4.8%, not significant, Figure 5-3). A similar pattern was seen for 
cases (1.3% vs 8.4%; p = 0.006, Figure 5-3). Although the proportion of a4b7+ 
lymphocytes within each mucosal compartment was lower in the cases, the differences 
were not of statistical significance. As the data have been analysed as proportions, 
rather than as cell numbers, differences may reflect either an increase in a4b7- 
lymphocytes or a decrease in a4b7+ lymphocytes.  
The pattern of subset distribution for a4b7+ lymphocytes in the mucosal compartments 
was visibly different to that seen for all lymphocytes (Figure 5-3). a4b7+ CD8+ cells 
predominate in both the LP and MEL of healthy controls, with a4b7+ CD19+ B cells 
being the next most prevalent cell type. In the MEL (Figure 4.12, panel B), the 
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proportions of a4b7+ CD4+ to a4b7+ CD8+ (13.1% vs 56.5%; p < 0.001) and a4b7+ 
CD19+ (13.1% vs 39.3%; p = 0.046) were significant, but not in the LP.  
For patients with IBD, the proportion of a4b7+CD4+ lymphocytes in both the LP (50.29% 
vs 19.76%; p = 0.001) and the MEL (26.59% vs 13.12%; p = 0.02) was significantly 
greater than in healthy controls. However, although the difference between the 
proportions of a4b7+CD4+ and a4b7+CD8+ cells remained significantly different in the 
MEL (26.6% vs 67.1%; p < 0.001; § Figure 5-4, panel B), the significance of the 
corresponding difference within the LP was lost.   
	
Figure 5-4: Relative proportions of a4b7+ lymphocytes subsets within the lamina propria (LP) and epithelial 
layers (MEL) of the gut mucosa of cases and healthy controls. Panel A - the proportions of a4b7+ 
lymphocytes subsets. * p = 0.001. Panel B - shows the proportions of proportions of a4b7+ lymphocytes 
subsets in the MEL. + p = 0.002 control a4b7+ CD4+ vs case CD4, ++ p < 0.001 control a4b7+ CD4+ vs 
control a4b7+ CD8+, +++ p = 0.046 control a4b7+ CD4+  vs control a4b7+ CD19+. Data are presented as 
the mean ± one standard error, sample size as in Table 5-1. 
It is difficult to explain why, despite the increase in the proportion of a4b7+CD4+ 
lymphocytes in cases there is also an increase in a4b7+CD8+ lymphocytes, with the 
sum of the subsets being greater than 100%. It is possible that this reflects the 
presence of CD4+CD8+ lymphocytes, which has indeed been reported in cases of 
IBD (Senju et al 1991b; Das et al 2003), although not in relation to a4b7+ lymphocytes. 
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It is important to note that there was no difference in the proportions of a4b7+CD8+ and 
a4b7+CD19+ in the LP and MEL between cases or controls. Significant differences 
were found in the proportion of a4b7+CD4+ lymphocytes in the LP and MEL of cases 
and controls (as discussed), but also in the proportion of a4b7+CD4+ lymphocytes in 
the LP and MEL of cases (49.6% vs 26.6%; p < 0.001 – see Figure 5-4).  
Expression	of	activation	markers	by	mucosal	CD4+	lymphocytes		
Overall, there is very little difference between cases and controls in expression of 
CD25 and CD69 by CD4+ cells isolated from the LP and MEL of the gut mucosa (Figure 
5-5). The percentage of CD4+ cells in the MEL expressing CD69 was significantly 
increased in cases compared with healthy controls (57.8% vs 27.3%; p = 0.043). The 
intensity of CD25 expression by CD4+ cells in the LP of cases was higher than that in 
controls (363.9 vs 211.0; p = 0.015). Otherwise, although there is an overall trend for 
increased expression of activation markers, the differences between cases and 
controls are not of statistical significance (p > 0.05). However, compared with 
expression by peripheral CD4+ lymphocytes, expression is markedly higher. In the 
peripheral blood the percentage of CD4+ lymphocytes expressing CD25 or CD69 is 
consistently less than 10%, with fluorescent intensities of 50 to 250. In the LP and 
MEL, the percentage of CD4+ lymphocytes expressing CD25 or CD69 is consistently 
10-20%, with fluorescent intensities of 1000 to 3000. This observation indicates greater 
activation of lymphocytes within the gut mucosa. 
A comparison of the proportion of CD25+ and/or CD69+ cells in the LP or MEL revealed 
that there were no significant differences between cases and controls, apart from 
expression of CD69 in the MEL (Figure 5-5 B). With regards to the intensity of CD25 
and CD69 expression, the former was higher in the LP of cases as compared to the 
control (Figure 5-5 C; p = 0.015), whilst the latter was higher in the MEL of cases as 
compared to the control but the difference was not of statistical significance (Figure 
5-5 D). 
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Figure 5-5: Expression of activation markers by CD4+ cells within the lamina propria and epithelial layers 
of the gut mucosa. Panel A - percentage expression by lamina propria cells; Panel B - percentage 
expression by epithelial cells, + p = 0.043. Panel C – fluorescent intensity of expression by lamina propria 
cells, * p = 0.015. Panel D – fluorescent intensity of expression by epithelial cells. Data are presented as 
means ± 1 standard error, sample size as in Table 5-1. 
Expression	of	activation	markers	by	mucosal	a4b7+CD4+	lymphocytes	
The expression of activation markers by mucosal a4b7+CD4+ lymphocytes isolated 
from cases and healthy controls were compared (Figure 5-6). Expression of CD25 and 
CD69 on a4b7+CD4+ cells was higher in both the LP and MEL of cases compared with 
controls, with both compartments showing similar patterns in cases and controls. 
Within the LP, the increase in expression was significant for the percentage of 
a4b7+CD4+ cells expressing CD69 (65.88% vs 22.97%; p = 0.021; Figure 5-6, panel 
A), and the FI (243.15 vs 1528.33; p = 0.029; + Figure 5-6, panel C). The increases in 
CD25 expression were not significant. Within the MEL, the higher proportion of 
a4b7+CD4+ cells expressing CD69 (20.18% vs 73.94%; p = 0.007; ** Figure 5-6, panel 
B), and the FI (1528.33 vs 273.27: p = 0.021; ++ Figure 5-6, panel D) were significant. 
In contrast, the higher CD25 expression by a4b7+CD4+ cells was not statistically 
significant. 
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Figure 5-6: Expression of activation markers by a4b7+CD4+ cells within the lamina propria and epithelial 
layers of the gut mucosa. Panel A - percentage expression by lamina propria cells, * p = 0.021. Panel B 
- percentage expression by epithelial cells, ** p = 0.007. Panel C – fluorescent intensity of expression by 
lamina propria cells, + p = 0.029. Panel D – fluorescent intensity of expression by epithelial cells, ++ p = 
0.021. Data are presented as the mean ± one standard error, sample size as in Table 5-1. 
These data show that there is a selective increase in the expression of activation 
markers by a4b7+CD4+ lymphocytes within the mucosa of patients with IBD. This 
would suggest greater stimulation of cells activated in the gut mucosa (and thus 
expressing a4b7+).  
Peripheral	blood	immune	cell	populations	
Peripheral	blood	lymphocyte	subsets	
Figure 5-7 shows the profile of CD4+, CD8+ and CD19+ lymphocytes and a4b7+CD4+, 
a4b7+CD8+ and a4b7+CD19+ lymphocytes in the peripheral blood of cases and 
controls. Whilst there was no difference in the proportion of a4b7+ cells in cases and 
controls (35.2% vs 36.5%), they are markedly higher than in mucosal samples. a4b7+ 
lymphocytes constitute only 1% to 5% of LP cells, and only 8% to 13% of MEL cells 
(see Figure 5-3). 
For the lymphocytes isolated from peripheral blood there is a significantly greater 
proportion of lymphocytes expressing CD4 than CD8 or CD19 in both the case and 
control groups (p values shown in Figure 5-7). Comparing cases and controls, a 
difference in CD19+ lymphocytes is statistically significant (26.97% vs 17.92%; p = 
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0.043). There are greater proportions of CD4+ lymphocytes and lower proportions of 
CD8+ lymphocytes, but these differences were not statistically significant.  
Comparing the lymphocytes isolated from controls there is a difference in the relative 
proportion of subsets between all lymphocytes and those expressing a4b7. Whereas 
for all lymphocytes CD4+ cells predominate, for a4b7+ lymphocytes CD19+ cells 
predominate. Whilst the differences between the control group a4b7+ lymphocyte 
subsets are not statistically significant, comparisons with all lymphocytes from the 
control group are. Proportions of CD8+ lymphocytes are higher in the a4b7+ group 
(29.54% vs 39.94%; p = 0.044), as are proportions of CD19+ lymphocytes (17.92% vs 
29.16%; p = 0.037). These data are not shown in Figure 5-7. 
	
Figure 5-7: Lymphocyte subsets in the peripheral blood of cases and controls. Panel A – subsets as a 
percentage of all lymphocytes * p = 0.042 ** p = 0.017 *** p = 0.043 § p = 0.002 §§ p < 0.001 Panel B – 
subsets as a percentage of lymphocytes expressing a4b7+ + p = 0.018. Data are presented as the mean 
± one standard error, sample size as in Table 5-1. 
Comparing a4b7+ lymphocytes isolated from cases and controls there is a difference 
in the relative proportions of lymphocyte subsets. As stated above, CD19+ lymphocytes 
predominate in controls, whereas CD4+ lymphocytes are increased and come to 
predominate in cases. This difference is concomitant with reductions in the proportion 
of CD8+ and CD19+ lymphocytes. However, the only statistically significant difference 
is the lower prevalence of CD8+ lymphocytes in cases (39.5% vs 29.8%; p = 0.018). 
Expression	of	activation	markers	by	peripheral	blood	CD4+	lymphocytes		
The proportion of lymphocytes, both CD4+ and a4b7+CD4+, expressing CD25 was 
higher in cases; although this difference was only significant for the CD4+ lymphocytes 
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(p = 0.006). The fluorescent intensity of CD25 expression was also increased in cases, 
with the differences being statistically significant for both CD4+ lymphocytes (p = 0.019) 
and a4b7+CD4+ lymphocytes (p = 0.005).  
The proportion of lymphocytes, both CD4+ and a4b7+CD4+, expressing CD69 was 
higher in cases. The increases were statistically significant for both CD4+ lymphocytes 
(p = 0.004) and a4b7+CD4+ lymphocytes (p = 0.031). There was no difference in the 
fluorescent intensity of CD69 expression in either the CD4+ or a4b7+CD4+ populations 
between cases and controls. 
These data are presented in Figure 5-8. In the peripheral blood lymphocytes there is, 
overall, greater statistical significance in the differences between cases and controls 
than is seen in those isolated from the gut mucosa (see Figure 5-3). There is also a 
difference in the pattern of activation marker expression by lymphocytes in the gut and 
peripheral blood. In the peripheral blood, increased expression of CD25 by 
lymphocytes of cases predominate. In the gut mucosa, and particularly for a4b7+ CD4+ 
lymphocytes, increases in CD69 expression predominate.   
In the gut mucosa of controls, the expression of CD25 and CD69 is much closer, with 
cases having a relatively greater increase in the expression of CD69 compared with 
the increases in CD25. In the peripheral blood of controls, expression of CD25 is 
relatively higher than that of CD69, with cases having a relatively higher greater 
increase in expression of CD25 compared to that of CD69.  
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Figure 5-8: Expression of CD25 and CD69 by CD4+ and a4b7+CD4+ cells isolated from peripheral blood. 
Panel A – percentage expression by peripheral blood CD4+ cells, * p = 0.006 ** p = 0.004. Panel B – 
percentage expression by peripheral blood a4b7+CD4+ cells, § p = 0.031. Panel C – fluorescent intensity 
of expression by peripheral blood CD4+ cells, + p = 0.019; Panel D – fluorescent intensity of expression 
by peripheral blood a4b7+CD4+, ++ p = 0.005. Data are presented as means ± 1 standard error, sample 
size as in Table 5-1. 
Bone	metabolism	and	bone	mineral	density	
The primary reason for this element of the study was to examine measurements of 
bone metabolism. Bone turnover markers were measured in all participants, and 
confirmed cases of IBD were subjected to a DXA scan. 
Bone	turnover	markers	
Figure 5-9 compares the measured bone turnover markers in cases and controls. 
Comparing cases to controls urine NTX levels (236.4nM bone collagen equivalent/mM 
creatinine ± 46.2 vs 325.7 ± 40.7) and serum osteocalcin levels (67.99ng/ml ± 11.56 
vs 78.06 ± 7.93) were both lower in cases but the differences was not statistically 
significant. P1NP levels were lower with the difference reaching statistical significance 
(211.60ng/ml ± 51.45 vs 407.50 ± 54.26; p = 0.012).  
0	
2	
4	
6	
8	
10	
 CD25	  	CD69	
Pe
rc
en
ta
ge
	p
os
i.
ve
	
A	–	peripheral	CD4	lymphocytes	
0	
50	
100	
150	
200	
250	
300	
 CD25	  	CD69	
Fl
uo
re
sc
en
t	i
nt
en
si
ty
	
B	–	peripheral	CD4	lymphocytes	
0	
2	
4	
6	
8	
10	
 CD25	  	CD69	
Pe
rc
en
ta
ge
	p
os
i.
ve
	
C	-	α4β7	CD4	lymphocytes	
0	
50	
100	
150	
200	
250	
300	
 CD25	  	CD69	
Fl
uo
re
sc
en
t	i
nt
en
si
ty
	
D	-	α4β7	CD4	lymphocytes		
Controls	 Cases	
++	
**	
§	
+	
*	
  Page	134	
	
Figure 5-9: Boxplots showing comparing bone turnover markers in cases and controls. Panel A - urine 
NTX lower in controls. Panel B - serum osteocalcin lower in cases. Panel C - serum PINP lower in cases 
p = 0.012. Data are presented as medians and inter-quartile range, sample size as in Table 5-1. 
Overall, these data demonstrate reductions in bone formation in children with IBD and 
a possible reduction in bone resorption. These findings are consistent with those of 
Sylvester et al (2006). 
Bone	mineral	density	
All patients diagnosed with IBD underwent a DXA to measure their bone mineral 
density (BMD). The control group was taken from a cohort of healthy children who had 
undergone DXA in a separate study, the data kindly provided by Dr Paul Arundel of 
The Sheffield Children’s Hospital. Three age and sex matched patients were selected 
for each case. As discussed in the Materials and Methods, there are several different 
approaches to reporting the BMD in children. The method chosen herein is that of 
Carter (Crabtree et al 2017) which calculates an approximate volume for the lumbar  
	
Figure 5-10: Boxplots comparing BMD, height and weight in cases and controls. Panel A - BMD (g/cm3) 
median 0.292 vs 0.263 p = 0.002 Panel B - weight (kg) median 49.9 vs 52.1 p = 0.448 Panel C - height 
(cm) median 161.5 vs 157.2 p = 0.847. Data are presented as medians and inter-quartile range, sample 
size as in Table 5-1. 
vertebrae, on the basis of their visible area, and relates to the measured bone mineral 
content (BMC) to give the BMD in g/cm3. As can be seen in Figure 5-10, BMD was 
significantly lower in cases (median BMD 0.2918 vs 0.263; p = 0.002). Height and 
A B C
A B C
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weight, recorded routinely when undertaking a DEXA, were also compared as it has 
been suggested they may influence measurement of bone mineral content. As can be 
seen in Figure 5-10 there was no difference in either parameter in terms of median, or 
in the distribution. 
Associations	between	the	immune	system	and	bone	metabolism	in	children	with	
inflammatory	bowel	disease	
The aim of this element of the study was look for associations between the immune 
response and bone metabolism in children with IBD. The laboratory studies showed 
that CD4+ lymphocytes may be the mediators of low bone mineral density, with resting 
CD4+ cells supporting the growth of Saos-2 cells, and activated cells inhibiting growth. 
Changes in the profile of lymphocytes (proportions, phenotypes and activation status) 
in patients with IBD were compared to measures of BMD using linear regression which 
measures the strength of the association between the two variables, expressed as “R”. 
The higher the value of R the stronger the association, and the value can be positive 
(for a direct relationship) or negative (for an inverse relationship). R2 (which is not 
simply the value of R, squared) can be used to indicate how much of the variation in 
the dependent variable (in this case BMD) is due to changes in the independent 
variable, and can be expressed as a percentage. 
Peripheral	blood	immune	cells	subsets	
CD4+ cells are important mediators of inflammatory bowel disease, and the laboratory 
studies indicate that they could potentially explain a significant proportion of the PBMC-
mediated effects on Saos-2 cells.  
White cell counts (WCC) in cases and controls were not significantly different, but the 
proportion of lymphocytes as a percentage of the WCC was. Whilst there was a weakly 
positive correlation between the proportion of lymphocytes and BMD (r = 0.186) which 
explained 3.4% of the variability in BMD, this relationship was not statistically 
significant (p = 0.585, Panel A of Figure 5-11).  
The full blood count quantified the number of lymphocytes within the peripheral blood. 
A direct comparison between cases and controls (see earlier section) found that whilst 
numbers were lower in cases, the difference did not reach significance (p = 0.053). 
There was a moderately positive correlation (r = 0.345) between the lymphocyte count 
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and bone mineral density (BMD) explaining 12% of the variation, but the correlation 
was not significant (p = 0.298; Panel B of Figure 5-11).  
	
Figure 5-11: Correlations between total lymphocyte numbers and BMD. Panel A - correlation between 
BMD and the lymphocytes as a percentage of the total white cell count (11 patients; r = 0.186; p = 0.585) 
Panel B - correlation between BMD and the total lymphocyte count (10 patients; r = 0.345; p = 0.298). 
The flow cytometry analysis determined the proportion of CD4+ cells, and these data 
could be combined with the lymphocyte count from full blood counts to convert the 
percentage to a concentration: 
,-./ℎ12-34	21673	8	(/492473:;4	<=4& 100) 	= <=4	21673	(24,,B810C/E) 
Density gradient isolation of PBMCs may change the relative proportions of 
lymphocytes from that in whole blood, but this approach still provides a more 
meaningful measure of the CD4+ cell number than the proportion alone since it better 
reflects numbers of circulating lymphocytes.  
Using this method there was a positive correlation between the CD4+ lymphocyte count 
and BMD (r = 0.403; p = 0.219) and explained 16% of the variation in BMD. Applying 
a similar approach, there was a weakly positive correlation for CD8+ cells (r = 0.152; p 
= 0.655), and a moderately positive correlation for CD19+ cells (r = 0.434; p = 0.183), 
although neither of these correlations were statistically significant. A similar analysis 
identified moderately positive correlations between BMD and the number of 
a4b7+CD4+ cells (r = 0.331; p = 0.320), a4b7+CD8+ (r = 0.313; p = 0.349) and 
a4b7+CD19+ (r = 0.435; p = 0.181) respectively explaining 11%, 9.8% and 19% of the 
variation in BMD. Scatterplots for these comparisons are shown in Figure 5-12. 
A	 B	
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Figure 5-12: Correlations between BMD and absolute counts of peripheral blood lymphocyte subsets. 
Panels 1A to 1C - CD4+, CD8+ and CD19+ cells. Panels 2A to 2C - a4b7+CD4+, a4b7+CD8+ and a4b7+ 
CD19+ cells. Sample size 11 for each analysis. 
Mucosal	immune	cell	subsets	
Interpreting immune cell populations and their relation to BMD is difficult. In the 
peripheral blood studies above, it can be confidently assumed that the numbers and 
proportions seen in the samples taken reflect (broadly) those throughout the 
circulation. This means the lymphocyte populations in the samples will reflect that in 
the patient’s circulation. However, this is not the case with the mucosal samples. 
The distribution of immune cells throughout the gut changes in different regions to 
reflect functionality. However, the distribution will vary even within a functionally distinct 
region (especially if taking small biopsies) due to the structural elements of the gut. 
This could have been partially overcome by having a strict series of locations for 
biopsy, but this would risk missing areas of inflammation. Finally, it has not been 
practical to quantify immune cell numbers within the gut mucosa samples. 
Despite these the findings still potentially add valuable information. There is a dynamic 
flow of immune cells between the gut and peripheral blood, and whilst it was possible 
to establish numbers in the blood, this flow of cells is not accounted for. Furthermore, 
IBD is primarily a mucosal disease and therefore the immune response within the 
bowel could be a better marker of disease severity. 
1
2
A B C
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Within the mucosal epithelium (Figure 5-13) there was a very weakly positive 
correlation between BMD and the percentage of CD4+ cells (r = 0.049; p = 0.893), a 
moderately positive correlation with CD8+ cells (r = 0.422; p = 0.225) and a moderately 
negative correlation with CD19+ cells (r = 0.316; p = 0.373). Lymphocytes expressing 
a4b7 also showed no significant correlations. 
	
Figure 5-13: Correlations between BMD and the percentage of lymphocyte subsets in the mucosal 
epithelium. Panels 1A to C - CD4+ (r = 0.049; p = 0.893), CD8+ (r = 0.422; p = 0.225) and CD19+ (r = 
0.316; p = 0.373) cells. Panels 2D to E - a4b7+CD4+ (r = 0.263; p = 0.463), a4b7+CD8+ (r = 0.125; p = 
0.732) and a4b7+CD19+ (r = 0.058; p = 0.873) cells. Sample size 10 for each analysis. 
Within the lamina propria, whilst none of the correlations were statistically significant, 
increases in the percentage of cells expressing CD4, CD8 and CD19 were all positively 
associated with BMD whereas amongst a4b7+ cells the same correlations were 
consistently negative. In fact, the correlation between the percentage of a4b7+CD8+ 
lamina propria cells and BMD almost reaches statistical significance (r = 0.615; p = 
0.059).  
It is worth noting that whilst 7.7% of lymphocytes within the epithelial layer were a4b7+, 
only 1% of lymphocytes in the lamina propria were a4b7+. This is compared to 36.5% 
in the peripheral blood. Therefore, to find that changes in the proportion of a4b7+CD8+ 
lymphocytes within the lamina propria potentially influences BMD is surprising. 
A	 B	 C	
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Figure 5-14: Correlations between BMD and lymphocyte subsets in the lamina propria. Panels 1 A to C 
- CD4+ cells (r = 0.25; p = 0.489), CD8+ cells (r = 0.25; p = 0.492) and CD19+ cells (r = 0.178; p = 0.623) 
Panels 2A to C - a4b7+CD4+ cells (r = 0.150; p = 0.678), a4b7+CD8+ cells (r = 0.615; p = 0.059) and 
a4b7+CD19+ cells (r = 0.245; p = 0.525). Sample size 10 for each analysis. 
Activation	of	circulating	and	gut	derived	lymphocytes	
The hypothesis is that immune cells, activated in the gut, negatively affect bone 
metabolism leading to osteoporosis. This was supported by the laboratory work which 
found that CD4+ lymphocytes, potentially, mediated the observed inhibition of Saos-2 
cells. Comparisons between cases and controls in this in vivo study showed primarily 
increased expression of CD25 by CD4+ cells in IBD patients, with some increase in 
CD69 expression. Therefore, correlations between expression of CD25 and CD69 by 
CD4+ lymphocytes (including those expressing a4b7) and BMD were investigated. 
This included lymphocytes isolated from the peripheral blood and gut mucosa. 
Figure 5-15 shows scatter plots for expression of CD25. There was a weak, negative 
correlation between the percentage of CD4+ lymphocytes expressing CD25 and BMD 
(r = 0.264p p = 0.432), and a4b7+CD4+CD25+ lymphocytes and BMD (r = 0.190, p = 
0.575). When the absolute number of CD4+ lymphocytes and a4b7+CD4+CD25 
lymphocytes was calculated, based on the total lymphocyte count, both the 
correlations became positive. For CD4+ lymphocytes r = 0.367 (p = 0.267) and for 
a4b7+CD4+ lymphocytes r = 0.220 (p = 0.516).  
1	
2	
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Figure 5-15: Correlations between expression of CD25 by CD4+ lymphocytes and BMD in patients with 
IBD. Panel 1A - r = 0.264, p = 0.432 Panel 1B - r = 0.367, p = 0.267 Panel 1C - r = 0.132, p = 0.698 
Panel 2A - r = 0.190 p = 0.575 Panel 2B - r = 0.220 p = 0.516 Panel 2C - r = 0.219 p = 0.517. Sample 
size 11 for each analysis. 
The intensity of CD25 expression by CD4+CD25+ lymphocytes showed a weakly 
negative correlation (r = 0.132, p = 0.698), similar to that for a4b7+CD4+ lymphocytes 
(r = 0.219, p = 0.517). However, as can be seen in the scatterplots in panels 1C and 
2C of Figure 5-15, there are 2 outliers with markedly higher expression of CD25. 
Removing these outliers resulted in a stronger correlation (see Figure 5-16). They still  
	
Figure 5-16: Correlations between the intensity of CD25 expression by circulating lymphocytes and BMD, 
with outliers removed. Panel A:  Intensity of CD25 expression by CD4+CD25+ lymphocytes (r = 0.330; p 
= 0.386). Panel B: Intensity of CD25 expression by a4b7+CD4+CD25+ lymphocytes (r = 0.435; p = 0.241). 
Sample size 9 for each analysis. 
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did not reach statistical significance, but the fluorescent intensity explained more of the 
variation in BMD. For CD4+ lymphocytes R2 increased from 1.8% to 10.9%, and from 
4.8% to 19% for a4b7+CD4+ lymphocytes. 
Relationships between CD69 expression and BMD was also studied, but no 
statistically significant correlations were found. Expression of CD69 by circulating CD4+ 
cells showed a negative correlation when measured by both the percentage of cells 
expressing CD69 (r = 0.505; p = 0.113), and their fluorescent intensity (r = 0.059; p = 
0.864). Similarly for a4b7+CD4+ cells, BMD was negatively correlated with expression 
of CD69 when measured by the percentage of cells expressing CD69 (r = 0.245; p = 
0.467) and the fluorescent intensity (r = 0.246, p = 0.466).  
	
Table 5-3: Output of statistical analysis of correlations between expression of activation markers by gut 
CD4+ cells and bone mineral density. Significant findings are highlighted in red a = 0.05. 
Studying further expression of CD25 and CD69 by mucosal CD4+ cells the majority of 
analyses were not statistically significant (see Table 5-3). Two analyses were 
significant: the fluorescent intensity of CD69 expression by epithelial CD4+CD69+ cells, 
and the fluorescent intensity of CD25 expression by epithelial a4b7+CD4+CD25+ cells. 
The former showed a positive correlation with BMD, and the latter a negative 
r	 r2	 p	
Ep
ith
el
ia
l	m
uc
os
a	 Percentage		posi3ve	
CD4CD25	 0.205	 0.042	 0.570	
CD4CD69	 0.283	 0.080	 0.428	
A4B7CD4CD25	 0.225	 0.050	 0.561	
A4B7CD4CD69	 0.124	 0.015	 0.732	
Fluorescent		
intensity	
CD4CD25	 0.140	 0.020	 0.700	
CD4CD69	 0.790	 0.625	 0.006	
A4B7CD4CD25	 0.818	 0.669	 0.007	
A4B7CD4CD69	 0.021	 0.000	 0.955	
La
m
in
a	
pr
op
ria
	
Percentage		
posi3ve	
CD4CD25	 0.072	 0.005	 0.844	
CD4CD69	 0.017	 0.000	 0.962	
A4B7CD4CD25	 0.033	 0.001	 0.932	
A4B7CD4CD69	 0.402	 0.162	 0.250	
Fluorescent		
intensity	
CD4CD25	 0.144	 0.021	 0.691	
CD4CD69	 0.270	 0.073	 0.450	
A4B7CD4CD25	 0.186	 0.034	 0.632	
A4B7CD4CD69	 0.622	 0.386	 0.055	
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correlation (see Figure 5-17). However, although statistically significant, even if it is not 
a false positive, it is difficult to describe a reason why the association would be 
causative. 
	
Figure 5-17: Correlations between expression of activation markers by gut CD4+ lymphocytes and bone 
mineral density. Panel A – Fluorescent intensity of CD69 expression by epithelial CD4+CD69+ 
lymphocytes (r = 0.625; p = 0.006). Panel B - Fluorescent intensity of CD25 expression by epithelial 
a4b7+CD4+CD69+ lymphocytes (r = 0.669; p = 0.007). Sample size 10 for A, 9 for B. 
Conclusion	
In this cohort of children with IBD there was increased expression of CD25 by 
circulating a4b7+CD4+ cells and reductions in BMD, compared with healthy controls. 
However, whilst expression of CD25 was negatively correlated with BMD, and the 
number of lymphocytes was positively correlated with BMD, neither of these 
correlations were statistically significant.  
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6 Discussion	
The hypothesis of this thesis is that reduced bone mineral density (BMD) in children 
with Crohn’s disease (CD) is, at least in part, mediated by interactions between 
activated lymphocytes that have migrated from the gut mucosal tissue to the bone 
where they come in contact with osteoblasts. An in-vivo study looked for correlations 
between gut derived and circulating lymphocytes, and measures of bone metabolism. 
An in-vitro study investigated the effects of immune cells on the growth and alkaline 
phosphatase activity of Saos-2 cells. 
Results	
In-vitro	study	
The first two co-culture experiments looked at the effect of immune cell populations 
(one PBMC, one CD4+ lymphocyte enriched), cell number, activation status, and cell 
contact, on the growth of Saos-2. These two experiments had some differences in their 
results but, broadly, the effects of PBMCs and CD4+ lymphocytes on the growth of 
Saos-2 were similar. Activated immune cells i.e. both the PBMCs and the CD4+ 
lymphocytes, inhibited the growth of Saos-2 whilst resting immune cells increased their 
growth. These opposing effects were potentiated by increasing numbers of immune 
cells. The presence of a transwell insert increased the number of Saos-2 in both the 
activated and resting conditions, indicating that contact with immune cells has a 
consistently negative effect on their growth. Saos-2 also appeared to alter the 
expression of CD25 and CD69 by immune cells, reducing the expression of these 
activation markers in the activated condition whilst increasing expression in the resting 
condition. These changes in expression were potentiated by increasing numbers of 
Saos-2 in a dose-dependent manner. 
Numbers of Saos-2 cells at the end the co-culture period, counted after fluorescent 
labelling, were in the hundreds of thousands when the expected number is nearer a 
million. Rather than indicating apoptosis, this may be due to the method of counting 
the fluorescently labelled cells. Fluorescent labelling requires cell to be washed i.e. 
diluted, centrifuged, and the supernatant aspirated; potentially leading to a loss of cells. 
This could have been overcome by having separate samples for counting and labelling; 
however, since the loss of cells during wash steps would have been proportional, valid 
comparisons can still be made between the experimental conditions. 
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The third experiment introduced a CD4+ lymphocyte depleted population, and studied 
how the three immune cell populations influenced the growth and alkaline phosphatase 
(ALP) activity of Saos-2. ALP is present on the membrane of Saos-2 cells and within 
immune cells so could not easily be measured if these cells had been cultured in 
contact: analysed together the ALP activity of both cell types would be measured, but 
if separated prior to analysis ALP on the membrane of the Saos-2 would be disrupted. 
It also wasn’t practical to measure Saos-2’s generation of a mineralised matrix: the 
prolonged incubation time would have required the generation of a series of immune 
cell populations. 
An unexpected finding of the third experiment was that immune cells no longer 
influenced the growth of Saos-2 cells, which can only be explained by the immune cells 
addition after the Saos-2 had adhered. There was a small increase in Saos-2 growth 
with increasing immune cell number, but the marked and opposing effects of activation 
and resting immune cells was lost. ALP activity was largely unaffected by the PBMCs 
or the CD4+ enriched population, but was increased by the presence of both the resting 
and activated CD4+ lymphocyte depleted populations. This was an unexpected finding 
and one possible explanation is that cell stress increases ALP activity and can induce 
mineralisation, but why it was associated with a depletion of CD4+ lymphocytes is not 
clear. It may indicate a significant role for CD4+ lymphocytes in supporting the survival 
of Saos-2 cells. 
There are limitations to these experiments which limit generalisation of the findings. 
Whilst each experiment was repeated at three time points there were not any replicates 
at each of those time points. Independent repeats are important in ensuring the 
experiment is reproducible, but replicates are necessary to provide internal quality 
control for each repeat (Vaux et al 2012). It is also possible that the effects seen were 
a non-specific interaction between the cells, rather than reflecting a specific 
osteoimmune effect. The experiment cultured immune cells with a tumour cell line, and 
when normal cells become tumour cells their interactions with the immune system are 
altered. Also, the two cell types are from different hosts; and whilst the culture period 
is short there is the potential for alloimmune reactions. However, as will be discussed 
below, our results are consistent with those published elsewhere. 
One group, investigating interactions between T cells and osteoblasts in rheumatoid 
arthritis, cultured PBMCs with human primary osteoblasts and the human osteoblastic 
cell line MG63 and showed that Fas (a protein known to be involved in cell apoptosis) 
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was necessary for T cell induced apoptosis of osteoblasts (Kawakami et al 1997). They 
found that activated PBMCs and their secreted factors induced apoptosis of both 
primary osteoblasts and MG63 cells, blocked with the addition of a Fas chimeric 
protein. The different cell types were not autologous, but they do not say if the 
osteoblasts had adhered before exposure to immune cells and their secreted factors. 
It seems possible that Fas mediated apoptosis of the Saos-2 cells occurred in the 
experiments presented here, and this apoptotic pathway is not specific to these 
osteoimmune interactions. But, as the authors point out, it may still have a role in 
mediating bone loss in inflammatory diseases. 
The Fas ligand pathway also mediates apoptosis of murine bone marrow 
mesenchymal stem cells (BMMSCs) by T cells (Yamaza et al 2008). Mouse BMMSCs 
cultured with autologous lymph node T cells, pre-activated with monoclonal antibodies 
(mAbs) to the CD3 component of the T Cell Receptor, resulted in the death of the 
BMMSCs. This effect was dependent on cell contact (it was not observed with 
conditioned media from activated T cells, nor in the presence of a transwell insert) pre-
activation of the T-cells. It did not occur in experiments using T cell deficient mice, nor 
in the presence of a CD3 or a Fas ligand blocking agent. Anti-TNF-a and anti-IFN-g 
antibodies did not stop cell death. This study confirms the Fas pathway’s role in 
mediating T cell induced death of BMMSCs. The importance of cell contact, also seen 
in our studies, further supports the potential for Fas ligand binding as the mechanism 
mediating the negative effects of contact between immune cells and Saos-2 in this 
thesis. That the cells were autologous overcomes one limitation of other cell culture 
experiments, and may explain why the effects were only seen in the presence of cell 
contact. 
The experiments presented in this thesis show activated immune cells in-vitro having 
a predominantly negative effect of on the growth of Saos-2, but mineralisation doesn’t 
just depend on growth. Osteoblasts can be generated from the differentiation of human 
BMMSCs and, once mature osteoblasts, ALP activity reflects their capacity to 
mineralise. It has been shown that factors secreted by activated immune cells may 
promote both growth and mineralising capacity (Rifas et al 2003). Human BMMSCs 
and osteoblasts were cultured in immune cell supernatants, generated from activated 
and resting CD4+ lymphocytes. The activated cell supernatant increased ALP activity 
by both human BMMSCs and osteoblasts, an effect not seen with the non-activated 
cell supernatant. Human BMMSCs increased their expression of Runx2 (an osteoblast 
transcription factor) and osteocalcin, confirming their osteoblast phenotype. This 
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suggests activated CD4+ lymphocytes may improve BMD, and the authors cite 
evidence that in rheumatoid arthritis there is increased osteoblast activity, ALP activity 
and osteocalcin; although this is the context of lower BMD. The findings of the data 
presented in this thesis, supported by others (Sylvester et al 2006), show in children 
with CD reduced bone formation and reductions in serum osteocalcin levels. It may be 
that the effects seen are due to cell stress which increases ALP activity and could, 
theoretically, also induce differentiation. That does not, however, exclude the 
possibility that cell stress in-vivo influences BMD. 
A more recent publication provides a more comprehensive investigation of interactions 
between immune cells and BMMSCs (Croes et al 2016), but their findings may still 
reflect non-specific cell interactions. BMMSCs were isolated from human bone 
marrow, and lymphocytes from the blood of different donors. Immune cells populations 
(PBMC, CD4+ lymphocyte enriched and CD8+ lymphocyte enriched) were activated 
prior to their introduction to BMMSCs, and whilst it appears they were added after the 
BMMSCs had become adherent this is not explicitly stated. Activated immune cells 
increased the ALP activity of the BMMSCs, indicating their development of an 
osteogenic phenotype. The presence of a transwell insert did not change the effects 
of the CD4+ lymphocytes. Lymphocytes (CD4+ and CD8+) had a greater effect than 
PBMCs, and conditioned media from CD4+ lymphocytes produced the greatest 
increase in the production of a mineralised matrix. Resting CD4+ lymphocytes also 
increased ALP activity. That both resting and activated T cells reduced growth of the 
BMMSCs could be due to less favourable culture conditions, but the effect was not 
statistically significant. Interestingly, although co-culture with a population enriched in 
Th17 cells showed no osteogenic effect, conditioned medium from those same cells 
markedly increased osteogenic differentiation of the BMMSCs. They suggest it may be 
the BMMSCs inhibiting proliferation of the TH17 cells, and they demonstrate that 
expression of CD25 by T cells was reduced by the BMMSCs. 
Whilst Saos-2 were shown in this thesis not to express MHC class II, that may change 
in the presence of activated immune cells. It has been shown that culture of Saos-2 in 
the cytokine IFN-g resulted in expression of MHC class II (Stanley et al 2006). Saos-2 
cells were also able to present antigen to T-cells and increased the proliferation of the 
latter, with this effect lost in the presence of an MHC class II blocking agent. This 
demonstrates the potential for bidirectional signalling between these mature cells of 
the haematopoietic and mesenchymal cells. 
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Therefore, whilst the in-vitro experiments have a number of limitations and can only be 
considered preliminary, they are in keeping with the findings of other well established 
research groups. Activated and resting immune cells can interact with osteoblasts and 
BMMSCs in ways that could, both positively and negatively, affect bone metabolism. 
It is also possible for cells of mesenchymal origin to influence immune cells. 
In-vivo	study	
Peripheral	blood	lymphocytes	
In the peripheral blood of IBD patients there was increased expression of CD25 and 
CD69 by CD4+ lymphocytes, indicating greater lymphocyte activation. There was no 
difference between cases and controls in the percentage of lymphocytes expressing 
a4b7, but was up to 18 times greater in peripheral blood compared to the mucosal 
layers. The phenotypic profile of a4b7+ lymphocytes in controls showed a slight 
predominance of CD19+ lymphocytes over CD4+ with the pattern reversed in cases, 
although these differences were not statistically significant. Activation marker 
expression by a4b7+ lymphocytes was similar to that of all lymphocytes i.e. showed 
greater expression of CD25 and CD69. 
These findings are consistent with those of other investigators. The number of 
CD4+CD25+ lymphocytes in adult patients with IBD has been found to be higher (18% 
vs 11%) (Chamouard et al 2009), and also in children with IBD (10% vs 5%) (Cseh et 
al 2010). Cseh et al (2010) also found that the proportion of CD4+ lymphocytes was 
not increased in children with IBD. In adult IBD patients, the total lymphocyte count 
has been shown to be reduced, whilst the ratio of CD4+ to CD8+ is unchanged (Selby 
et al 1983; Senju et al 1991a), with Senju et al (1991a) additionally observing 
reductions in the number of CD19+ lymphocytes. Chamouard et al (2009) also looked 
at expression of the b7 integrin by CD4+ lymphocytes, and found no difference between 
cases and controls (although they did not differentiate between a4b7+ and aEb7+, the 
latter indicating cells activated in the epithelial layer). Meenan et al (1997) found 
around 50% of circulating CD4+ lymphocytes expressed a4b7, with no difference 
between cases and controls (Meenan et al 1997). There was an increase in the 
percentage of CD4+a4b7+ lymphocytes expressing CD25 from 4% in controls to 7% in 
CD and 5.2% in UC. They also found that CD4+CD25+ correlated with disease severity 
with steroids having no effect on these measures. 
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If expression of CD25 was used as a marker of T regulatory cells an increase in the 
number of CD4+ lymphocytes taken from patients with IBD and expressing this marker, 
as found in this thesis and the work of others (Chamouard et al 2009; Cseh et al 2010), 
may seem counterintuitive. However, in isolation CD25 is not specific to T regulatory 
cells and, as discussed earlier in this thesis, it is also a marker of immune cell 
activation. This may explain why multiple markers, including CD127 and FOXP3, need 
to be included to differentiate activated CD4+ lymphocytes from T regulatory 
cells (Santegoets et al 2015). 
Mucosal	lymphocytes	
Numerous studies have reported on cell populations within the gut mucosa of healthy 
individuals and those affected by IBD and, as discussed in the introduction, help 
understand the mucosal immune system. One objective of this thesis was to compare 
gut mucosal lymphocyte populations in cases and controls, and to look for associations 
between them and measures of bone metabolism. This is much more difficult with 
mucosal samples than with blood for several reasons.  
Within both the LP and epithelial layers of controls, CD19+ lymphocytes predominated; 
but in the lamina propria (LP) of cases there was a marked increase in the proportion 
of CD4+ lymphocytes, thereby making it the predominant lymphocyte subset. The 
distribution of lymphocyte subsets with the epithelial layer of cases and controls did 
not differ. Numbers of a4b7+ lymphocytes were greater in the epithelial layer than in 
the LP, although the difference was only significant in cases. In the LP and epithelial 
layer of controls, a4b7+ lymphocytes were predominantly CD8+, and in cases the only 
difference was an increase in the percentage of CD4+ lymphocytes in the LP. In the 
mucosal samples taken from cases, LP lymphocytes showed increased expression of 
CD25 whilst epithelial layer lymphocytes showed increased expression of CD69. When 
selected on the basis of a4b7, it was only expression of CD69 by both LP and epithelial 
layer lymphocytes that was significantly increased. 
Selby et al (1984) isolated lymphocytes from the gut mucosa of patients with IBD using 
dithiothreitol (DTT) and ethylenediamine tetra-acetic acid (EDTA) with an overnight 
incubation in collagenase, as well as immunohistochemistry. They found 80% of 
lymphocytes in the epithelial layer were CD8+, and 60% in the LP were CD4+. In a 
separate paper, the same group found no difference in the ratio of CD4+ to CD8+ 
lymphocytes between cases and controls. Comparing immunohistochemistry and 
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isolated immune cells, the latter showed relative reductions in the prevalence of CD8+ 
lymphocytes. Senju et al (1991c) isolated LP cells from the gut mucosa of patients with 
IBD, but did so using no collagenase. Cells were incubated in DTT and EDTA, but the 
process completed by passing the digested tissue through a nylon mesh. They found 
an increase in the proportion of CD8+ lymphocytes in patients with Crohn’s, and no 
increase in the percentage of lymphocytes expressing CD25. Yacyshyn (1993) studied 
B cell populations in the colonic mucosa of patients with IBD, isolating cells using 
EDTA and an overnight incubation in collagenase. They found around 10% LP 
lymphocytes were CD19+, with no differences between controls and IBD. Meenan et 
al (1997) isolated immune cells from endoscopic biopsies, incubating for one hour in 
collagenase. They found that in healthy controls 72% of colonic T-cells expressed 
a4b7, with this percentage reduced to around 50% in IBD. However, as was shown by 
Farstad et al (1996), the proportion of lymphocytes expressing a4b7+ are higher in the 
lamina propria (around 70%) and lower in the epithelial layer (at 30-50%).  
Whilst some of the findings are consistent with those in the published literature, there 
are also many differences which may reflect the difficulties in studying lymphocyte 
populations in gut mucosa. The first problem is where samples are taken from. Immune 
cell populations within a blood sample are likely to be similar regardless of which larger 
blood vessel it is taken from. There may be some variation, but it is much less than for 
samples of gut mucosa in which it will vary depending on the location (Mowat et al 
2014). The relative proportions of CD4+ lymphocytes and CD8+ lymphocytes changes 
along the GI tract with a decrease in CD8+ lymphocytes (17 to 12%) and an increase 
in CD4+ lymphocytes (36 to 42%) (Tauschmann et al 2013). Then each region of the 
gut mucosa contains regions of organised lymphoid tissue, such Peyer’s Patches in 
the terminal ileum, which contain different populations to the surrounding mucosa. 
Finally, in patients with IBD populations will differ in inflamed and non-inflamed 
mucosa. 
In this study biopsy samples were not taken in a consistent way. One important reason 
for this was the difficulty in ensuring the obtaining research samples did not have any 
detrimental effect on the patient, but also some uncertainty about the yield from small 
biopsy samples.  Having developed the technique, in future studies a more structured 
approach could be used. It would be possible to take sufficient samples from only the 
terminal ileum, and in cases to do so from areas of inflamed and non-inflamed mucosa. 
However, the distribution of inflammation can vary between patients. 
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Secondly, the technique of immune cell isolation used affects the result. Flow 
cytometry allows multiple cell surface markers to be analysed but, as was shown in 
this works optimisation, whilst enzyme methods cleave the cell surface proteins 
mechanical methods resulted in non-specific binding that prevented meaningful 
analysis. The use of different enzymes is described as a method to release separately 
cells from the epithelial and lamina propria layers from large sections of mouse 
bowel (Weigmann et al 2007), but a study published after completion of this work 
highlights the problems with using this technique on endoscopic biopsy 
samples (Carrasco et al 2013). The investigators isolated lymphocytes using “smooth” 
and “intense” enzyme digestion solutions to epithelial cells (using EDTA and DTT) then 
lamina propria cells (using collagenase). Immunohistochemistry was used to establish 
the effectiveness of epithelial layer removal. Their conclusion is that a more intense 
enzyme digestion method achieves the best, but not complete, epithelial layer removal; 
whereas as a gentler method preserves the surface proteins of lamina propria cells. 
Van Damme et al (2000) found similar problems with enzymes cleaving surface 
proteins. 
In this thesis the finding of CD19+ lymphocytes in the epithelial samples means there 
was contamination with cells of the lamina propria. Whilst the technique could be 
further optimised the work of Carrasco et al (2013) found a smooth enzyme protocol 
(low dose enzymes for a longer period) resulted in 42% of epithelial leucocytes being 
CD19+, whilst a more intense protocol (high dose enzymes for a shorter period) 
reduced that to 16%. Immunohistochemistry could be used but it does also have 
limitations. The sections are smaller than the endoscopic biopsy, being less than one 
cell thick, and a series taken from one biopsy may show quite different populations. 
Also, fewer cell surface markers can be studied than with multi-colour flow cytometry. 
This may explain why Carrasco et al (2013) don’t make any effort to compare the 
lymphocyte populations in samples analysed by flow cytometry to those analysed by 
immunohistochemistry. Both techniques have their role, but in the context of this study 
looking for correlations between gut immune cell populations and measures of bone 
mineral density is inherently problematic. 
The finding in this study of a greater number of a4b7+ lymphocytes in the epithelial 
layer conflicts with the published work of Farstad et al (1996) who found greater 
numbers in the lamina propria (LP). This is unlikely to reflect contamination of the 
epithelial population with LP cells as it shouldn’t be able to reverse the ratio overall, 
but simply reduce the difference. It may reflect problems with using two separate 
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fluorescent antibodies, one for a4 and one for b7. This requires gating based on the 
fluorescent intensity of two different fluorphores, and whilst that is done using 
appropriate isotypes it introduces the possibility of greater error. A more stringent 
gating strategy may have addressed this, but the same strategy was used for both 
mucosal and peripheral lymphocytes and the proportion of circulating lymphocytes 
expressing a4b7 was comparable to that of Meenan et al (1997). There is an 
alternative explanation for the finding. It was shown in the experiments assessing the 
effects of enzymes on cell surface markers that a4b7 was especially sensitive to those 
used for both epithelial and LP digestion. The epithelial population was exposed to 
enzymes for a shorter period than those of the LP, and the latter were additionally 
exposed to collagenase. This could have resulted in greater degradation of a4b7 
altering the relative proportions creating the appearance of lower numbers in the LP. 
It would explain the magnitude of difference in expression of a4b7 between mucosal 
and peripheral lymphocytes. 
Bone	turnover	and	bone	mineral	density	
The measurement of bone turnover markers showed reductions in markers of bone 
formation and resorption. Of the two formation markers, although both PINP and 
osteocalcin were lower in cases, only the reduction in PINP was significant. The 
reduction in NTX, a marker of resorption, was not significant; but this contrasts with 
increased bone resorption in adult IBD. The DEXA scans did show a significant 
reduction in bone mineral density (BMD) in cases compared with controls. This is in 
keeping with numerous studies of BMD in IBD (discussed in the introduction), although 
reductions are not always found in IBD patients. These findings would suggest that the 
reductions in BMD have occurred due to low bone formation, with a possible reduction 
in bone resorption. 
The	influence	of	immune	cells	on	bone	mineral	density	
No statistically significant correlations between the proportion of circulating lymphocyte 
subsets and their activation status with BMD were found. This was also true for most 
gut mucosal immune cells, and whilst two measures were positive (epithelial CD4+ cell 
expression of CD69, and a4b7+CD4+ cell expression of CD25) the limitations 
discussed mean they must be interpreted with caution.  
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Of all the measures looked at, circulating CD4+ cells expression of CD25 seems to be 
the cell surface marker most likely to be associated with changes in BMD so its 
measurement by fluorescent intensity was used in a power calculation. Based on the 
variability of CD25 expression by CD4+ lymphocytes and BMD, and the number of 
subjects, the power of the study was only 20%. To achieve the necessary power of 
80% a cohort of 80 cases would be required, and so it was unlikely that this study 
would have been able to find a significant correlation. Therefore, whilst associations 
between immune cells expressing a4b7 and BMD are not seemingly different when 
expression of a4b7 is not considered, it is still possible that gut activated immune cells 
could have a greater effect.  
Even though there were no statistically significant correlations between the peripheral 
immune cells and BMD there are some potentially interesting observations. BMD was 
positively correlated with the circulating lymphocyte count, but negatively correlated 
with expression of CD25 by CD4+ cells (both the percentage of cells positive, and the 
fluorescent intensity). Similar patterns were seen in a4b7+CD4+ cells, and in 
expression of CD69. This fits with the observations in the laboratory study of resting 
CD4+ cells supporting bone formation, and activated CD4+ cells inhibiting growth. 
Statistical	analysis	
The use of 3- and 4-way ANOVA to analyse the co-culture experiments data was 
unusual, and such a complex analysis may not have been appropriate given the quality 
of the data. A simpler approach could have been taken and individual data points 
compared by a series of T-tests. This is how data is usually analysed, although the 
one-way ANOVA is sometimes seen. But laboratory experiments are typically set up 
to compare only two variables, and the co-culture experiments in this thesis compared 
4 or 5. The use of 3- and 4- way ANOVA considers, and statistically measures, how 
those variables affect each other. The relative merits of these two approaches is 
discussed in chapter 2 of this thesis. 
Summary	
The findings of this thesis support the hypothesis that activated immune cells can have 
a negative impact on bone formation. The in-vitro work shows that activated 
lymphocytes have a negative impact on the proliferation of osteoblasts, although only 
if the two cell types are combined before the cells of mesenchymal origin have become 
adherent. Resting immune cells seem able to support the growth of osteoblasts, and 
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there is evidence of bi-directional signalling with Saos-2 influencing the activation 
status of resting and activated lymphocytes. The overall effects of PBMCs and CD4+ 
lymphocytes were not different. 
The in-vivo work found children with IBD had reduced bone mineral density, with 
reductions in both formation and resorption. Expression of CD25 was negatively 
correlated with BMD whilst the number of lymphocytes was positively correlated with 
BMD, which can be said to be in keeping with the in-vitro observations that immune 
cells can both increase and decrease bone formation. Associations between bone 
mineral density and lymphocyte populations cannot be said with any confidence to 
differ based on expression of a4b7. 
So far there has been limited discussion of whether gut-activated lymphocytes traffic 
to bone, and if they do whether they enter the bone marrow or reach the mineralised 
bone tissue. In setting up this study it was assumed to occur, given the evidence for 
interactions between T cells and osteoclasts. This will now be discussed prior to 
describing how best to take this work forward. In addition, whilst there are significant 
limitations to the experimental work presented here, it raises the potential importance 
of osteoimmune interactions in both inflammatory disorders and the normal functioning 
of both bone and the immune system. 
The	broader	context	of	osteoimmune	interactions	
Bone	marrow	and	its	relationship	with	mineralised	bone	tissue	
The bone marrow is found within the cancellous portions of bone, coming in contact 
with the trabeculae and the endosteal surface (Guillerman 2013). Bone marrow 
consists of “red marrow” (with a significant blood supply) and “yellow marrow” (less 
blood supply and more fat). Whilst in young children all cancellous bone contains red 
marrow, by adulthood this has been replaced by yellow marrow in peripheral bones. In 
central bones, such as the vertebrae, red marrow persists throughout life. 
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Figure 6-1: Distribution of red and yellow marrow from childhood to adulthood. Reproduced un creative 
commons license (Malkiewicz et al 2012). 
Whilst mineralised bone and the bone marrow are considered separate organs they 
function as a single unit (Compston 2002). Bone histomorphometry is technically 
challenging, but an important study by Hauge et al (2001) was able to describe the 
interface between bone marrow and bone. The two were separated by a single layer 
of bone lining cells expressing osteoclacin, osteonectin and alkaline phophatase 
which, during remodelling, lift away from the mineralised bone surface. The article 
discusses observations of small tubular extensions reaching from the surface of bone 
marrow sinusoids through this layer of bone lining cells, and that these may be a direct 
connection between marrow vessels and mineralised bone. Whether these extensions 
deliver osteoblasts to the bone surface is still debated (Parfitt 2001; Compston 2002). 
Bone is the third most common site for metastases (Ottewell 2016), and their 
dissemination to bone could be analogous, but the close association between bone 
marrow and mineralised bone makes it difficult to establish how they come into contact 
with OBs. Expression of CXCL12 by haematopoietic and endosteal niches enables 
attachment of CXCR4 expressing breast and prostate tumour cells. Whilst metastases 
do induce the development of bone resorbing and bone forming lesions the aggressive 
nature of tumour cells may simply erode through the thin cell layer lining the bone, 
rather than reflecting a physiological route by which cells can access the bone surface. 
Perhaps more telling is the consistent requirement for a blood supply for bone to form. 
This has been discussed in the introduction to this thesis, but is also necessary for 
tissue engineering of bone (Pirraco et al 2010). Given the difficulties in identifying the 
various niches and small blood vessels by immunohistochemistry (Parfitt 2001; 
Ottewell 2016) a synthetic model, like that used for tissue engineering, may help.  
  Page	155	
The	 role	 of	 osteoimmune	 interactions	 in	 normal	 bone	 metabolism	 and	 immune	
function	
It has been shown, at least in mice, that OB precursors and their secreted factors 
regulate haematopoiesis within the stem cell niche (Calvi et al 2003; Zhang et al 2003). 
Within bone HSCs are found primarily at the endosteal surface, entering bone by its 
central blood vessel (Nilsson et al 2001; Xie et al 2009), although more recently they 
have been shown to be more prevalent in the central bone marrow (Acar et al 2015). 
It may also be that the stem cell niches exist around arterial and venous sinusoids, 
which reach to the endosteal surface (Calvi et al 2015).  
Haematopoiesis seems to be dependent on the presence of OBs on the endosteal and 
trabecular surfaces of bone. A mouse model was developed in which, following a 
course of ganciclovir, it was possible to ablate osteoblast lineage cells lining the 
endosteal and trabecular surfaces with a decrease in osteoclast numbers (Visnjic et al 
2001). This had no effect on the ability of MSCs, isolated from these mice after 
treatment with ganciclovir, to successful undergo osteogenic differentiation. What they 
did find was a marked loss of cellular elements of the bone marrow in those regions 
where OBs were lost. The group went on to show that it was B-cells and erythroid cells 
that were most affected, with an associated initiation of extra-medullary 
haematopoiesis and no loss of function in secondary lymphoid organs (Visnjic et al 
2004). 
MSCs may have a role in maintaining haematopoiesis within the stem cell niche. 
Having identified a population of bone marrow cells expressing the green fluorescent 
protein (GFP) regulated by the nestin promoter (nestin is an intermediate filament 
expressed by neural cells) (Mignone et al 2004) that met the requirements of a stromal 
cell. The group went on to show that these cells co-located with HSCs in a perivascular 
distribution adjacent to the bone (Mendez-Ferrer et al 2010). These cells went on to 
form both osteoblasts and chondrocytes, and their depletion resulted in a reduction in 
HSCs.  
Conversely, haematopoietic cells appear necessary for normal bone development with 
one group having carried out a series of studies of bone in T cell and B cell knockout 
mice. They were initially interested in the role of T cells as mediators of bone loss due 
to oestrogen deficiency and studied BMD in ovariectomised, athymic mice (Cenci et al 
2000). When sacrificed at 9 weeks of age (when they are still classed as young, and 
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their bone potentially in a growth/modelling phase), they found the athymic mice to 
have normal BMD whilst their euthymic controls’ BMD was reduced by 30%. Bone loss 
was associated with a reduction in osteoclast number. To establish the role of T-cells 
in mediating bone loss in rheumatoid arthritis, athymic mice were again used. This time 
it was shown that administration of IL-7 to euthymic mice resulted in a reduction of 
BMD and increased CTX (very similar to NTX measured in this theses patient group), 
indicating increased OC activity, but had no effect in athymic mice (Toraldo et al 2003). 
One observation was that, in the placebo groups, athymic mice had a lower BMD than 
euthymic. This suggests that whilst T cells mediate pathological bone loss, under 
physiological conditions they are necessary for normal bone development. A third 
paper by this group showed that both B cells and T cells are necessary for bone 
homeostasis and achievement of peak bone mass (Li et al 2007). B cell KO mice at 
16 weeks (when peak bone mass is achieved) were osteopaenic because of elevated 
bone resorption with trabecular bone more affected than cortical. They also found 
reductions in BMD in athymic mice at 12 weeks, with on-going losses to 16 weeks of 
age.  
Lymphocytes also appear to be important for bone healing following fracture, reflecting 
processes out with those that influence early development, although specific 
populations may have delay healing. After fracturing the bone of wild type mice there 
is an influx of lymphocytes there is an influx of T-cells within 24 hours, shifting the 
balance from CD8+ to CD4+ predominance localising to the endosteal surface initially 
but then appearing in the areas of woven bone (Konnecke et al 2014). The 
lymphocytes that migrated to the bone were predominantly B cells. There was 
evidence of close contact between immune cells and bone cells, with B cells in direct 
contact with OBs, and T cells in close contact with OCs. Another study investigating 
the role of lymphocytes in bone healing after fracture identified, in humans, that a 
greater proportion of CD8+ effector memory cells was associated with delayed 
healing (Reinke et al 2013). Conditioned media from those CD8+ effector memory cells 
inhibited osteogenic differentiation of MSCs, and their depletion in a mouse model 
reduced fracture healing times. 
It is also likely that proliferation of lymphocytes, as opposed to lymphopoiesis, is 
influenced by MSCs. Bone marrow stromal cells (BMSCs), isolated from human iliac 
crest bone marrow aspirates, inhibited the proliferation of CD4+ and CD8+ T cells (Li 
Pira et al 2006). Proliferation was induced by DCs, and the BMSC mediated this by 
inhibiting cell contact between DCs and T cells. Monocytes also mediate umbilical 
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MSCs suppression of T cell proliferation (Cutler et al 2010). Whilst there was evidence 
that MSCs affected monocyte activation, MSCs had no direct on T cell proliferation in 
the absence of monocytes. But BMSCs can induce the proliferation of regulatory T 
cells. The culture of a highly-purified population of CD8+ lymphocytes with BMSCs, in 
the presence anti-CD3 monoclonal antibodies, resulted in the generation of a 
population of CD8+ able to inhibit the proliferation of lymphocytes with peripheral blood 
mononuclear cell population (Poggi et al 2008). 
These studies demonstrate the inter-dependency of the haematopoietic and 
mesenchymal cell lines, and how this relationship is important in maintaining BMD and 
normal immune function. 
The	potential	for	immune	cell	trafficking	to	bone	
There is evidence in the literature that memory T cells, carrying memory of antigen to 
which the immune system has been exposed, reside in the bone marrow. A number of 
studies infect mice with specific viruses, and then study the response of immune cells 
to antigen from that virus to study T cell memory responses. CD8+ lymphocytes 
isolated from the blood, spleen and bone marrow of infected mice all respond equally 
to virus re-exposure (Slifka et al 1997). Adoptive transfer of bone marrow CD8+ 
lymphocytes conferred immunity in the recipient. Amongst those antigen experienced 
CD8+ lymphocytes some circulate through lymphoid tissue, but a phenotypically 
distinct population circulate through non-lymphoid tissue where they are maintained 
for longer and still present 60 days after the infection (Masopust et al 2001). It was 
subsequently shown that antigen experienced CD8+ lymphocytes were still present in 
the bone marrow 7 months after infection, but were no longer present in the spleen (Di 
Rosa et al 2002). Compared with those from the spleen and lymph nodes, a greater 
proportion of memory CD8+ lymphocytes from the BM were proliferating (Parretta et al 
2005). A similar fate for memory CD4+ lymphocytes activated in secondary lymphoid 
organs has been shown, but with the additional observation that they were found within 
the bone marrow stroma 3-8 weeks after infection (Tokoyoda et al 2009). 
This process has also been demonstrated in humans. Okhrimenko et al (2014) noted 
the observation of Tokoyoda et al (2009) that memory T cell populations in secondary 
lymphoid organs are gradually depleted if not exposed to antigen and in BM dock with 
stromal cells to support their survival. They isolated cells from the blood and BM of 
healthy adults and found that CD4+ memory T-cells to CMV and measles are prevalent 
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in the bone marrow in a resting state (Okhrimenko et al 2014). Memory CD8+ 
lymphocytes, responding to CMV infection, are almost exclusively found in the 
BM (Letsch et al 2007). 
The presence of these cells in the BM may have a role in the wider functioning of the 
immune system. In mice DCs in the bone marrow have been shown able to activate 
BM resident memory T cells (Cavanagh et al 2005), with one mechanism being they 
present antigen to CD8+ lymphocytes which then express CD69 and proliferate (Milo 
et al 2013). In splenectomized mice, no longer filtering antigen, the BM took up the role 
of the spleen generating an appropriate primary immune response (Tripp et al 1997). 
Whilst an interesting observation, they acknowledge that the changes seen in lymphoid 
organs during the generation of a primary immune response may well be undesirable 
in the bone marrow. In a mouse model of colitis, induced by adoptive transfer of 
CD4+CD45RBhigh T cells into SCID mice, Nemoto et al (2007) found that a4b7+CD4+ 
memory T cells migrated to the bone marrow. These cells produce a Th1 cytokine 
response and are more actively diving than those in mesenteric lymph nodes and the 
lamina propria (Nemoto et al 2007). Adoptive transfer of colitic cells from the BM 
induced colitis in the recipient. 
Whilst it has been suggested that bone could function as a secondary lymphoid 
organ (Warnawin et al 2005) this may be an incorrect use of terminology. Although it 
is correct that memory cells have been found in bone but, unlike a lymph node, it 
remains a primary lymphoid organ. An editorial by Ceredig (2009) discusses the 
evidence for the return of memory T cells to the thymus. He points to work suggesting 
that the purpose of this is to support the process by which the thymus regulates 
production of new lymphocytes. This is nicely demonstrated in the image shown in 
Figure 6-2. The retention of memory cells in the bone marrow appears to have a slightly 
different role, perhaps acting as a memory bank. Therefore, whilst bone marrow is not 
a secondary lymphoid organ, antigen-experienced lymphocytes do seem to enter 
reside there. 
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Figure 6-2: Cartoon representation of the thymus, and in B it can see that experienced pupils return to 
help educate their naïve colleagues. Reproduced with permission (Ceredig 2009). 
Further	work	
Whilst the experiments undertaken for this thesis could be repeated with greater 
numbers, to do so seems unlikely to be worthwhile. The in-vivo study as it is only looks 
at associations and the in-vitro study, compared to other published studies, is relatively 
crude. More pressing is the need to establish whether lymphocytes, including those 
activated in the gut, come into contact with OBs at a location which means they affect 
the mineralisation of bone. 
This could be done by conducting a study similar to that presented in this thesis, but 
to also take a bone biopsy as was done by Ward et al (2010). However, this is a highly 
invasive procedure which can lead to some pain and discomfort, and without clinical 
benefit doing so may not be ethical. The study of Ward et al (2010) had undergone 
external review, and consent was given by parents and patients, but they do not 
indicate any formal review by an ethics board. Also, as already discussed, even it was 
approved, the separation of mineralised tissue and bone marrow by a single layer of 
cells means it may not be possible to establish the exact location of OBs and 
lymphocytes. 
An alternative approach would be to recruit patients who are undergoing orthopaedic 
surgery or bone biopsy for other reasons. This would overcome the problem of taking 
bone sample solely for research, and would be appropriate since it seems likely that 
osteoimmune interactions are relevant in healthy individuals. Of course, that they are 
having a procedure undertaken on their bone suggests they are not entirely “healthy”, 
but there may be circumstances where the micro-anatomy is not expected to be 
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abnormal. This methodology could be used to identify a4b7+ lymphocytes, providing 
evidence for trafficking of gut activated immune cells to the bone. However, given the 
disruption of blood vessel, bone marrow, and mineralised tissue, it may be difficult to 
establish whether any identified a4b7+ lymphocytes have passed from blood vessels 
to the bone marrow in-vivo or whilst obtaining the sample. 
Animal models could also be used. The problems of identifying the exact location of 
lymphocytes and osteoblasts, and where they come into contact, will still be difficult as 
the separation of bone and bone marrow is presumably no different to that in humans. 
But the smaller size of the bones, and the ability to remove the whole for analysis, may 
make it possible to overcome some of the technical difficulties. For example, a whole 
bone could be removed and a stabilising agent injected, before preparing histological 
sections. With animal models there is then greater potential to interrogate the 
osteoimmune system by using gene knockout species, blocking specific pathways and 
labelling of cells. 
There is also a role for more refined co-culture experiments. It would be possible to 
isolate cells of both haematopoietic and mesenchymal origin, from single human 
subjects or animals, to overcome the problems of alloimmune reactions when 
considering their interactions. MSCs and OBs may need a period of expansion to 
generate sufficient numbers for co-culture experiments, and this may mean either 
taking a later blood sample for immune cells, or maintaining or storing them in some 
way. It would be possible to study the influence of lymphocytes on cells as they mature 
from MSC to OB. This could be undertaken using 3D collagen scaffolds or other tissue 
engineering approaches to study this in the context of bone development. There is the 
potential to alter the lymphocyte populations and their activation status, but it would 
also be interesting to further study why the time point at which lymphocytes were added 
had such a profound effect on the outcome. It is also important to consider how cells 
of mesenchymal origin affect those of haematopoietic origin. 
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The following questions warrant further investigation: 
• Do a4b7+ lymphocytes enter the bone marrow after being exposed to antigen 
in the gut? 
• Do antigen experienced lymphocytes, including those expressing a4b7, 
interact directly with osteoblasts? 
o Does this occur in the bone marrow, on mineralised bone tissue, or 
both? 
o How is that interaction mediated? 
o What are the roles of cell contact and humoral factors? 
o At what stage of differentiation from MSC to osteoblast does the 
interaction occur? 
o How does this interaction alter the outcome for both the cell lineages 
involved? 
• How do these interactions influence bone development, modelling and re-
modelling? Are there reciprocal effects on immune function? 
Perhaps the most exciting aspect of this work is to provide the opportunity for 
researchers from different disciplines (immunology and bone biology) to work together 
with clinicians to better understand what appears to be the fundamental role of 
osteoimmune interactions in bone health and immunocompetence. 
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Medical Sch ool Office 
Ms Sara Watkin son  
Research  Adm in istr at ive Officer  
Beech  Hill Road 
Sheffield   S10 2RX 
 
 28th Apr il 2009 
 
REF: SMBRER116 
 Telephon e: +44 (0) 114  226 1458 
Fax: +44 (0) 114 271 3960 
Em ail:  s.watkin son@ sh effield.ac.uk  
Dear Gareth 
 
A systematic analysis of immune and bone interactions 
 
I am pleased to inform you that on 28th April 2009 the School’s Ethics Reviewers approved 
the above-named project on ethics grounds, on the basis that you will adhere to and use the 
following documents that you submitted for  ethics review. 
 
i)  Ethics form (revised) [27.04.09] 
ii)  Participant Information Sheet [27.04.09] 
iii)  Consent Form [27.04.09] 
iv)  Subject Information Sheet [12.03.09] 
 
If dur ing the course of the project you need to deviate from the above-approved documents 
please inform mew.  The wr itten approval of the School’s Ethics Review Panel will be required 
for  significant deviations form or  significant changes to the above-approved documents.  If 
you decide to terminate the project prematurely please inform me. 
 
Yours  sincerely 
 
 
 
Sara Watkinson 
School Research Ethics Administrator 
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School 
Of 
Medicine 
& Biomedical Sciences. 
 
 
 
Immunobiology Research Unit 
School of Medicine 
University of Sheffield 
 
PARTICIPANT INFORMATION SHEET 
 
A systematic analysis of immune and bone cell interactions 
 
You are being asked to provide a sample of blood for research being conducted by staff of the 
Immunobiology Research Unit on behalf of the University of Sheffield. Before you decide to provide this 
sample, it is important for you to understand why the research is being done, what it will involve and the 
possible benefits, risks and discomforts. Please take time to read the following information carefully and 
discuss it with others if you wish. Do not hesitate to ask us if there is anything which is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this….. 
 
What is the purpose of the study? 
 
The importance of bone and its cells (known as osteoblasts and osteoclasts) in the immune system has been 
increasingly recognized over the last decade. Osteoclasts and immune cells share a common cellular origin 
originating from the bone marrow. But it was the discovery of cell surface proteins common to both of these 
cell types, with the potential to mediate their interactions, which pointed toward an ongoing relationship 
between these two apparently very different types of cells. 
 
One important area this affects is bone metabolism in autoimmune disease. Inflammatory bowel disease 
(IBD) in adults is associated with reduced bone strength, and in children with the additional problem of 
reduced growth. Whilst there are a number of possible reasons for IBD to affect the bones e.g. malnutrition, 
reduced physical activity, the role of interactions between the immune system and bone are increasingly 
being investigated. 
 
We want to investigate how the immune system affects bone cells. Osteoblasts, which build bone, are 
currently being grown in the lab. We also want to grow osteoclasts, which breakdown bone. This can be 
done by taking blood from normal healthy adults, extracting a particular type of immune cell (known as a 
monocyte) and helping it grow into an osteoclast in a test tube. In addition, we want to see how the immune 
cells affect the growth and function of the bone cells. This can be done by incubating the various cell types 
together.   
 
What will happen if I take part? 
 
We will check that you are suitable for the study and that you have not had any recent serious illnesses or 
anaemia, or recently received any medication which is likely to affect the function of your immune (white 
blood) cells, including anti-inflammatory pain killers. A blood sample will be taken from the vein in your 
arm (a maximum of around 50 mL, or about 3 tablespoons) using a syringe and needle or similar device. The 
blood will only be used for the research outlined above. You should not donate more than 200 mL of blood 
in any 1-month period and so you should let us know if you have donated blood in the last month. The blood 
testing is not designed to detect any blood abnormalities.  
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What do I have to do? 
You will need to attend the premises of the University of Sheffield. Blood will be taken within the 
Immunobiology Research Unit by a person qualified to do so and should take no more than 15 minutes of 
your time. 
 
What are the possible side effects, risks and discomforts of taking part? 
Taking blood with a syringe and needle or a similar device from a vein in the arm can cause some pain and 
bruising. 
 
What are the possible benefits of taking part? 
You will not obtain any benefit from taking part in this research. We hope that the information obtained from 
the research will be of benefit to patients in the future. 
 
What if something goes wrong? 
There are no special compensation arrangements should you be harmed by taking part in this research. If you 
are harmed due to someone’s negligence, then you might have grounds for a legal action, but you may have 
to pay for this. Regardless of this, if you wish to complain or you have any concerns about any aspect of the 
way in which you have been approached or treated during the course of this research, then the normal 
University of Sheffield complaints mechanism should be available to you. 
 
What will happen to the results of the research? 
The results of the research may be published in the scientific and medical literature. Your identity will not be 
revealed in any publication arising from this work. 
 
Who is organising and funding the research? 
The Research is funded by the University of Sheffield, charitable institutions and Research Councils. None 
of the staff involved in the research study will be paid for including you in it. 
 
Who has reviewed the project? 
This research programme has been reviewed by the University of Sheffield Research Ethics Committee 
 
Who should I contact if I need more information or help? 
In case of a study-related injury, or whenever you have questions about the research, please contact either of 
the following: 
 
Dr Gareth Penman 
Specialist Registrar/Clinical Fellow 
Immunobiology Research Unit 
 
Tel: 07974 836033  
Professor Graham Pockley 
Professor of Immunobiology 
Immunobiology Research 
Tel: 0114 271 2027 (secretary) 
 
Expenses 
No payment can be made. 
 
You will be given a copy of this Information Sheet to keep if you decide to take part in this research.  
 
Thank you for your help with this research project. 
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School 
Of 
Medicine 
& Biomedical Sciences. 
 
 
 
Immunobiology Research Unit 
School of Medicine 
University of Sheffield 
 
CONSENT FORM 
 
Title of Project: A systematic analysis of immune and bone cell interactions 
 
 Please 
initial box 
 
1. I confirm that I have read and understand the information sheet for the above project dated 
10th March 2009, and that I have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time without 
giving reason. 
 
 
3. I agree to take part in the above project. 
 
 
 
 
Name of Participant:   ……………..………………………..  
 
Date:     …………………….    
 
Signature:    …………………………………………… 
 
 
Name of Person Taking Consent:  ……………..………………………..  
 
Date:     …………………….    
 
Signature:    …………………………………………… 
 
 
 
Copies:  Participant 
  Immunobiology Research Unit 
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Sheffield Research Ethics Committee 
Yorkshire and Humber REC Office 
First Floor, Millside 
Mill Pond Lane 
Meanwood 
Leeds 
LS6 4RA 
 
Tel: 0113 3050122 
Fax:  
 
09 September 2010 
 
Dr David Campbell 
Consultant Paediatric Gastroenterologist 
Sheffield Children's Hospital 
Western Bank 
Sheffield 
S10 2TH 
 
 
Dear Dr Campbell 
 
Study title: A comparative phenotypic characterisation of intestinal 
and peripheral blood leukocytes in children with and 
without Crohn's disease. 
REC reference: 08/H1308/275 
Protocol number: Awaited 
Amendment number: 3 
Amendment date: 11 August 2010 
 
Thank you for submitting the above amendment, which was received on 11 August 2010.  It 
is noted that this is a modification of an amendment previously rejected by the Committee 
(our letter of 14/7/2010 refers). 
 
The modified amendment was reviewed by the Sub-Committee in correspondence. A list of 
the members who took part in the review is attached.  
 
Ethical opinion 
 
Favourable Opinion  
 
I am pleased to confirm that the Committee has given a favourable ethical opinion of the 
modified amendment on the basis described in the notice of amendment form and 
supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved are: 
 
 Document  Version  Date  
Modified Amendment    11 August 2010  
  
R&D approval 
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All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
08/H1308/275:     Please quote this number on all correspondence 
 
Yours sincerely 
 
 
 
 
Mrs Elaine Hazell 
Committee Co-ordinator 
 
E-mail: Elaine.hazell@leedsth.nhs.uk 
 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Mrs Wendy Swann, Sheffield Children's NHS Trust Research 
Department 
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PARTICIPANT INFORMATION SHEET 
FOR YOUNG PEOPLE 
 
 
Study title 
 
Growing the Bones of It! 
 
Part 1 – to give you first thoughts about the project 
 
1. Invitation paragraph 
 
We would like you to help us with our research study.  Please read this information 
carefully and talk to your mum, dad or carer about the study.  Ask us if there is anything 
that is not clear or if you want to know more.  Take time to decide if you want to take 
part.  It is up to you if you want to do this.  If you don’t then that’s fine, you’ll be looked 
after at the hospital just the same. 
 
This research is helping one of the doctors involved to learn more about carrying out 
research, and the information that is gathered will be used in his final assessment for a 
qualification from the University of Sheffield. 
 
 
2. Why are we doing this research? 
 
Some children have a condition called inflammatory bowel disease. Their bowel 
becomes inflamed and they suffer from diarrhoea and abdominal pain. Inflammatory 
bowel disease can affect the bones making them weaker and more likely to break. We 
want to know why this happens so we can find the best way to make their bones 
stronger. 
 
3. Why have I been asked to take part? 
 
You have been chosen because you are having an endoscopy, where we look inside 
your bowel with a long flexible camera, whilst under a general anaesthetic. We would 
like 30 children and young people to take part in this project. 
 
4. Do I have to take part? 
 
No! It is entirely up to you.  If you do decide to take part: 
 
- you will be asked to sign a consent form to say that you agree to take part  
 
 
  Page	203	
Growing the Bones of It! 
Participant Information Sheet Age 13-15 
Version 4 
Date 04/01/2010 
Page 2 of 5 
© Sheffield Children’s NHS Foundation Trust 
- you will be given this information sheet and a copy of your signed consent form to 
keep. 
 
You are free to stop taking part at any time during the research without giving a reason.  
If you decide to stop, this will not affect the care you receive whilst in hospital. 
 
5. What will happen to me if I take part? 
 
Having an endoscopy involves a general anaesthetic so you sleep through the whole 
thing. It can be done in a day so you shouldn’t have to stay overnight, and you could go 
back to school the next day. 
 
You’ll come to hospital in the morning. We’ll give your parents a container to collect the 
second wee you do that day. Once you get to the ward a cream that numbs the  skin will 
be put on the back of your hand. One of the doctors will put a small tube, called a 
cannula, in the back of the hand. This is to give medicines to make you sleep, but will 
also be used to take 15 ml (about 3 teaspoons) of your blood. Once you are asleep a 
long, flexible camera is used to look at the upper and lower parts of your bowel, and 
small pieces of your bowel (about the size of a breadcrumb) are taken to be looked at 
under a microscope. The doctors then start to wake you up and you’re taken out of the 
theatre. This takes about 40-60 minutes. You then stay in hospital until you are awake 
and able to eat and drink. Taking part means you will be under a general anaesthetic for 
about an extra 10 minutes. You won’t be aware of this and it won’t take any longer for 
you to wake up, or mean you need to stay in hospital any longer. Also we will record 
details of your symptoms, blood test results, and what we see with the camera. 
 
6. What will I be asked to do? 
 
If you’re happy to be involved in the study we’ll ask you to sign a form confirming we 
can take the additional samples. You won’t need to do anything else.  
 
7. Is there anything else to be worried about if I take part? 
 
Lots of teenagers have an endoscopy and it is very unusual for there to be any 
problems. However very occasionally (about once in every 1000 endoscopies) the 
endoscope makes a hole in the wall of the bowel. Since we are taking some extra 
biopsies this risk is increased, but the increase is very small and if it was thought to be 
too great we wouldn’t be allowed to take the samples. 
 
If we find out something that we think is important about you we will talk to your mum, 
dad or carer and ask them if they want to come back and have you checked again at 
the hospital. 
 
8. Will the study help me? 
 
No, but the information we get might help us to better treat young people with 
inflammatory bowel disease in the future. 
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9. What happens when the research study stops? 
 
We will collect all the information together and see if we are able to identify cells that 
have passed through the gut, and how they differ between patients with and without 
inflammatory bowel disease. If we are successful we will organise further studies to 
look at the effects of these cells on bone. 
 
10. Contact for further information 
 
If you would like any further information about this study you could contact: 
 
Name:   Dr David Campbell 
Designation:   Paediatric Gastroenterology Consultant 
Hospital/Department: Sheffield Children’s Hospital 
Tel:    0114 2717000 
Email:    David.Campbell@sch.nhs.uk 
 
Thank you for reading so far - if you are still interested, please go to Part 2: 
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Part 2 - more detail – information you need to know if you still want to take part. 
 
11. What if I don’t want to do the research anymore? 
 
Just tell your mum, dad, carer, doctor or nurse at any time.  They will not be cross with 
you.  You will still have the same care whilst you are at hospital. 
 
12. What if there is a problem or something goes wrong? 
 
Tell us if there is a problem and we will try and sort it out straight away.  You and your 
mum, dad or carer can either contact the project co-ordinator: 
 
Name:   Dr David Campbell 
Designation:   Paediatric Gastroenterology Consultant 
Hospital/Department: Sheffield Children’s Hospital 
Tel:    0114 2717000 
Email:    David.Campbell@sch.nhs.uk 
 
Or the hospital complaints co-ordinator: 
 
Mrs Linda Towers 
Patient Advice & Liaison Co-ordinator 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 271 7594 
Email: Linda.Towers@sch.nhs.uk 
 
13. Will anyone else know I’m doing this? 
 
The people in our research team will know you are taking part.  The doctor looking after 
you while you are in hospital will also know. Your medical notes may also be looked at 
by other people who work at the hospital to check that the study is being carried out 
correctly. 
 
We keep a record of your name, date of birth and copies of the consent form in one 
place along with a unique number. We then use this number for all the other information 
we collect e.g. your gender, whether you have any other illnesses and what we find in 
the samples we take. We need to keep a record of your personal details in case we 
need to identify who gave a particular sample, we keep this information but only a few 
people in the research team can access it. The unique number allows us to keep track 
of who all the other information belongs to but the rest of the research team, and 
anyone we discuss the results with, won’t know who you are. Once the study is 
complete all information will kept, but we will be keeping your details separately from 
any information we get from the samples we take. 
 
14. What will happen to any samples I give? 
 
The samples you give will be taken to a science lab where we will look at the cells. 
Samples don’t have your name on, and can only be traced back to you one of the 
doctors in the lab. Anything we don’t use we would keep in case we found new tests we 
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could do on them. We ask you to sign a consent form for this now, but we may need to 
contact you to speak to you about it in the future. We would speak to our ethics 
committee before doing any extra tests. 
 
15. What are genetic tests and will any be done? 
 
Genetic tests look at the molecules which control your cells. For this research we don’t 
need to do any genetic tests. 
 
16. What will happen to the results of the research study? 
 
When the study has finished we will present our findings to other doctors, and we will 
put the results in medical magazines and websites that doctors read.  We would also 
like to put a brief summary on the hospital research website so that you will be able to 
read about our results too. This will be available at the end of the study on 
www.sheffieldchildrenscrf.nhs.uk. The results will also be included as part of the chief 
investigator’s educational qualification. They will be anonymous, which means that you 
will not be able to be identified from them. 
 
17. Who is organising and funding the research? 
 
The research is being organised by Sheffield Children’s NHS Foundation Trust and paid 
for by Sheffield Children’s Hospital Charity. 
 
18. Who has checked the study? 
Before any research goes ahead it has to be checked by a Research Ethics Committee.  
This is a group of people who make sure that the research is OK to do.  This study has 
been looked at by North Sheffield Research Ethics Committee. 
 
It has also been checked by the Research Department at this hospital. 
 
19. How can I find out more about research? 
The Clinical Research Facility at this hospital has an Information for families section 
on its website (http://www.sheffieldchildrenscrf.nhs.uk/info_families.html), or you could 
contact the hospital Clinical Research Facility: 
 
Mrs Tracy N’Diaye 
R&D Manager 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 226 7904 
Email: tracy.ndiaye@sch.nhs.uk 
 
Thank you for taking the time to read this – please ask any questions if you need 
to. 
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PARENT/LEGAL GUARDIAN INFORMATION SHEET 
 
 
Study title 
 
Growing the Bones of It! 
 
Part 1 – to give you first thoughts about the project 
 
1. Invitation paragraph 
 
You and your child are being invited to take part in a research study.  Before you decide 
it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others 
about the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you and your 
child if you take part. 
 
 Part 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you want your child to take part. 
 
This research is helping one of the doctors involved to learn more about carrying out 
research, and the information that is gathered will be used in his final assessment for a 
qualification (a Phd) from the University of Sheffield. 
 
 
2. What is the purpose of the study? 
 
Inflammatory bowel disease is a condition where the bowel becomes inflamed causing 
diarrhoea and abdominal pain. Children and adults with inflammatory bowel disease can 
develop osteoporosis (brittle bones). This can make it more likely their bones will break 
(or fracture) and in children can affect the growth and development of their skeleton. 
 
There is a lot we don’t know about osteoporosis in inflammatory bowel disease, 
including why it occurs and how best to prevent or treat it. We in the gastroenterology 
team want to try to understand more about why brittle bones occur. This will help us 
decide the best way to prevent and treat the problem, improving patients bone health 
and reducing problems of fracture and poor growth and development. 
 
We believe that it may be cells from the gut which travel to the bone and interact with 
bone cells resulting in less healthy bones. In order to investigate this problem we want 
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to identify cells which have passed through the gut and entered the bloodstream, and 
investigate how these relate to the activity of bone cells. 
 
3. Why has my child been chosen? 
 
Your child has been chosen as they are having an endoscopy to investigate symptoms 
related to the bowel. To do this a flexible camera is used to look inside the bowel. We 
are interested in looking at biopsies (small pieces) of the bowel from children who have 
a condition called Crohn’s disease, one of the two types of inflammatory bowel disease, 
and from children who’s bowel appears normal. That way we can see whether there are 
any important differences between the two. 
 
4. Does my child have to take part? 
 
No. It is up to you and your child (wherever possible) to decide whether or not to take 
part. You are both free to withdraw from the research at any time and without giving a 
reason. Your decisions about this will not affect the standard of care your child will 
receive. 
 
If you are happy to take part, and are satisfied with the explanations from the research 
team, you will be asked to sign a consent form.  If your child is able to understand the 
research and is happy to take part and can write their name, they will be asked to sign a 
consent form with you, if they want to.  You will be given a copy of the information sheet 
and the signed consent forms to keep for your records. 
 
5. What will happen to my child if we agree to take part? 
 
Children who are having an endoscopy usually need to take laxatives, at home, to 
empty the bowel. During this time they can only drink clear fluids. They will then come 
to hospital on the day and will be seen by the doctors and nurses looking after them. 
This will includes asking how they are and explaining what will happen. They will be 
taken to the operating theatres where the anaesthetist puts a cannula (a small flexible 
tube) into the back of the hand so that medicines can be given. To make it less painful 
an cream is used which numbs the back of the hand. Once your child is asleep a long 
flexible camera is used to look into the upper and lower parts of the bowel, and small 
pieces of the bowel wall (biopsies) are taken to be looked at under a microscope. This 
normally takes around 40 minutes. Afterwards your child will be woken up and can take 
up to an hour to stop feeling sleepy. You would usually be allowed home 2 to 3 hours 
after the procedure, provided your child felt well enough. 
 
If you and your child agreed to be in the study we would need to collect a few additional 
samples, and if your child is on the afternoon list then we would ask you to come to 
hospital 2 hours earlier. Doing this shouldn’t cause any additional distress, but the 
endoscopy was in the afternoon we might need you to come to hospital two hours 
earlier.  
 
Firstly we would need a urine sample which has to be the second one of the day. We 
would give you a container for it and ask you to bring it along on the day. Secondly we 
need to take a 13 ml blood sample before 11am. This would mean having the cannula 
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put in earlier, but we would still use the cream, and the cannula would be used to give 
the anaesthetic so there would not be any additional needles required. Finally, during 
the endoscopy, we would take an additional ten biopsies of the gut. The most difficult 
part of the procedure is guiding the endoscope through the bowel, so the extra biopsies 
would add at most 10 minutes to the time under anaesthetic. However it wont affect how 
long it takes to recover from the anaesthetic, or how long your child spends in hospital. 
All these samples would then be taken to the laboratory to be analysed.  
 
In normal circumstances biopsies of the bowel are sent to be looked at under a 
microscope. The majority of the time this result confirms our diagnosis. However it is 
possible that we may take the additional samples and analyse them, but then discover 
that the microscopic appearance changes our diagnosis. If the diagnosis was one that 
we’re not looking at in this study we would still like to use the results. 
 
6. What will we have to do? 
 
We would ask you to collect your child’s second urine sample of the day. If the 
endoscopy is in the afternoon then we would need you to come to hospital by 10am, 
about 2 hours earlier than usual. We would then collect the samples as described 
above. Otherwise nothing else is required, and your child shouldn’t need to stay any 
longer in hospital after the procedure. 
 
If you wanted to be involved in the study, but were unable to come to hospital earlier, 
we would still want to collect some blood and the additional gut biopsy samples. If you 
wanted to be involved in the study and you were able to come hospital earlier we would 
give you £5 to cover the cost of parking and some refreshments for the parents. 
 
7. What are the possible disadvantages and risks of taking part? 
 
Diagnostic endoscopy is a relatively safe procedure with a low risk of complications. 
There is a 1 in 1000 risk of the endoscope making a hole in the wall of the bowel. This 
mostly occurs as a result of the endoscope moving through the bowel, and is more likely 
in patients who have unhealthy bowel. Taking additional biopsies could increase the 
possibility of making a hole. But this increase would be small, and taking double the 
number of biopsies doesn’t double the risk. Otherwise, taking part should not affect your 
child in any way.  
  
8. What are the possible benefits of taking part? 
 
Your child will not benefit from being part of this study. However the information we 
collect may help us to better treat future patients with inflammatory bowel disease. 
 
9. What happens when the research study stops? 
 
We will collect all the information together and see if we are able to identify cells that 
have passed through the gut, and how they differ between patients with and without 
Crohn’s disease. If we are successful we will organise further studies to look at the 
effects of these cells on bone. 
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10. What if there is a problem? 
 
Any complaint about the way you or your child have been dealt with during the study or 
any possible harm you or your child might suffer will be addressed.  The detailed 
information on this is given in Part 2. 
 
11. Will my child’s taking part in the research project be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about your child will be 
handled in confidence. The details are included in Part 2. 
 
12. Contact for further information 
 
If you would like any further information about this study you could contact: 
 
Name:    Dr David Campbell 
Designation:    Paediatric Gastroenterology Consultant 
Hospital/Department: Sheffield Children’s Hospital 
Tel:     0114 2717000 
Email:    David.Campbell@sch.nhs.uk 
 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are considering 
participation, please continue to read the additional information in Part 2 before 
making any decision. 
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Part 2 - more detail – information you need to know if you still want to take part. 
 
13. What will happen if we don’t want to carry on with the research? 
 
If you withdraw from the study we will destroy all your child’s identifiable samples if you 
wish; but we will need to use the data collected up to their withdrawal. 
 
14. What if there is a problem? 
 
Complaints 
 
If you have any cause to complain about any aspect of the way in which you or your 
child has been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you and are not 
compromised in any way because you have taken part in a research study.  If you have 
any complaints or concerns please contact either the project co-ordinator: 
 
Name:   Dr David Campbell  
Designation:   Paediatric Gastroenterology Consultant 
Hospital/Department: Sheffield Children’s Hospital 
Tel:     0114 2717000 
Email:    David.Campbell@sch.nhs.uk 
 
Otherwise you can use the normal hospital complaints procedure and contact the 
following person: 
 
Mrs Linda Towers 
Patient Advice & Liaison Co-ordinator 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 271 7594 
Email: linda.towers@sch.nhs.uk 
 
Harm 
If your child is harmed by taking part in this research project, there are no special 
compensation arrangements.  If your child is harmed due to someone else's fault, then 
you may have grounds for a legal action – but you may have to pay for it. 
 
15. Will taking part in this study be kept confidential? 
 
All information which is collected about your child during the course of the research will 
be kept strictly confidential.  Any information about your child which leaves the hospital 
will have their name and address removed so that your child cannot be recognised from 
it.  
 
Once the study is complete information about your child (name, date of birth) and 
copies of the consent forms you have signed will be kept securely for five years in a 
locked cabinet, and then placed in an archive. Only members of the research team will 
be able to access this. Information obtained from the samples your child has given will 
be kept indefinitely, but separately from details that would identify your child. This data 
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would be shared in various formats with people outside of the research team. We will 
use a numbering system to allow us to trace who particular data came from. This would 
only be accessible by the main members of the research team. 
 
Our procedures for handling, processing, storage and destruction of data are compliant 
with the Data Protection Act 1998. 
 
Your child’s medical notes may also be looked at by other people within the hospital 
involved in the running and supervision of the study to check that it is being carried out 
correctly. 
 
16. What will happen to any samples my child gives? 
 
In order to maintain confidentiality each participant is given a unique number. When the 
samples are taken this number, not your child’s name or date of birth, is used to identify 
the sample. However we do keep a separate record of this number with your child’s 
details in case we need to identify who gave the sample. Your child’s data would only 
be accessible to the two principal members of the research team. 
 
Sometimes when we analyse samples we discover new things to look for. Therefore we 
would, with your permission, keep the samples for future testing. If any of this testing 
could have implications for your child, if testing found something relating to your child’s 
health, or a research team other than us was going to use the samples, we would 
contact you.  
 
17. Will any genetic tests be done? 
 
No genetic testing will be done. 
 
18. What will happen to the results of the research study? 
 
When the study has finished we will present our findings to other doctors, and we will 
put the results in medical magazines and websites that doctors read. We would also like 
to put a brief summary on the hospital research website so that you will be able to read 
about our results too. This will be available at the end of the study on 
www.sheffieldchildrenscrf.nhs.uk. The results will also be included as part of the chief 
investigator’s educational qualification. They will be anonymous, which means that your 
child will not be able to be identified from them. 
 
19. Who is organising and funding the research? 
 
The research is being organised by Sheffield Children’s NHS Foundation Trust and paid 
for by the Sheffield Children’s Hospital Charity. 
 
20. Who has reviewed the study? 
 
This study was given a favourable ethical opinion for conduct in the NHS by North 
Sheffield Research Ethics Committee.  It has also been approved by the Research 
Department at this hospital. 
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21. How can we find out more about research? 
The Clinical Research Facility at this hospital has an Information for families section 
on its website (http://www.sheffieldchildrenscrf.nhs.uk/info_families.html), or you could 
contact the hospital Clinical Research Facility: 
 
Mrs Tracy N’Diaye 
R&D Manager 
Sheffield Children’s NHS Foundation Trust 
Tel: 0114 226 7904 
Email: tracy.ndiaye@sch.nhs.uk 
 
If you and your child decide to take part in this study, you will be given this 
information sheet and signed consent and assent forms to keep. 
 
Thank you for taking the time to read this information sheet. 
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Patient study number: 
 
PARENT/LEGAL GUARDIAN CONSENT FORM 
 
Title of project: Growing the Bones of it! 
 
Names of researchers: Dr David Campbell, Dr Gareth Penman 
 
          Please initial box 
 
1. I confirm that I have read and understand the information sheet 
 dated 04/01/2010 (version 4) for the above study and have had the 
 opportunity to ask questions. 
 
2. I understand that my child’s participation is voluntary and that I am free to 
 withdraw my child at any time, without giving any reason, without my child’s 
 medical care or legal rights being affected. 
 
3. I understand that sections of any of my child’s clinical record may be looked 
 at by researchers and those involved in the running and supervision of the 
 study from Sheffield Children’s NHS Trust where it is relevant to my child 
 taking part in research.  I give permission for these individuals to have 
 access to my child’s records. 
 
4. I agree to my child taking part in the above study. 
 
 
4. I agree to my child having the following samples taken 
 
• Urine sample         
  
 
• Additional 13mls of blood 
 
 
• Additional gut biopsies 
 
 
6. I agree to any samples not used being stored for further testing as outlined 
 in the information sheet 
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7. I understand that I will be informed if any of the results of the medical 
tests done as part of the research are important for my child’s health. 
 
 
8. I know how to contact the research team if I need to, and how to get 
information about the results of the research. 
 
 
9. I agree that if I wish to withdraw from this study, any data or samples already 
collected can be used as described in the information sheet. 
 
 
 
 
________________________ ________________ ____________________ 
Name of Parent/Guardian Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature 
 
 
Would you like to be sent information about the progress of this project? 
 
  Yes No  
 
 
 
1 copy for parent; 1 copy for researcher; 1 copy to be kept with hospital notes 
